PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
11040064-8	2000	Functional validation of the isogenic model was provided by the much greater sensitivity of the NQO1-transfected cells to the known DT-diaphorase substrates and bioreductive agents streptonigrin (113- to 132-fold) and indoloquinone EO9 (17- to 25-fold) and the inhibition of this potentiation by the DT-diaphorase inhibitor dicoumarol.	Dicumarol	324-334	NAD(P)H quinone dehydrogenase 1	Homo sapiens	96-100
11040064-8	2000	Functional validation of the isogenic model was provided by the much greater sensitivity of the NQO1-transfected cells to the known DT-diaphorase substrates and bioreductive agents streptonigrin (113- to 132-fold) and indoloquinone EO9 (17- to 25-fold) and the inhibition of this potentiation by the DT-diaphorase inhibitor dicoumarol.	Dicumarol	324-334	NAD(P)H quinone dehydrogenase 1	Homo sapiens	132-145
10755406-2	2000	Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.	Dicumarol	27-37	NAD(P)H dehydrogenase, quinone 1	Mus musculus	60-91
10755406-2	2000	Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.	Dicumarol	27-37	NAD(P)H dehydrogenase, quinone 1	Mus musculus	93-97
10755406-12	2000	This activity, like NQO1, was inhibited by dicoumarol and immunologically related to NQO1.	Dicumarol	43-53	NAD(P)H dehydrogenase, quinone 1	Mus musculus	20-24
10755406-12	2000	This activity, like NQO1, was inhibited by dicoumarol and immunologically related to NQO1.	Dicumarol	43-53	NAD(P)H dehydrogenase, quinone 1	Mus musculus	85-89
10561120-5	1999	Dicumarol, a potent inhibitor of quinone oxidoreductase, at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin.	Dicumarol	0-9	crystallin zeta	Homo sapiens	33-55
10681517-3	2000	NQO1 expression directly correlated with sensitivity to a 4-h pulse of beta-lapachone in a panel of breast cancer cell lines, and the NQO1 inhibitor, dicoumarol, significantly protected NQO1-expressing cells from all aspects of beta-lapachone toxicity.	Dicumarol	150-160	NAD(P)H quinone dehydrogenase 1	Homo sapiens	134-138
10681517-3	2000	NQO1 expression directly correlated with sensitivity to a 4-h pulse of beta-lapachone in a panel of breast cancer cell lines, and the NQO1 inhibitor, dicoumarol, significantly protected NQO1-expressing cells from all aspects of beta-lapachone toxicity.	Dicumarol	150-160	NAD(P)H quinone dehydrogenase 1	Homo sapiens	134-138
10419545-11	1999	The binding orientations of dicoumarol, flavones, and phenindone in the active site of DT-diaphorase were predicted by results from our inhibitor-binding studies and computer modeling based on published X-ray structures.	Dicumarol	28-38	NAD(P)H quinone dehydrogenase 1	Homo sapiens	87-100
10470180-1	1999	BACKGROUND: The concentration of Des-gamma-carboxy-prothrombin (DCP) or PIVKA-II has been described to be increased in patients with hepatocellular cancer, along with its elevation in vitamin K deficient states by warfarin or dicoumarol treatment.	Dicumarol	226-236	angiotensin I converting enzyme	Homo sapiens	33-62
20654563-9	1999	Treatment of cells with dicoumarol, an inhibitor of DT-diaphorase activity, also decreased the toxicity of Cr VI, suggesting that this enzyme is involved in the intracellular reduction of the metal.	Dicumarol	24-34	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	52-65
10535745-2	1999	In mice pretreated with dicoumarol (30 mg/kg), an inhibitor of QR, hepatic necrosis caused by APAP (400 mg/kg) was potentiated.	Dicumarol	24-34	crystallin, zeta	Mus musculus	63-65
10535745-10	1999	In the presence of dicoumarol, however, QR activity was inhibited, and conversion of the toxic quinone metabolite back to APAP became inhibited and diminished the alcohol-dependent protective effect against APAP-induced hepatic injury.	Dicumarol	19-29	crystallin, zeta	Mus musculus	40-42
10531305-6	1999	Dicoumarol prevented SAPK activation in vivo by chemical cell stressors and also prevented SAPK activation induced by expression of the tumor necrosis factor alpha (TNFalpha) receptor-associated protein TRAF2 but not by expression of truncated active MEKK1.	Dicumarol	0-10	mitogen-activated protein kinase 9	Homo sapiens	21-25
10531305-6	1999	Dicoumarol prevented SAPK activation in vivo by chemical cell stressors and also prevented SAPK activation induced by expression of the tumor necrosis factor alpha (TNFalpha) receptor-associated protein TRAF2 but not by expression of truncated active MEKK1.	Dicumarol	0-10	mitogen-activated protein kinase 9	Homo sapiens	91-95
10531305-6	1999	Dicoumarol prevented SAPK activation in vivo by chemical cell stressors and also prevented SAPK activation induced by expression of the tumor necrosis factor alpha (TNFalpha) receptor-associated protein TRAF2 but not by expression of truncated active MEKK1.	Dicumarol	0-10	tumor necrosis factor	Homo sapiens	165-173
10531305-6	1999	Dicoumarol prevented SAPK activation in vivo by chemical cell stressors and also prevented SAPK activation induced by expression of the tumor necrosis factor alpha (TNFalpha) receptor-associated protein TRAF2 but not by expression of truncated active MEKK1.	Dicumarol	0-10	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	251-256
10531305-8	1999	Cells deficient in a major quinone reductase, NQO1, displayed hypersensitivity to dicoumarol stress inhibition, whereas SAPK in cells reconstituted with the NQO1 gene displayed relative dicoumarol resistance.	Dicumarol	82-92	NAD(P)H quinone dehydrogenase 1	Homo sapiens	46-50
10531305-8	1999	Cells deficient in a major quinone reductase, NQO1, displayed hypersensitivity to dicoumarol stress inhibition, whereas SAPK in cells reconstituted with the NQO1 gene displayed relative dicoumarol resistance.	Dicumarol	186-196	mitogen-activated protein kinase 9	Homo sapiens	120-124
10531305-8	1999	Cells deficient in a major quinone reductase, NQO1, displayed hypersensitivity to dicoumarol stress inhibition, whereas SAPK in cells reconstituted with the NQO1 gene displayed relative dicoumarol resistance.	Dicumarol	186-196	NAD(P)H quinone dehydrogenase 1	Homo sapiens	157-161
10531305-9	1999	Consistent with the proposed role of overlapping upstream signaling cascades in activation of NFkappaB, dicoumarol also blocked NFkappaB activation in primary macrophages stimulated with either lipopolysaccharide or TNFalpha.	Dicumarol	104-114	nuclear factor kappa B subunit 1	Homo sapiens	94-102
10531305-9	1999	Consistent with the proposed role of overlapping upstream signaling cascades in activation of NFkappaB, dicoumarol also blocked NFkappaB activation in primary macrophages stimulated with either lipopolysaccharide or TNFalpha.	Dicumarol	104-114	nuclear factor kappa B subunit 1	Homo sapiens	128-136
10531305-9	1999	Consistent with the proposed role of overlapping upstream signaling cascades in activation of NFkappaB, dicoumarol also blocked NFkappaB activation in primary macrophages stimulated with either lipopolysaccharide or TNFalpha.	Dicumarol	104-114	tumor necrosis factor	Homo sapiens	216-224
10531305-10	1999	In addition, dicoumarol strongly potentiated TNFalpha-induced apoptosis in HeLa cells, probably by blocking the anti-apoptotic effect of NFkappaB.	Dicumarol	13-23	tumor necrosis factor	Homo sapiens	45-53
10531305-10	1999	In addition, dicoumarol strongly potentiated TNFalpha-induced apoptosis in HeLa cells, probably by blocking the anti-apoptotic effect of NFkappaB.	Dicumarol	13-23	nuclear factor kappa B subunit 1	Homo sapiens	137-145
10531305-11	1999	The ability of dicoumarol to simultaneously inhibit SAPK and NFkappaB activation and to potentiate apoptotic cell death suggests that SAPK is not an obligate participant in apoptosis.	Dicumarol	15-25	mitogen-activated protein kinase 9	Homo sapiens	52-56
10531305-11	1999	The ability of dicoumarol to simultaneously inhibit SAPK and NFkappaB activation and to potentiate apoptotic cell death suggests that SAPK is not an obligate participant in apoptosis.	Dicumarol	15-25	nuclear factor kappa B subunit 1	Homo sapiens	61-69
10531305-12	1999	Dicoumarol, currently in clinical use as an oral anticoagulant, represents a potential therapeutic inhibitor of the SAPK and NFkappaB response.	Dicumarol	0-10	mitogen-activated protein kinase 9	Homo sapiens	116-120
10531305-12	1999	Dicoumarol, currently in clinical use as an oral anticoagulant, represents a potential therapeutic inhibitor of the SAPK and NFkappaB response.	Dicumarol	0-10	nuclear factor kappa B subunit 1	Homo sapiens	125-133
9882448-11	1999	Dicoumarol inhibited significantly TBE-R1 activity but not TBE-R2 activity.	Dicumarol	0-10	aldo-keto reductase family 1, member C12	Rattus norvegicus	35-41
9920282-4	1999	The HT-29 cell line was only vulnerable to NQ and MEN after inhibition of DT-diaphorase (DTD) with dicoumarol, whereas dicoumarol did not affect the toxicity of quinones to Caco-2 cells.	Dicumarol	99-109	NAD(P)H quinone dehydrogenase 1	Homo sapiens	74-87
9548807-7	1998	Wild type p53 induction by AZQ was suppressed when DT-diaphorase activity was inhibited by pretreating the cells with dicumarol.	Dicumarol	118-127	tumor protein p53	Homo sapiens	10-13
9685354-7	1998	Moreover, using inhibitors of GST (dicumarol) or MRP1 (sulfinpyrazone), it was shown that in MCF7 cells resistance to chlorambucil requires both intact MRP1-dependent efflux pump activity and, for full protection, GST A1-1 catalytic activity.	Dicumarol	35-44	ATP binding cassette subfamily B member 1	Homo sapiens	152-156
9703365-10	1998	Treatment of the cells with dicumarol, an inhibitor of DT-diaphorase, reduced the cytotoxicity of FK317 to Lu99 cells, but not to Lu99/317 cells.	Dicumarol	28-37	NAD(P)H quinone dehydrogenase 1	Homo sapiens	55-68
9548807-7	1998	Wild type p53 induction by AZQ was suppressed when DT-diaphorase activity was inhibited by pretreating the cells with dicumarol.	Dicumarol	118-127	NAD(P)H quinone dehydrogenase 1	Homo sapiens	51-64
9367528-12	1997	NQO2 is resistant to typical inhibitors of DT-diaphorase, such as dicumarol, Cibacron blue, and phenindone.	Dicumarol	66-75	N-ribosyldihydronicotinamide:quinone reductase 2	Homo sapiens	0-4
9572303-3	1998	This LY 83583-dependent staining could be blocked by the NAD(P)H:quinone oxidoreductase inhibitor dicumarol.	Dicumarol	98-107	crystallin zeta	Homo sapiens	65-87
9572303-5	1998	Transfection of human embryonic kidney 293 cells with the rat liver isoform of NAD(P)H:quinone oxidoreductase resulted in robust NADPH- and LY 83583-dependent staining that was completely blocked by dicumarol and was not observed in untransfected cells.	Dicumarol	199-208	crystallin zeta	Rattus norvegicus	87-109
9536516-9	1998	Dicumarol (an inhibitor of DT diaphorase) enhanced the capacity of menadione to induce Hep 3B cell degeneration from 71.3% to 86.2% after 120 min of menadione treatment at 37 degrees C, but did not have this effect in Hep G2, CCRF-CEM or MOLT-3 cells.	Dicumarol	0-9	NAD(P)H quinone dehydrogenase 1	Homo sapiens	27-40
9473494-4	1998	In sepiapterin-supplemented cells, iNOS protein levels were increased while in dicumarol-treated cells, iNOS levels were diminished.	Dicumarol	79-88	nitric oxide synthase 2	Rattus norvegicus	104-108
9473494-8	1998	The decrease of iNOS mRNA by dicumarol was abolished by sepiapterin.	Dicumarol	29-38	nitric oxide synthase 2	Rattus norvegicus	16-20
9528687-5	1998	In the present study, rats were treated with dicoumarol, an inhibitor of DT-diaphorase, or butylated hydroxyanisole (BHA), a substance that increases the activity of this enzyme in vivo.	Dicumarol	45-55	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	73-86
9266502-6	1997	The role of DT-diaphorase in the antioxidant activity of CoQ was demonstrated by the co-incorporation of dicoumarol (dic), a potent inhibitor of DT-diaphorase, resulting in a loss of protection by incorporated CoQ10.	Dicumarol	105-115	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	12-25
9343369-7	1997	The toxicity of nitrobenzimidazoles to bovine leukemia virus-transformed lamb kidney fibroblasts (line FLK) with a moderate amount of DT-diaphorase (260 U/mg protein) is partly prevented by dicumarol.	Dicumarol	190-199	NAD(P)H quinone dehydrogenase 1	Homo sapiens	134-147
23889067-7	1997	Incubation of rat hepatocytes with ethanol or lactate (increase NADH levels), dicoumarol (inhibitor of DT-diaphorase), aminopyrine or hexobarbitone (substrates for the NADPH-requiring cytochrome P450-dependent microsomal monooxygenase) led to significant increases in the level of cellular MTT reduction.	Dicumarol	78-88	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	103-116
23889067-9	1997	It is also possible that cellular generation of superoxide (as might be expected on redox cycling of endogenous quinones following inhibition of DT diaphorase by dicoumarol) may be another source of MTT reduction.	Dicumarol	162-172	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	145-158
9045901-7	1997	Dicumarol, an inhibitor of DT-diaphorase, decreased PFM uptake and reduced the growth-inhibitory action of MMC in AH130/P cells.	Dicumarol	0-9	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	27-40
9343369-2	1997	Nitrobenzimidazoles were competitive with NADPH inhibitors of DT-diaphorase in menadione reductase reactions, their inhibition constant being unchanged in the presence of dicumarol and being increased in the presence of 2",5"-ADP.	Dicumarol	171-180	NAD(P)H quinone dehydrogenase 1	Homo sapiens	62-75
9343369-2	1997	Nitrobenzimidazoles were competitive with NADPH inhibitors of DT-diaphorase in menadione reductase reactions, their inhibition constant being unchanged in the presence of dicumarol and being increased in the presence of 2",5"-ADP.	Dicumarol	171-180	NAD(P)H quinone dehydrogenase 1	Homo sapiens	79-98
9310146-6	1997	When pretreated with the DT diaphorase inhibitor dicoumarol, HepG2 cells exhibited an exacerbation of genotoxicity in the presence of 4NQ, indicating a protective influence of the enzyme.	Dicumarol	49-59	NAD(P)H quinone dehydrogenase 1	Homo sapiens	25-38
9310146-7	1997	In contrast, 4NQ genotoxicity in BB cells was reduced in the presence of dicoumarol, indicating a deleterious effect of DT diaphorase activity.	Dicumarol	73-83	NAD(P)H quinone dehydrogenase 1	Homo sapiens	120-133
9324955-0	1997	Measurement of dicumarol-sensitive NADPH: (menadione-cytochrome c) oxidoreductase activity results in an artifactual assay of DT-diaphorase in cell sonicates.	Dicumarol	15-24	cytochrome c, somatic	Homo sapiens	53-65
9324955-0	1997	Measurement of dicumarol-sensitive NADPH: (menadione-cytochrome c) oxidoreductase activity results in an artifactual assay of DT-diaphorase in cell sonicates.	Dicumarol	15-24	thioredoxin reductase 1	Homo sapiens	67-81
9324955-0	1997	Measurement of dicumarol-sensitive NADPH: (menadione-cytochrome c) oxidoreductase activity results in an artifactual assay of DT-diaphorase in cell sonicates.	Dicumarol	15-24	NAD(P)H quinone dehydrogenase 1	Homo sapiens	126-139
9324955-1	1997	Purified DT-diaphorase can be assayed as either dicumarol-inhibitable NAD(P)H:menadione oxidoreductase or dicumarol-inhibitable NAD(P)H:dichlorophenolindophenol reductase.	Dicumarol	48-57	NAD(P)H quinone dehydrogenase 1	Homo sapiens	9-22
9324955-1	1997	Purified DT-diaphorase can be assayed as either dicumarol-inhibitable NAD(P)H:menadione oxidoreductase or dicumarol-inhibitable NAD(P)H:dichlorophenolindophenol reductase.	Dicumarol	106-115	NAD(P)H quinone dehydrogenase 1	Homo sapiens	9-22
9324955-3	1997	When DT-diaphorase activity was measured as dicumarol-inhibitable NADPH:dichlorophenolindophenol reductase in sonicates of two cell lines previously shown to not have any measurable activity of this enzyme, no enzymatic activity was detected.	Dicumarol	44-53	NAD(P)H quinone dehydrogenase 1	Homo sapiens	5-18
9163701-8	1997	NADH consumption was accompanied by dicumarol-sensitive oxygen uptake both with the purified enzyme and with cytosol from human melanoma cells with high levels of DT-diaphorase activity.	Dicumarol	36-45	NAD(P)H quinone dehydrogenase 1	Homo sapiens	163-176
9050836-9	1997	Recombinant human QR2: (i) reacts with N-ribosyl- and N-alkyldihydronicotinamides, but not with NADH, NADPH, or NMNH; (ii) is very weakly inhibited by dicumarol or Cibacron blue; (iii) is very potently inhibited by benzo[a]pyrene.	Dicumarol	151-160	N-ribosyldihydronicotinamide:quinone reductase 2	Homo sapiens	18-21
9275022-6	1997	The cytotoxicity of BMS-181174, however, was not affected in either cell line by pretreatment with dicoumarol, which is an inhibitor of DT-diaphorase activity.	Dicumarol	99-109	NAD(P)H quinone dehydrogenase 1	Homo sapiens	136-149
9054588-6	1997	In the presence of dicoumarol, a DT-diaphorase inhibitor, the damage was detected at concentrations five times lower indicating that free radicals generated during the redox cycling play a key role.	Dicumarol	19-29	NAD(P)H quinone dehydrogenase 1	Homo sapiens	33-46
9266502-6	1997	The role of DT-diaphorase in the antioxidant activity of CoQ was demonstrated by the co-incorporation of dicoumarol (dic), a potent inhibitor of DT-diaphorase, resulting in a loss of protection by incorporated CoQ10.	Dicumarol	105-115	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	145-158
8763837-7	1996	The DT-diaphorase inhibitor, dicoumarol, inhibited the effect of D3T on the antitumour activity of the bioreductive agents, supporting the proposal that the enhanced anticancer activity was due to the elevated enzyme level.	Dicumarol	29-39	NAD(P)H dehydrogenase, quinone 1	Mus musculus	4-17
8837752-5	1996	These inhibitions were abolished by dicoumarol, an inhibitor of DT-diaphorase.	Dicumarol	36-46	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	64-77
8883403-2	1996	At present, there is no validated assay reported in the literature for measuring the activity of B5R in tumour cells, and current measurements have assumed that the enzyme activity can be measured either as the NADH-dependent reduction of cytochrome c or as the non-dicoumarol-inhibitable activity in the DT-diaphorase assay.	Dicumarol	266-276	cytochrome b5 reductase 3	Homo sapiens	97-100
8883403-6	1996	We also found that the non-dicoumarol-inhibitable activity in the DT-diaphorase assay underestimated B5R activity, especially in cell lines with high DT-diaphorase activity.	Dicumarol	27-37	NAD(P)H quinone dehydrogenase 1	Homo sapiens	66-79
8883403-6	1996	We also found that the non-dicoumarol-inhibitable activity in the DT-diaphorase assay underestimated B5R activity, especially in cell lines with high DT-diaphorase activity.	Dicumarol	27-37	cytochrome b5 reductase 3	Homo sapiens	101-104
8883403-6	1996	We also found that the non-dicoumarol-inhibitable activity in the DT-diaphorase assay underestimated B5R activity, especially in cell lines with high DT-diaphorase activity.	Dicumarol	27-37	NAD(P)H quinone dehydrogenase 1	Homo sapiens	150-163
8806780-6	1996	Surprisingly, the dicumarol-inhibitable quinoid detoxification enzyme DT-diaphorase was a significant source of phthiocol and pyocyanine-mediated O2.- generation in cells.	Dicumarol	18-27	NAD(P)H quinone dehydrogenase 1	Homo sapiens	70-83
8687482-2	1996	Many cell lines that overexpress DT-diaphorase and are sensitive to the mitomycins are protected from the aerobic cytotoxicity of these drugs by the DT-diaphorase inhibitor dicumarol.	Dicumarol	173-182	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	33-46
8687482-2	1996	Many cell lines that overexpress DT-diaphorase and are sensitive to the mitomycins are protected from the aerobic cytotoxicity of these drugs by the DT-diaphorase inhibitor dicumarol.	Dicumarol	173-182	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	149-162
8637908-9	1996	The incorporation of dicoumarol, a potent inhibitor of DT-diaphorase, interfered with the protection provided by CoQ.	Dicumarol	21-31	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	55-68
8657209-6	1996	When pretreated with the DT diaphorase inhibitor, dicoumarol, HepG2 cells exhibited a marked exacerbation of genotoxicity in the presence of either MND or PQ, indicating protective influence of the enzyme.	Dicumarol	50-60	NAD(P)H quinone dehydrogenase 1	Homo sapiens	25-38
8536688-9	1995	This and the above properties suggest some relationship of NAD(P)H-QR to DT-diaphorase, an animal flavoprotein which, however, has distinct structural properties and is strongly inhibited by dicumarol.	Dicumarol	191-200	2,4-dienoyl-CoA reductase 1	Homo sapiens	59-66
8536688-9	1995	This and the above properties suggest some relationship of NAD(P)H-QR to DT-diaphorase, an animal flavoprotein which, however, has distinct structural properties and is strongly inhibited by dicumarol.	Dicumarol	191-200	NAD(P)H quinone dehydrogenase 1	Homo sapiens	73-86
7531691-10	1995	The results suggest that DT-diaphorase shows the same properties as the C-C transhydrogenases, and the binding of dicumarol elicits a conformational change or an adjustment in the polarity of the FAD pocket.	Dicumarol	114-123	NAD(P)H quinone dehydrogenase 1	Homo sapiens	25-38
7536024-3	1995	DNA cross-link formation by EO9 following DT-diaphorase reduction was completely inhibited by addition 10 microM dicoumarol, whereas only a minor effect of dicoumarol on xanthine oxidase-mediated DNA cross-linking by EO9 was observed.	Dicumarol	113-123	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	42-55
7710944-4	1995	By contrast, dicoumarol, a DT-diaphorase inhibitor, markedly increased tirapazamine-induced cytotoxicity.	Dicumarol	13-23	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	27-40
21552905-6	1995	The IC50 value of PC-9 against EO9 was significantly increased by co-incubation with dicumarol under oxic conditions.	Dicumarol	85-94	proprotein convertase subtilisin/kexin type 9	Homo sapiens	18-22
7677784-2	1995	However, these conclusions have mainly been drawn from the experiments using the DT-diaphorase inhibitor, dicoumarol.	Dicumarol	106-116	NAD(P)H dehydrogenase, quinone 1	Mus musculus	81-94
7541730-8	1995	Studies with the enzyme inhibitors, dicoumarol (inhibits DT-diaphorase) and metyrapone (inhibits cytochrome P450), indicate that at least two reactive species are involved in mitoxantrone cytotoxicity.	Dicumarol	36-46	NAD(P)H quinone dehydrogenase 1	Homo sapiens	57-70
7537551-0	1995	Induction of diaphorase-1 by dicoumarol in Drosophila virilis larvae.	Dicumarol	29-39	Dvir\Dia1	Drosophila virilis	13-25
7790319-8	1995	Addition of dicumarol resulted in a two-fold increase in IC50 value in PC-9, whereas the IC50 value showed no change in PC-9/MC4.	Dicumarol	12-21	proprotein convertase subtilisin/kexin type 9	Homo sapiens	71-75
7537551-1	1995	Drosophila diaphorase-1 (DIA-1) is an enzyme similar to mammalian DT-diaphorase and is inhibited in vitro by dicoumarol.	Dicumarol	109-119	cytochrome b5 reductase 3	Homo sapiens	11-23
7537551-1	1995	Drosophila diaphorase-1 (DIA-1) is an enzyme similar to mammalian DT-diaphorase and is inhibited in vitro by dicoumarol.	Dicumarol	109-119	cytochrome b5 reductase 3	Homo sapiens	25-30
7537551-1	1995	Drosophila diaphorase-1 (DIA-1) is an enzyme similar to mammalian DT-diaphorase and is inhibited in vitro by dicoumarol.	Dicumarol	109-119	NAD(P)H quinone dehydrogenase 1	Homo sapiens	66-79
7537551-2	1995	However, a ten-fold increase in DIA-1 activity was observed when third instar Drosophila virilis larvae were fed on a diet containing 0.1 M dicoumarol for 48 h. This induction was shown to be dose dependent and immunoprecipitation experiments with DIA-1 anti-serum demonstrated an increase in the DIA-1 protein level in dicoumarol-treated larvae.	Dicumarol	140-150	Dvir\Dia1	Drosophila virilis	32-37
8572925-10	1995	The protective effect of ALD was significantly reduced by dicoumarol, a QR-specific inhibitor.	Dicumarol	58-68	crystallin zeta	Homo sapiens	72-74
7537551-2	1995	However, a ten-fold increase in DIA-1 activity was observed when third instar Drosophila virilis larvae were fed on a diet containing 0.1 M dicoumarol for 48 h. This induction was shown to be dose dependent and immunoprecipitation experiments with DIA-1 anti-serum demonstrated an increase in the DIA-1 protein level in dicoumarol-treated larvae.	Dicumarol	140-150	Dvir\Dia1	Drosophila virilis	248-253
7537551-2	1995	However, a ten-fold increase in DIA-1 activity was observed when third instar Drosophila virilis larvae were fed on a diet containing 0.1 M dicoumarol for 48 h. This induction was shown to be dose dependent and immunoprecipitation experiments with DIA-1 anti-serum demonstrated an increase in the DIA-1 protein level in dicoumarol-treated larvae.	Dicumarol	140-150	Dvir\Dia1	Drosophila virilis	248-253
7537551-2	1995	However, a ten-fold increase in DIA-1 activity was observed when third instar Drosophila virilis larvae were fed on a diet containing 0.1 M dicoumarol for 48 h. This induction was shown to be dose dependent and immunoprecipitation experiments with DIA-1 anti-serum demonstrated an increase in the DIA-1 protein level in dicoumarol-treated larvae.	Dicumarol	320-330	Dvir\Dia1	Drosophila virilis	32-37
7537551-3	1995	The induction of DIA1 by dicoumarol was found to be blocked by actinomycin D, which suggests a transcriptional mechanism of regulation.	Dicumarol	25-35	Dvir\Dia1	Drosophila virilis	17-21
7537551-4	1995	The opposite effect of dicoumarol on DIA-1 in vitro vs. in vivo suggests that a metabolic conversion takes place after the ingestion of this compound by D. virilis larvae.	Dicumarol	23-33	Dvir\Dia1	Drosophila virilis	37-42
21559647-6	1994	The IC50 value of PC-9 against MMC significantly decreased by co-incubation with dicumarol under aerobic, but not under hypoxic conditions.	Dicumarol	81-90	proprotein convertase subtilisin/kexin type 9	Homo sapiens	18-22
7927920-8	1994	Addition of dicumarol, an inhibitor of DTD, decreased the sensitivity of ADM of PC-9 but not of PC-9/MC4.	Dicumarol	12-21	proprotein convertase subtilisin/kexin type 9	Homo sapiens	80-84
7927920-9	1994	DTD activity in the PC-9 cell line was inhibited by treatment with dicumarol while in PC-9/MC4 it remained unchanged.	Dicumarol	67-76	proprotein convertase subtilisin/kexin type 9	Homo sapiens	20-24
7526885-11	1994	Moreover, this correlation was lost when cells were exposed to drug in the presence of dicoumarol, supporting an involvement of DT-diaphorase in this relationship.	Dicumarol	87-97	NAD(P)H quinone dehydrogenase 1	Homo sapiens	128-141
8077054-5	1994	Further support is indicated by: 1) reduction in the differential in toxicity between the 2 cell lines by BMY 25282; and 2) a higher effect of DT-diaphorase inhibitor dicumarol on the wild-type cells compared with J82/MMC.	Dicumarol	167-176	NAD(P)H quinone dehydrogenase 1	Homo sapiens	143-156
7982895-5	1994	No generation of oxygen radicals in the NAD(P)H-menadione reductase reaction by cytosol was found, and the activity was abolished in the presence of dicoumarol, an inhibitor of DT-diaphorase.	Dicumarol	149-159	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	177-190
7966357-6	1994	Both dicumarol (an inhibitor of DT-diaphorase) and diethyldithiocarbamate (an inhibitor of superoxide dismutase) enhanced the capacity of menadione to induce cellular damage and to cause depletion of intracellular glutathione.	Dicumarol	5-14	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	32-45
7527260-10	1994	Although mouse quinone reductase has an amino acid sequence similar to those of the rat and human enzymes, the mouse enzyme has a higher NAD(P)H-menadione reductase activity and is less sensitive to flavones and dicoumarol, 2 known inhibitors of the enzyme.	Dicumarol	212-222	crystallin, zeta	Mus musculus	15-32
7982895-10	1994	44, 489-493] and this activity was also inhibited by dicoumarol, suggesting that it was due to DT-diaphorase.	Dicumarol	53-63	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	95-108
7510954-3	1994	Using the sepiapterin reductase inhibitors phenprocoumon or dicumarol as BH4 synthesis inhibitors, we achieved a pronounced and selective suppression of induced NO production in cytokine-activated endothelial cells.	Dicumarol	60-69	sepiapterin reductase	Mus musculus	10-31
7505009-3	1993	Pretreatment of the cells with dicoumarol, an inhibitor of DT-diaphorase, enhanced the cytotoxicity of 1,4-naphthoquinone but not of the hydroxylated naphthoquinones.	Dicumarol	31-41	NAD(P)H quinone dehydrogenase 1	Homo sapiens	59-72
8216372-4	1993	Whereas NAD(P)H:quinone reductase (NAD(P)H:(quinone acceptor) oxidoreductase; DT diaphorase; EC 1.6.99.2) was the predominant 4NQO reductase present in liver cytosol from Sprague-Dawley rats, dicumarol-resistant NADH:4NQO nitroreductase specific activities were comparable with those of mouse liver cytosols.	Dicumarol	192-201	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	78-91
8262670-7	1994	DT-diaphorase-deficient BE cells show markedly increased sensitivity to mitomycin C and particularly EO9 in hypoxic conditions, whereas DT-diaphorase-rich HT29 cells show little hypoxic sensitization to these agents unless exposed in the presence of dicoumarol.	Dicumarol	250-260	NAD(P)H quinone dehydrogenase 1	Homo sapiens	0-13
7946565-3	1994	The role of DT-diaphorase in determining drug sensitivity was confirmed by using the enzyme inhibitor dicoumarol, which protects cells containing high levels of DT-diaphorase from the cytotoxic action of EO9.	Dicumarol	102-112	NAD(P)H quinone dehydrogenase 1	Homo sapiens	12-25
7946565-3	1994	The role of DT-diaphorase in determining drug sensitivity was confirmed by using the enzyme inhibitor dicoumarol, which protects cells containing high levels of DT-diaphorase from the cytotoxic action of EO9.	Dicumarol	102-112	NAD(P)H quinone dehydrogenase 1	Homo sapiens	161-174
8268208-6	1993	This observed activity was sensitive to dicumarol, a potent inhibitor of quinone reductase activity.	Dicumarol	40-49	crystallin, zeta	Mus musculus	73-90
7685584-6	1993	When DT-diaphorase activity was inhibited by non-toxic dicoumarol (50 microM), DNA damage and cytotoxic activity induced by MMC were decreased in all cells examined.	Dicumarol	55-65	NAD(P)H quinone dehydrogenase 1	Homo sapiens	5-18
7690996-6	1993	At concentrations of dicumarol that completely block NMO1 and GSTA1 activities, the 14CoS/14CoS cells show more than twice as much resistance to menadione toxicity than the ch/ch cells.	Dicumarol	21-30	NAD(P)H dehydrogenase, quinone 1	Mus musculus	53-57
7690996-6	1993	At concentrations of dicumarol that completely block NMO1 and GSTA1 activities, the 14CoS/14CoS cells show more than twice as much resistance to menadione toxicity than the ch/ch cells.	Dicumarol	21-30	glutathione S-transferase, alpha 1 (Ya)	Mus musculus	62-67
7684532-4	1993	Cells grown in serum from cows treated with dicoumarol produce about 20% more prothrombin in 24 h than those cells grown in control serum.	Dicumarol	44-54	coagulation factor II, thrombin	Bos taurus	78-89
7684532-5	1993	The humoral factor causing this response is present early in the course of dicoumarol treatment, and the increase in prothrombin production is dependent on the amount of serum from a dicoumarol-treated cow in the media.	Dicumarol	183-193	coagulation factor II, thrombin	Bos taurus	117-128
1281039-0	1992	Enhancement of xanthine dehydrogenase mediated mitomycin C metabolism by dicumarol.	Dicumarol	73-82	xanthine dehydrogenase	Homo sapiens	15-37
8461317-6	1993	Also, dicumarol treatment, which markedly depressed DT-diaphorase activity, did not diminish the hyperoxic survival rate in an O2-tolerant adult rat model.	Dicumarol	6-15	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	52-65
1472082-9	1992	7-Deoxyaglycone metabolite formation by purified cytochrome P450 reductase had an absolute requirement for NADPH as co-factor, was inhibited by molecular oxygen and dicoumarol (IC50 approx.	Dicumarol	165-175	cytochrome p450 oxidoreductase	Rattus norvegicus	49-74
1280990-5	1992	Dicoumarol, an inhibitor of DT-diaphorase, was shown to cause only small reductions in misonidazole binding to oesophageal epithelium and smooth muscle in vitro and to EMT6 tumours, liver, oesophageal and tracheal epithelium, parotid gland and smooth muscle in vivo.	Dicumarol	0-10	NAD(P)H dehydrogenase, quinone 1	Mus musculus	28-41
7505723-3	1993	Treatment of the cells with dicoumarol, an inhibitor of DT-diaphorase, reduced the cytotoxicity of MMC in DT-diaphorase proficient HT-29 cells but not in HT-29/MMC cells.	Dicumarol	28-38	NAD(P)H quinone dehydrogenase 1	Homo sapiens	56-69
7505723-3	1993	Treatment of the cells with dicoumarol, an inhibitor of DT-diaphorase, reduced the cytotoxicity of MMC in DT-diaphorase proficient HT-29 cells but not in HT-29/MMC cells.	Dicumarol	28-38	NAD(P)H quinone dehydrogenase 1	Homo sapiens	106-119
1281039-1	1992	These studies examined the effect of dicumarol on xanthine dehydrogenase (XDH), an enzyme recently shown to bioreduce mitomycin C.	Dicumarol	37-46	xanthine dehydrogenase	Homo sapiens	50-72
1281039-1	1992	These studies examined the effect of dicumarol on xanthine dehydrogenase (XDH), an enzyme recently shown to bioreduce mitomycin C.	Dicumarol	37-46	xanthine dehydrogenase	Homo sapiens	74-77
1281039-2	1992	Dicumarol, which has previously been shown to inhibit xanthine oxidase (XO), inhibited both XDH and XO mediated conversion of xanthine to uric acid but potentiated the metabolism of mitomycin C by XDH and XO.	Dicumarol	0-9	xanthine dehydrogenase	Homo sapiens	92-95
1281039-2	1992	Dicumarol, which has previously been shown to inhibit xanthine oxidase (XO), inhibited both XDH and XO mediated conversion of xanthine to uric acid but potentiated the metabolism of mitomycin C by XDH and XO.	Dicumarol	0-9	xanthine dehydrogenase	Homo sapiens	197-200
1281039-3	1992	Formation of 2,7-diaminomitosene following mitomycin C bioactivation by XDH was increased 3-fold aerobically and 4-fold hypoxically when 20 microM dicumarol was included in the reaction mixture.	Dicumarol	147-156	xanthine dehydrogenase	Homo sapiens	72-75
1382426-1	1992	Dicumarol, often used as a specific inhibitor of DT diaphorase (NAD(P)H:(quinone-acceptor) oxidoreductase; EC 1.6.99.2), was found to potently inhibit GSH transferases (EC 2.5.1.18).	Dicumarol	0-9	NAD(P)H dehydrogenase, quinone 1	Mus musculus	49-62
1382426-7	1992	Whereas several other non-substrate ligands were more potent inhibitors of 1-chloro-2,4-dinitrobenzene conjugation, dicumarol effectively inhibited GSH transferase and GSH peroxidase II activities in the range of dicumarol concentrations frequently used for detection of DT diaphorase action.	Dicumarol	116-125	NAD(P)H dehydrogenase, quinone 1	Mus musculus	271-284
1382426-8	1992	These results indicate that physiological consequences resulting from the use of supramicromolar concentrations of dicumarol should not be interpreted in terms of DT diaphorase inhibition alone.	Dicumarol	115-124	NAD(P)H dehydrogenase, quinone 1	Mus musculus	163-176
1544832-5	1992	Enzyme activity was measured spectrophotometrically by dicoumarol inhibitable cytochrome c reduction in the presence of drug, and aerobic cytotoxicity was assessed by the MTT assay.	Dicumarol	55-65	cytochrome c, somatic	Homo sapiens	78-90
1379126-2	1992	The cytosol-dependent decrease in chromium(VI) mutagenicity was found to be counteracted in the presence of dicumarol, an inhibitor of the cytosolic enzyme NAD(P)H:quinone oxidoreductase (DT-diaphorase).	Dicumarol	108-117	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	188-201
1379126-7	1992	Inhibition of 90% of the cytosolic DT-diaphorase activity by dicumarol led to only partial (20-22%) inhibition of chromium(V) formation.	Dicumarol	61-70	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	35-48
1375532-6	1992	Inhibition of hepatocyte DT-diaphorase by dicumarol increased trenimon-induced cytotoxicity by approximately 10-fold, and markedly inhibited hydroquinone formation.	Dicumarol	42-51	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	25-38
1375532-11	1992	Inactivation of hepatocyte DT-diaphorase by dicumarol under hypoxic conditions increased trenimon-induced cytotoxicity by approximately 3.5-fold and increased semiquinone radical levels 2-fold without affecting its reduction rate.	Dicumarol	44-53	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	27-40
1370822-7	1992	Dicumarol, an inhibitor of quinone acceptor oxidoreductase, decreased the production of the hydroxyl radical and attenuated DNA strand breaks in MCF-7 cells treated with MD.	Dicumarol	0-9	thioredoxin reductase 1	Homo sapiens	44-58
1371615-11	1992	Additionally, dicoumarol, an inhibitor of QR activity, potentiated HQ-induced toxicity in both strains of bone marrow stromal cells.	Dicumarol	14-24	crystallin, zeta	Mus musculus	42-44
1371987-3	1992	Inhibition of DT-diaphorase by dicoumarol markedly inhibited the cytotoxic activity of trenimon to the resistant L5178Y/HBM10 cells.	Dicumarol	31-41	NAD(P)H dehydrogenase, quinone 1	Mus musculus	14-27
1373799-4	1992	In L5178Y/HBM10 cells, dicoumarol, an inhibitor of DT-diaphorase, decreased cell kill and DNA cross-linking by mitomycin C in air but had no significant effect on these activities under hypoxia.	Dicumarol	23-33	NAD(P)H dehydrogenase, quinone 1	Mus musculus	51-64
20732090-7	1992	Dicumarol (10 mum), an inhibitor of quinone oxidoreductase, had only a small effect on the production of resorufin by the LS174T cell line (111% of control).	Dicumarol	0-9	crystallin zeta	Homo sapiens	36-58
1377439-8	1992	Formation of metabolites M1 and M2 was inhibited completely by dicumarol (10(-4) M), an inhibitor of DT-diaphorase.	Dicumarol	63-72	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	101-114
1939124-15	1991	Photoaffinity labeling and protection experiments carried out on purified preparations of L-FABP paralleled the labeling results obtained in the microsomes and cytosol, confirming that L-FABP is capable of specifically binding AzBHC, warfarin, and dicoumarol.	Dicumarol	248-258	fatty acid binding protein 1	Rattus norvegicus	185-191
1893498-4	1991	Concerning the reduction mechanism by PB-3c cells we can see that superoxide dismutase (SOD) has no influence on the rate of reduction, but dicumarol almost completely inhibits the reduction at a concentration greater than 1 x 10(-6) M. Therefore, it can be concluded that CV-6504 is reduced mainly by two electron donating enzymes without the intermediary of a semiquinone radical and that the resulting hydroquinone inhibits lipid peroxidation as well as 5-lipoxygenase activity.	Dicumarol	140-149	arachidonate 5-lipoxygenase	Mus musculus	457-471
1874176-1	1991	A water-soluble quinone, coenzyme Q0 (CoQ0), was shown to stimulate insulin release, and dicumarol, an inhibitor of quinone reductase, inhibited glucose-induced insulin release in pancreatic islets.	Dicumarol	89-98	insulin	Homo sapiens	161-168
1874176-4	1991	The relative rates of activity with various substrates (CoQ0 approximately equal to durohydroquinone greater than menadione greater than duroquinone greater than CoQ6 = CoQ10 greater than ferricyanide) were similar to those described previously for quinone reductase from liver Dicumarol, chlorpromazine, and T3 were much more potent inhibitors of the enzyme when NADPH was the coenzyme than when NADH was the coenzyme.	Dicumarol	278-287	coenzyme Q6, monooxygenase	Homo sapiens	162-166
1720333-7	1991	Dicumarol, an inhibitor of quinone reductase, did not inhibit CoQ0-induced insulin release, but it did inhibit glucose-induced insulin release suggesting that the enzyme and quinones play a role in glucose-induced insulin release.	Dicumarol	0-9	insulin	Homo sapiens	127-134
1720333-7	1991	Dicumarol, an inhibitor of quinone reductase, did not inhibit CoQ0-induced insulin release, but it did inhibit glucose-induced insulin release suggesting that the enzyme and quinones play a role in glucose-induced insulin release.	Dicumarol	0-9	insulin	Homo sapiens	127-134
1703398-6	1990	The expressed DT-diaphorase exhibited high activity of menadione reduction and was inhibited by dicumarol at a concentration of 10(-5)M. After purification by Cibacron Blue affinity chromatography, the expressed enzyme migrated as a single band on 12.5% sodium dodecyl sulfate-polyacrylamide gel with a molecular weight equivalent to that of the purified rat liver cytosolic DT-diaphorase.	Dicumarol	96-105	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	14-27
1902110-6	1991	Dicumarol, an inhibitor of the quinone reductase DT-diaphorase (EC 1.6.99.2), decreased aerobic drug accumulation and cytotoxicity in the control cell strain, but did not alter the lack of accumulation noted in the resistant cell strain.	Dicumarol	0-9	NAD(P)H quinone dehydrogenase 1	Homo sapiens	49-62
1718826-0	1991	A note on the inhibition of DT-diaphorase by dicoumarol.	Dicumarol	45-55	NAD(P)H quinone dehydrogenase 1	Homo sapiens	28-41
1718826-7	1991	The variable inhibition of DT-diaphorase by dicoumarol dependent on the efficiency of the electron acceptor can be explained on the basis of the complete rate equation describing its ping pong type kinetic mechanism.	Dicumarol	44-54	NAD(P)H quinone dehydrogenase 1	Homo sapiens	27-40
1718826-8	1991	Thus, the concentration of dicoumarol used to inhibit DT-diaphorase must be chosen carefully and consideration should be given to the efficiency of the electron acceptor.	Dicumarol	27-37	NAD(P)H quinone dehydrogenase 1	Homo sapiens	54-67
1718826-10	1991	Although higher doses of dicoumarol may be required to inhibit DT-diaphorase mediated metabolism of less efficient electron acceptors, the use of such doses in cells may also affect biochemical processes other than DT-diaphorase and should be approached with caution.	Dicumarol	25-35	NAD(P)H quinone dehydrogenase 1	Homo sapiens	63-76
1701687-2	1990	The addition of dicoumarol (10(-4) M-3 x 10(-4) M), a specific inhibitor of DT diaphorase, resulted in an intensification of the cytotoxicity of menadione, supporting the hypothesis that DT diaphorase protects cells against the oxidative stress induced by quinones.	Dicumarol	16-26	NAD(P)H quinone dehydrogenase 1	Homo sapiens	76-89
1701687-2	1990	The addition of dicoumarol (10(-4) M-3 x 10(-4) M), a specific inhibitor of DT diaphorase, resulted in an intensification of the cytotoxicity of menadione, supporting the hypothesis that DT diaphorase protects cells against the oxidative stress induced by quinones.	Dicumarol	16-26	NAD(P)H quinone dehydrogenase 1	Homo sapiens	187-200
1701687-3	1990	On the other hand, the toxicity of 4NQO was greatly reduced by the addition of dicoumarol (10(-5) M-3 x 10(-4) M), showing that DT diaphorase is the key (or the sole) enzyme involved in the activation of 4NQO in the above cells.	Dicumarol	79-89	NAD(P)H quinone dehydrogenase 1	Homo sapiens	128-141
1703398-6	1990	The expressed DT-diaphorase exhibited high activity of menadione reduction and was inhibited by dicumarol at a concentration of 10(-5)M. After purification by Cibacron Blue affinity chromatography, the expressed enzyme migrated as a single band on 12.5% sodium dodecyl sulfate-polyacrylamide gel with a molecular weight equivalent to that of the purified rat liver cytosolic DT-diaphorase.	Dicumarol	96-105	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	375-388
1768430-10	1991	Pyrazole, progesterone and phenobarbital did not inhibit, whereas dicoumarol, rutin and indomethacin inhibited NQR activity in murine skin and liver as well as in human keratinocytes.	Dicumarol	66-76	crystallin zeta	Homo sapiens	111-114
2113029-2	1990	The reaction is strongly inhibited by dicoumarol, a classical inhibitor of DT-diaphorase.	Dicumarol	38-48	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	75-88
2121335-1	1990	Reduction of 2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone (diaziquone; AZQ) by purified rat hepatic DT-diaphorase was NADH and enzyme dependent and was inhibited by prior boiling of the enzyme or by dicumarol.	Dicumarol	214-223	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	115-128
2121335-5	1990	AZQ (0-20 microM) induced dicumarol-inhibitable DNA interstrand cross-linking and cytotoxicity in HT-29 human colon carcinoma cells which have high DT-diaphorase activity but not in BE cells which have low DT-diaphorase activity.	Dicumarol	26-35	NAD(P)H quinone dehydrogenase 1	Homo sapiens	148-161
2121335-5	1990	AZQ (0-20 microM) induced dicumarol-inhibitable DNA interstrand cross-linking and cytotoxicity in HT-29 human colon carcinoma cells which have high DT-diaphorase activity but not in BE cells which have low DT-diaphorase activity.	Dicumarol	26-35	NAD(P)H quinone dehydrogenase 1	Homo sapiens	206-219
1692249-9	1990	Dicoumarol, an inhibitor of DT-diaphorase, increased the cytotoxic activity of both benzoquinone mustard and benzoquinone dimustard in L5178Y/HBM10 cells.	Dicumarol	0-10	NAD(P)H dehydrogenase, quinone 1	Mus musculus	28-41
2116241-4	1990	Experiments on the identification of reduction products and on the inhibition with dicoumarol and the antiserum indicated that DT-diaphorase catalyzes 4-electron reduction of C-nitroso-compounds and plays a major role in the reduction of these compounds by rat liver cytosol.	Dicumarol	83-93	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	127-140
2125671-3	1990	Dicumarol exerts characteristic inhibition on DT-diaphorase, whereas serum albumin and certain non-ionic detergents exert activation.	Dicumarol	0-9	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	46-59
1701346-11	1990	Metabolism of mitomycin C by purified HT-29 DT-diaphorase was also dicoumarol inhibitable and pH dependent.	Dicumarol	67-77	NAD(P)H quinone dehydrogenase 1	Homo sapiens	44-57
1699555-0	1990	Dicoumarol-induced 9-gamma-carboxyglutamic acid prothrombin: isolation and comparison with the 6-, 7-, 8-, and 10-gamma-carboxyglutamic acid isomers.	Dicumarol	0-10	coagulation factor II, thrombin	Homo sapiens	48-59
1699555-1	1990	The role of gamma-carboxyglutamic acid (Gla) in prothrombin function can be effectively evaluated by characterizing dicoumarol-induced, Gla-deficient prothrombin structural isomers.	Dicumarol	116-126	coagulation factor II, thrombin	Homo sapiens	48-59
1699555-1	1990	The role of gamma-carboxyglutamic acid (Gla) in prothrombin function can be effectively evaluated by characterizing dicoumarol-induced, Gla-deficient prothrombin structural isomers.	Dicumarol	116-126	coagulation factor II, thrombin	Homo sapiens	150-161
2113030-4	1990	Prior boiling of cytosol, omission of NADH or NADPH or inclusion of dicoumarol, an inhibitor of DT-diaphorase, inhibited removal of AZQ.	Dicumarol	68-78	NAD(P)H quinone dehydrogenase 1	Homo sapiens	96-109
2113031-12	1990	Both the DTT-dependent reduction of vitamin K1 epoxide and quinone, and the reduction of DCPIP by purified DT-diaphorase were inhibited by dicoumarol, warfarin, lapachol, and sulphaquinoxaline.	Dicumarol	139-149	NAD(P)H quinone dehydrogenase 1	Homo sapiens	107-120
2553092-5	1989	Menadione, at concentrations up to 25 microM, did not inhibit either protein or RNA synthesis unless dicoumarol, an inhibitor of DT-diaphorase, was also present.	Dicumarol	101-111	NAD(P)H quinone dehydrogenase 1	Homo sapiens	129-142
2105732-3	1990	Both reductions had the classic characteristics of DT-diaphorase: they were equally supported by NADPH and NADH and almost entirely inhibited by dicumarol.	Dicumarol	145-154	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	51-64
34252539-5	2021	Similar to dicoumarol, the specific inhibitor of NQO1, both Nec-1 and Nec-1s significantly suppress NQO1-dependent cell death.	Dicumarol	11-21	NAD(P)H quinone dehydrogenase 1	Homo sapiens	49-53
2500115-1	1989	The dicoumarol-sensitive NAD(P)H:quinone reductase (E.C.1.6.99.2), often referred to as DT-diaphorase, has been purified from both the cytosolic and microsomal fractions from rat liver using a novel, highly efficient, two-step purification procedure utilizing immobilized Cibacron Blue F3GA dye affinity chromatography as the principal step.	Dicumarol	4-14	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	88-101
2471583-4	1989	Dicoumarol, an inhibitor of DT-diaphorase, significantly inhibited crosslinking and cytotoxicity by mitomycin C in the quinone resistant cells.	Dicumarol	0-10	NAD(P)H dehydrogenase, quinone 1	Mus musculus	28-41
2703701-8	1989	The enzyme was also resistant to dicumarol, an inhibitor of DT-diaphorase activity.	Dicumarol	33-42	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	60-73
2494259-9	1989	The response to chymase was non-cytotoxic and was blocked by active site inhibitors of chymase (soybean trypsin inhibitor and chymostatin) and by inhibitors of cellular energy metabolism (azide,2,4-dinitrophenol, dicumarol).	Dicumarol	213-222	chymase 1	Canis lupus familiaris	16-23
2472556-7	1989	By contrast, the pretreatment with the NAD(P)H-quinone reductase (DT-diaphorase) inhibitor, dicumarol, markedly increased the rate of appearance of the toxic effect of menadione.	Dicumarol	92-101	NAD(P)H dehydrogenase [quinone] 1	Cavia porcellus	66-79
3115561-1	1987	Dicumarol sensitive DT-diaphorase (EC 1.6.99.2) activity has been measured in human cytosol from liver and various extrahepatic tissues not containing tumors which were removed during elective operations.	Dicumarol	0-9	NAD(P)H quinone dehydrogenase 1	Homo sapiens	20-33
2455523-5	1988	When control and induced cells were also exposed to dicoumarol, a specific and potent inhibitor of DT-diaphorase, the cytotoxicity of the quinones in both control and induced cells was enhanced markedly.	Dicumarol	52-62	NAD(P)H dehydrogenase, quinone 1	Mus musculus	99-112
2451576-1	1988	The metabolic activation or detoxification of mutagens and carcinogens of several chemical classes was investigated in the presence of various rat liver and lung subcellular fractions and of dicoumarol, a specific inhibitor of DT diaphorase activity.	Dicumarol	191-201	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	227-240
2451512-11	1988	Ubiquinone-6, ubiquinone-10 and dicoumarol stimulate protoporphyrinogen oxidase activity at low concentrations (less than 15 microM), whereas coenzyme Q0 and menadione show no activation at these concentrations.	Dicumarol	32-42	protoporphyrinogen oxidase	Mus musculus	53-79
3338873-7	1988	An anti-coagulant, dicoumarol, abrogated the effect of rTNF-alpha.	Dicumarol	19-29	tumor necrosis factor	Rattus norvegicus	55-65
2465220-5	1988	However, we were unable to confirm the comparatively marked increase AT III for dicoumarol treatment found by Roka and Bleyl.	Dicumarol	80-90	serpin family C member 1	Homo sapiens	69-75
2465958-3	1988	In a group of 347 patients under dicoumarol therapy of different intensity and duration PIVKA was detected in BaSO4 adsorbed PPP only in samples where prothrombin level (Quick"s test) was lower than 50% of normal values.	Dicumarol	33-43	coagulation factor II, thrombin	Homo sapiens	151-162
3304203-10	1987	Inhibition of phase II led to a significant increase in the steady state level of singlet oxygen, as did the inhibition of two-electron reduction by using the inhibitor dicoumarol for DT diaphorase.	Dicumarol	169-179	NAD(P)H quinone dehydrogenase 1	Homo sapiens	184-197
2434474-5	1987	Thus, in previous studies, we showed that treatment of mice with BHA (2(3)-tert-butyl-4-hydroxyanisole), which elevates cytosolic quinone reductase activity about 10-fold, reduced menadione-dependent chemiluminescence of hepatic post-mitochondrial supernatant fractions, whereas inhibition of quinone reductase by dicoumarol greatly intensified light emission.	Dicumarol	314-324	crystallin, zeta	Mus musculus	130-147
2435285-4	1987	Since both NADP and dicoumarol inhibited the naphthazarin-stimulated non-stoichiometric consumption of NADPH and oxygen then naphthazarin redox cycling probably involves both DT-diaphorase and NADPH cytochrome P-450 reductase.	Dicumarol	20-30	cytochrome p450 oxidoreductase	Homo sapiens	193-225
6204727-4	1984	Quantitative cytochemistry of unfixed, undemineralized sections showed that dicumarol also markedly affected the periosteal activities of glucose 6-phosphate dehydrogenase and of alkaline phosphatase in the first 2 mm from the fracture measured at 3 and 5 days postfracture when normally, new bone is first formed.	Dicumarol	76-85	glucose-6-phosphate dehydrogenase	Rattus norvegicus	138-171
2431654-1	1986	The effect of dicoumarol on glucuronidation of 3-OH-benzo(a)pyrene (BP) appears to be due to inhibition of UDPglucuronosyltransferase (UDPGT) and not to an inhibited DT-diaphorase (NAD(P)H:quinone oxidoreductase); to date the only enzyme known to be inhibited by dicoumarol.	Dicumarol	14-24	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	166-179
2425252-4	1986	The presence of dicumarol, a specific inhibitor of the two-electron reduction of quinones by DT-diaphorase, afforded some protection against cytotoxicity.	Dicumarol	16-25	NAD(P)H quinone dehydrogenase 1	Homo sapiens	93-106
4060194-3	1985	In fibroblasts, effects on both DNA and membrane integrity were potentiated by the presence of dicoumarol, a specific inhibitor of the 2-electron reduction of quinones by DT-diaphorase, whereas in hepatocytes only the cell membrane damage was sensitive to dicoumarol.	Dicumarol	95-105	NAD(P)H quinone dehydrogenase 1	Homo sapiens	171-184
6437671-7	1984	Exposure of cell sonicates to dicumarol inhibited DT-diaphorase activity, while the rate of formation of reactive metabolites of MC was enhanced.	Dicumarol	30-39	NAD(P)H dehydrogenase, quinone 1	Mus musculus	50-63
6203538-3	1984	Dicoumarol, an inhibitor of DT diaphorase, did not potentiate menadione-induced DNA strand breaks.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	28-41
30260338-1	1987	THE EFFECTS OF DICUMAROL, A SPECIFIC INHIBITOR OF DT-DIAPHORASE, WERE INVESTIGATED IN THE AMES REVERSION TEST BY ASSAYING SEVERAL MUTAGENS OF DIFFERENT CHEMICAL CLASSES IN THE PRESENCE OF A VARIETY OF METABOLIC SYSTEMS.	Dicumarol	15-24	NAD(P)H quinone dehydrogenase 1	Homo sapiens	50-63
3934922-10	1985	The DT-diaphorase inhibitor dicoumarol was employed to show that this enzyme is not involved in the activation of mitomycin C to a cytotoxic agent.	Dicumarol	28-38	NAD(P)H dehydrogenase, quinone 1	Mus musculus	4-17
2419579-6	1985	Moreover, we have found that the cytotoxic effects of DBNQ on human tumor and murine bone marrow stem cells can be prevented or lessened by pretreatment of the cells with dicoumarol, a potent inhibitor of DT-diaphorase.	Dicumarol	171-181	NAD(P)H dehydrogenase, quinone 1	Mus musculus	205-218
6200119-5	1984	The toxicity of 1-naphthol and the naphthoquinones was potentiated by dicoumarol, an inhibitor of DT-diaphorase (NAD(P)H:quinone oxidoreductase).	Dicumarol	70-80	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	98-111
6749127-9	1984	This effect was reversed in the presence of dicumarol, a specific inhibitor of DT-diaphorase.	Dicumarol	44-53	NAD(P)H dehydrogenase [quinone] 1	Cavia porcellus	79-92
6200119-5	1984	The toxicity of 1-naphthol and the naphthoquinones was potentiated by dicoumarol, an inhibitor of DT-diaphorase (NAD(P)H:quinone oxidoreductase).	Dicumarol	70-80	crystallin zeta	Rattus norvegicus	121-143
6188454-3	1983	Daunorubicin toxicity increased in the presence of dicoumarol, a specific inhibitor of DT-diaphorase.	Dicumarol	51-61	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	87-100
6165325-0	1981	Biospecific adsorption of hepatic DT-diaphorase on immobilized dicoumarol.	Dicumarol	63-73	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	34-47
6191666-2	1983	Chemiluminescence was augmented when the two-electron reduction of the quinone catalyzed by NAD(P)H:quinone reductase was inhibited by dicoumarol, thus underlining the protective function of this enzyme also known as DT-diaphorase.	Dicumarol	135-145	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	217-230
6802189-4	1982	The inhibitor of mitochondrial NADH-cytochrome b5 reductase dicumarol prevented the cytochrome P-450 reduction in the presence of glutamate, NAD+ and amytal but did not affect the reduction of cytochrome P-450 by the added NADH.	Dicumarol	60-69	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	84-100
6165326-0	1981	Biospecific adsorption of hepatic DT-diaphorase on immobilized dicoumarol.	Dicumarol	63-73	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	34-47
6933553-2	1980	The present report concerns the enhancement of dicoumarol-inhibited NAD(P)H:quinone reductase [NAD(P)H dehydrogenase (quinone); NAD(P)H:(quinone acceptor) oxidoreductase, EC 1.6.99.2] activity in mouse tissues in response to dietary administration of BHA.	Dicumarol	47-57	crystallin, zeta	Mus musculus	76-93
6157217-0	1980	Protein M and the activation of dicoumarol induced atypical prothrombin.	Dicumarol	32-42	coagulation factor II, thrombin	Homo sapiens	60-71
50434-3	1975	Over 91% of the primary metabolites was converted to dicumarol and 7-hydroxydicumarol by hydrolysis with beta-glucuronidase.	Dicumarol	53-62	glucuronidase, beta	Rattus norvegicus	105-123
6168225-0	1981	Degradation of normal and dicoumarol-induced prothrombins with thrombin.	Dicumarol	26-36	coagulation factor II, thrombin	Homo sapiens	48-56
158207-2	1979	Uncouplers (2,4-dinitrophenol, dicoumarol), which are also activators of the hydrolytic activity of ATPase, were more potent activators on the oxidized form of the enzyme.	Dicumarol	31-41	dynein axonemal heavy chain 8	Homo sapiens	100-106
1024599-5	1976	Mitochondrial menadione reductase is inhibitied by dicumarol and p-chloromecuribenzoate.	Dicumarol	51-60	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	14-33
53896-0	1975	Proceedings: Activation of dicoumarol-induced atypical prothrombin.	Dicumarol	27-37	coagulation factor II, thrombin	Homo sapiens	55-66
1141226-2	1975	The bovine plasma zymogen prothrombin contains a number of gamma-carboxyglutamic acid residues which are not found in an abnormal prothrombin produced when cattle are given the vitamin K antagonist dicoumarol.	Dicumarol	198-208	coagulation factor II, thrombin	Bos taurus	26-37
4138039-2	1974	Isolation of peptides containing prosthetic groups from normal prothrombin and the corresponding peptides from dicoumarol-induced prothrombin.	Dicumarol	111-121	coagulation factor II, thrombin	Homo sapiens	130-141
20989497-0	1946	Experimentally induced changes in the prothrombin level of the blood; prothrombin concentration of new-born pups of a mother given dicumarol before parturition.	Dicumarol	131-140	coagulation factor II, thrombin	Homo sapiens	38-49
4181975-0	1966	[Change in the fibrinogen concentration in the blood following an intravenous injection of thrombin to dicoumarin-fed animals].	Dicumarol	103-113	fibrinogen beta chain	Homo sapiens	15-25
4181975-0	1966	[Change in the fibrinogen concentration in the blood following an intravenous injection of thrombin to dicoumarin-fed animals].	Dicumarol	103-113	coagulation factor II, thrombin	Homo sapiens	91-99
13766979-0	1961	[The use of prothrombin determination with hirudin in the supervision of treatment with dicoumarol derivatives].	Dicumarol	88-98	coagulation factor II, thrombin	Homo sapiens	12-23
13349502-0	1956	[Effect of heparin on percentage content of prothrombin; range of variations and their significance in relation to heparin with dicumarol therapy].	Dicumarol	128-137	coagulation factor II, thrombin	Homo sapiens	44-55
13209750-0	1954	The control of dicumarol therapy in myocardial infarction by a simple blood prothrombin test.	Dicumarol	15-24	coagulation factor II, thrombin	Homo sapiens	76-87
13057268-0	1953	The comparative action of dicumarol and of phenylindanedione on the coagulase reacting factor and on prothrombin.	Dicumarol	26-35	coagulation factor II, thrombin	Homo sapiens	101-112
14933315-0	1952	The action of dicumarol in the human being on plasma prothrombin time and total prothrombin time.	Dicumarol	14-23	coagulation factor II, thrombin	Homo sapiens	53-64
14933315-0	1952	The action of dicumarol in the human being on plasma prothrombin time and total prothrombin time.	Dicumarol	14-23	coagulation factor II, thrombin	Homo sapiens	80-91
14936621-0	1952	[Comparative studies on the effect of dicumarol and tromexan on prothrombin level, capillary resistance and capillary permeability].	Dicumarol	38-47	coagulation factor II, thrombin	Homo sapiens	64-75
14950380-0	1952	The prothrombin level in patients on dicoumarol therapy; a simplified capillary technique.	Dicumarol	37-47	coagulation factor II, thrombin	Homo sapiens	4-15
14939638-0	1952	[Problems of prothrombin determination; comparative studies with the one- and two-phase method in the control of the dicoumarin medication].	Dicumarol	117-127	coagulation factor II, thrombin	Homo sapiens	13-24
14869347-0	1951	The effect of dicoumarol on co-thromboplastin, a factor in blood concerned with the conversion of prothrombin to thrombin.	Dicumarol	14-24	coagulation factor II, thrombin	Homo sapiens	101-109
14854798-0	1951	A comparison between the effect of intravenously and orally administrated dicumarol on the plasma prothrombin levels in man.	Dicumarol	74-83	coagulation factor II, thrombin	Homo sapiens	98-109
14788260-0	1950	Observations on the synergistic effect of salicylate and dicoumarol of the depression of plasma prothrombin activity in humans.	Dicumarol	57-67	coagulation factor II, thrombin	Homo sapiens	96-107
14773979-0	1950	EFFECTS of dicumarol on prothrombin levels.	Dicumarol	11-20	coagulation factor II, thrombin	Homo sapiens	24-35
15432322-2	1950	Prothrombin as determined with the isolation technic, in patients receiving dicumarol.	Dicumarol	76-85	coagulation factor II, thrombin	Homo sapiens	0-11
18139386-0	1949	Dicumarol therapy controlled by the stabilized thrombin method for determination of prothrombin.	Dicumarol	0-9	coagulation factor II, thrombin	Homo sapiens	47-55
18139386-0	1949	Dicumarol therapy controlled by the stabilized thrombin method for determination of prothrombin.	Dicumarol	0-9	coagulation factor II, thrombin	Homo sapiens	84-95
16810826-0	1949	Estimation of Prothrombin in Dicoumarin Therapy.	Dicumarol	29-39	coagulation factor II, thrombin	Homo sapiens	14-25
18130447-0	1949	The nature of the prothrombin deficiency in dicoumarin plasma.	Dicumarol	44-54	coagulation factor II, thrombin	Homo sapiens	18-29
18935077-0	1948	Dicumarol poisoning and vitamin K deficiency in relation to Quick"s concept of the composition of prothrombin.	Dicumarol	0-9	coagulation factor II, thrombin	Homo sapiens	98-109
18865331-0	1948	Vitamin K for the balancing of prothrombin index in dicoumarin treatment.	Dicumarol	52-62	coagulation factor II, thrombin	Homo sapiens	31-42
20265749-0	1947	Variations in prothrombin and antithrombin following the administration of dicumarol.	Dicumarol	75-84	coagulation factor II, thrombin	Homo sapiens	14-25
20265749-0	1947	Variations in prothrombin and antithrombin following the administration of dicumarol.	Dicumarol	75-84	serpin family C member 1	Homo sapiens	30-42
20289826-0	1947	On the relation of calcium to the activation of prothrombin and its significance in dicumarol poisoning.	Dicumarol	84-93	coagulation factor II, thrombin	Homo sapiens	48-59
20322380-0	1942	The Effect of the Synthetic Haemorrhagic Agent, 3,3"-Methylenebis (4-Hydroxycoumarin), in Prolonging the Coagulation and Prothrombin Time in the Human Subject.	Dicumarol	48-84	coagulation factor II, thrombin	Homo sapiens	121-132
4519629-7	1973	The properties of the isolated peptide would appear to account for the major differences observed between prothrombin and its biologically inactive form produced by animals administered Dicumarol orally.	Dicumarol	186-195	coagulation factor II, thrombin	Bos taurus	106-117
4125867-2	1973	Structural comparison of an NH2-terminal fragment from normal and from dicoumarol-induced bovine prothrombin.	Dicumarol	71-81	coagulation factor II, thrombin	Bos taurus	97-108
4126258-0	1973	A conformational study of normal and dicoumarol-induced prothrombin.	Dicumarol	37-47	coagulation factor II, thrombin	Homo sapiens	56-67
4121396-0	1973	The nature of the heterogeneity of prothrombin during dicoumarol therapy.	Dicumarol	54-64	coagulation factor II, thrombin	Homo sapiens	35-46
4119069-0	1973	Binding of Ca 2+  to normal and dicoumarol-induced prothrombin.	Dicumarol	32-42	coagulation factor II, thrombin	Homo sapiens	51-62
4118352-2	1972	Identification and purification of a dicoumarol-induced abnormal prothrombin from bovine plasma.	Dicumarol	37-47	coagulation factor II, thrombin	Bos taurus	65-76
4118353-2	1972	Structural comparison of normal and dicoumarol-induced bovine prothrombin.	Dicumarol	36-46	coagulation factor II, thrombin	Bos taurus	62-73
4120903-0	1972	Atypical prothrombin in purified preparations from dicoumarol-treated steers.	Dicumarol	51-61	coagulation factor II, thrombin	Homo sapiens	9-20
4109212-0	1971	Synthesis of an abnormal prothrombin in malnutrition and biliary obstruction and during dicumarol treatment.	Dicumarol	88-97	coagulation factor II, thrombin	Homo sapiens	25-36
4106764-0	1971	Effect of steroids, acetylsalicylic acid and bishydroxycoumarin on prothrombin time.	Dicumarol	45-63	coagulation factor II, thrombin	Homo sapiens	67-78
4105907-1	1971	V. The interaction of phenylbutazone, flufenamic acid, and dicoumarol with acetylsalicylic acid-treated human serum albumin.	Dicumarol	59-69	albumin	Homo sapiens	110-123
4101412-0	1971	Effects of testosterone propionate and dicumarol on plasma prothrombin rate and serum cholesterol level in capons and orchiectomized rats.	Dicumarol	39-48	coagulation factor II	Rattus norvegicus	59-70
4111388-0	1971	Site of inhibition by dicoumarol of prothrombin biosynthesis: carbohydrate content of prothrombin from dicoumarol-treated rats.	Dicumarol	22-32	coagulation factor II	Rattus norvegicus	36-47
4111388-0	1971	Site of inhibition by dicoumarol of prothrombin biosynthesis: carbohydrate content of prothrombin from dicoumarol-treated rats.	Dicumarol	22-32	coagulation factor II	Rattus norvegicus	86-97
4111388-0	1971	Site of inhibition by dicoumarol of prothrombin biosynthesis: carbohydrate content of prothrombin from dicoumarol-treated rats.	Dicumarol	103-113	coagulation factor II	Rattus norvegicus	86-97
4114801-0	1970	Response of prothrombin rate to exogenous testosterone in rats fed dicumarol.	Dicumarol	67-76	coagulation factor II	Rattus norvegicus	12-23
4100515-0	1970	Dicumarol-induced prothrombin in bovine plasma.	Dicumarol	0-9	coagulation factor II, thrombin	Bos taurus	18-29
4185033-0	1969	The role of cytochrome P-450 in the mechanism of inhibition of steroid 11 beta-hydroxylation by dicumarol.	Dicumarol	96-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
4191184-0	1968	[Physiologic reaction of the organism to dicoumarin therapy: incidence on prothrombin activity; statistical study].	Dicumarol	41-51	coagulation factor II, thrombin	Homo sapiens	74-85
4178912-0	1968	Plasma prothrombin during treatment with Dicumarol.	Dicumarol	41-50	coagulation factor II, thrombin	Homo sapiens	7-18
4178913-0	1968	Plasma prothrombin during treatment with Dicumarol.	Dicumarol	41-50	coagulation factor II, thrombin	Homo sapiens	7-18
4167446-0	1967	Study of the interaction of barbiturates and dicumarol and their effect on prothrombin activity, hemorrhage, and sleeping time in rats.	Dicumarol	45-54	coagulation factor II	Rattus norvegicus	75-86
4164320-0	1966	Efect of "Dicumarol" (bishydroxycoumarin) on insulin secretion in vitro.	Dicumarol	10-19	insulin	Homo sapiens	45-52
4164320-0	1966	Efect of "Dicumarol" (bishydroxycoumarin) on insulin secretion in vitro.	Dicumarol	22-40	insulin	Homo sapiens	45-52
14051485-4	1963	Prothrombin activity levels returned to pretreatment values only after ten days following termination of coumarin or Dicumarol administration.	Dicumarol	117-126	coagulation factor II, thrombin	Homo sapiens	0-11
13238066-0	1954	Prothrombin time longer than recalcification time; a paradoxical phenomenon in dicoumarol hypersensitivity.	Dicumarol	79-89	coagulation factor II, thrombin	Homo sapiens	0-11
13217722-0	1954	Control of dicumarol therapy by means of a micromethod for the quantitative determination of plasma prothrombin and proconvertin.	Dicumarol	11-20	coagulation factor II, thrombin	Homo sapiens	100-111
13196956-0	1954	Comparison of two methods for determining prothrombin during dicumarol therapy.	Dicumarol	61-70	coagulation factor II, thrombin	Homo sapiens	42-53
20989497-0	1946	Experimentally induced changes in the prothrombin level of the blood; prothrombin concentration of new-born pups of a mother given dicumarol before parturition.	Dicumarol	131-140	coagulation factor II, thrombin	Homo sapiens	70-81
33600944-10	2021	These effects of TSB were completely abolished by specific NQO1 inhibitor dicoumarol (DIC).	Dicumarol	74-84	NAD(P)H quinone dehydrogenase 1	Homo sapiens	59-63
13060907-0	1953	[Plasma content of accelerator and antithrombin active substance in dicumarol induced prothrombinemia].	Dicumarol	68-77	serpin family C member 1	Homo sapiens	35-47
33600944-10	2021	These effects of TSB were completely abolished by specific NQO1 inhibitor dicoumarol (DIC).	Dicumarol	86-89	NAD(P)H quinone dehydrogenase 1	Homo sapiens	59-63
33506674-6	2021	The NQO1 inhibitor, dicoumarol, rescued the cytotoxicity of XD2-149 but not ZFP91 degradation, suggesting that the NQO1-induced cell death is independent of ZFP91.	Dicumarol	20-30	NAD(P)H quinone dehydrogenase 1	Homo sapiens	4-8
32987030-0	2021	Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	15-19
32987030-0	2021	Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx.	Dicumarol	0-10	X protein	Hepatitis B virus	87-90
32987030-7	2021	RESULTS: Dicoumarol, an inhibitor of NAD(P)H:quinone oxidoreductase (NQO1), significantly reduced HBx expression.	Dicumarol	9-19	crystallin zeta	Homo sapiens	45-67
32987030-7	2021	RESULTS: Dicoumarol, an inhibitor of NAD(P)H:quinone oxidoreductase (NQO1), significantly reduced HBx expression.	Dicumarol	9-19	NAD(P)H dehydrogenase, quinone 1	Mus musculus	69-73
32987030-7	2021	RESULTS: Dicoumarol, an inhibitor of NAD(P)H:quinone oxidoreductase (NQO1), significantly reduced HBx expression.	Dicumarol	9-19	X protein	Hepatitis B virus	98-101
32987030-8	2021	Moreover, dicoumarol showed potent antiviral activity against HBV RNAs, HBV DNA, HBsAg and HBc protein in HBV-infected cells and a humanized liver mouse model.	Dicumarol	10-20	keratin 88, pseudogene	Homo sapiens	91-94
32987030-10	2021	NQO1 knockdown or dicoumarol treatment significantly reduced the recruitment of HBx to cccDNA and inhibited cccDNA transcription activity, which was correlated with establishment of a repressive chromatin state.	Dicumarol	18-28	X protein	Hepatitis B virus	80-83
32987030-11	2021	The absence of HBx markedly blocked the antiviral effect induced by NQO1 knockdown or dicoumarol treatment in HBV-infected cells.	Dicumarol	86-96	X protein	Hepatitis B virus	15-18
33460769-8	2021	Treatment of BV2 cells with the NQO1-specific inhibitor, dicoumarol, or with NQO1 siRNA significantly blocked NKT-mediated inhibition of NO, ROS, TNF-alpha, IL-1beta, and upregulation of IL-10.	Dicumarol	57-67	tumor necrosis factor	Mus musculus	146-155
33460769-8	2021	Treatment of BV2 cells with the NQO1-specific inhibitor, dicoumarol, or with NQO1 siRNA significantly blocked NKT-mediated inhibition of NO, ROS, TNF-alpha, IL-1beta, and upregulation of IL-10.	Dicumarol	57-67	interleukin 1 alpha	Mus musculus	157-165
33460769-8	2021	Treatment of BV2 cells with the NQO1-specific inhibitor, dicoumarol, or with NQO1 siRNA significantly blocked NKT-mediated inhibition of NO, ROS, TNF-alpha, IL-1beta, and upregulation of IL-10.	Dicumarol	57-67	interleukin 10	Mus musculus	187-192
33460769-10	2021	Intriguingly, we found that the AMPK inhibitor, compound C, mimicked the effects of dicoumarol, suggesting the presence of a crosstalk between NQO1 and AMPK.	Dicumarol	84-94	NAD(P)H dehydrogenase, quinone 1	Mus musculus	143-147
33506674-6	2021	The NQO1 inhibitor, dicoumarol, rescued the cytotoxicity of XD2-149 but not ZFP91 degradation, suggesting that the NQO1-induced cell death is independent of ZFP91.	Dicumarol	20-30	NAD(P)H quinone dehydrogenase 1	Homo sapiens	115-119
33204397-8	2020	The inhibition of NQO1 by dicoumarol increased mitochondrial superoxide and sensitized cancer cells to M/A.	Dicumarol	26-36	NAD(P)H quinone dehydrogenase 1	Homo sapiens	18-22
31902045-4	2021	In addition, the reaction was highly sensitive towards dicoumarol with Kic values in the low nanomolar range, suggesting that the NAD(P)H:quinone oxidoreductase 1 (NQO1) catalyzes the menadione-dependent WST1 reduction in astrocytes.	Dicumarol	55-65	NAD(P)H quinone dehydrogenase 1	Homo sapiens	130-162
31902045-4	2021	In addition, the reaction was highly sensitive towards dicoumarol with Kic values in the low nanomolar range, suggesting that the NAD(P)H:quinone oxidoreductase 1 (NQO1) catalyzes the menadione-dependent WST1 reduction in astrocytes.	Dicumarol	55-65	NAD(P)H quinone dehydrogenase 1	Homo sapiens	164-168
33228195-6	2020	The cytotoxicity of compounds in murine hepatoma MH22a cells was decreased by antioxidants and the inhibitor of NQO1, dicoumarol.	Dicumarol	118-128	NAD(P)H dehydrogenase, quinone 1	Mus musculus	112-116
32975120-5	2020	The binding free energy calculations showed that some metabolites exhibited strong predicted binding affinity and found that the binding orientation of the EGCG metabolites overlapped with that of dicoumarol found in an NQO1 X-ray crystal structure.	Dicumarol	197-207	NAD(P)H quinone dehydrogenase 1	Homo sapiens	220-224
32789798-8	2020	The sequential application of beta-lap and dicoumarol to rapidly induce and terminate oxidative stress, respectively, is a suitable experimental paradigm to study consequences of a defined period of acute oxidative stress in NQO1-expressing cells.	Dicumarol	43-53	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	225-229
32682198-3	2020	Dicoumarol partially inhibited the activity of these compounds against A549 cell lines, indicating that the activation of biological reduction mediated by NQO1 might partly affect the antiproliferative effects.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	155-159
32789798-0	2020	beta-Lapachone Induces Acute Oxidative Stress in Rat Primary Astrocyte Cultures that is Terminated by the NQO1-Inhibitor Dicoumarol.	Dicumarol	121-131	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	106-110
32705170-0	2020	Inhibition of pyruvate dehydrogenase kinase-1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming.	Dicumarol	49-59	pyruvate dehydrogenase kinase 1	Homo sapiens	14-45
32789798-5	2020	The beta-lap-induced ROS production and GSSG accumulation were completely prevented in the presence of the NQO1 inhibitor dicoumarol.	Dicumarol	122-132	endoplasmic reticulum aminopeptidase 1	Rattus norvegicus	4-12
32789798-5	2020	The beta-lap-induced ROS production and GSSG accumulation were completely prevented in the presence of the NQO1 inhibitor dicoumarol.	Dicumarol	122-132	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	107-111
32789798-6	2020	In addition, application of dicoumarol to beta-lap-exposed astrocytes caused rapid regeneration of the normal high cellular GSH to GSSG ratio.	Dicumarol	28-38	endoplasmic reticulum aminopeptidase 1	Rattus norvegicus	42-50
32705170-4	2020	In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA).	Dicumarol	35-45	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	83-105
32705170-4	2020	In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA).	Dicumarol	35-45	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	107-110
32705170-4	2020	In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA).	Dicumarol	35-45	pyruvate dehydrogenase kinase 1	Homo sapiens	142-146
32705170-4	2020	In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA).	Dicumarol	47-50	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	83-105
32705170-4	2020	In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA).	Dicumarol	47-50	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	107-110
32705170-4	2020	In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA).	Dicumarol	47-50	pyruvate dehydrogenase kinase 1	Homo sapiens	142-146
32825392-4	2020	Our results systematically support the existence of two pathways for hydride transfer throughout the NQO1 catalytic cycle, likely reflecting that the two active sites in the dimer catalyze two-electron reduction with different rates, consistent with the cooperative binding of inhibitors such as dicoumarol.	Dicumarol	296-306	NAD(P)H quinone dehydrogenase 1	Homo sapiens	101-105
32063361-0	2020	Dicoumarol suppresses HMGA2-mediated oncogenic capacities and inhibits cell proliferation by inducing apoptosis in colon cancer.	Dicumarol	0-10	high mobility group AT-hook 2	Homo sapiens	22-27
32063361-6	2020	Moreover, we utilized dicoumarol (DIC), a derivative of coumarin which has been suggested to be involved in oxidation regulation with anticancer effects, and demonstrated that DIC could induce apoptosis and inhibit cell migration of HMGA2 overexpressing colon cancer cells.	Dicumarol	22-32	high mobility group AT-hook 2	Homo sapiens	233-238
32063361-6	2020	Moreover, we utilized dicoumarol (DIC), a derivative of coumarin which has been suggested to be involved in oxidation regulation with anticancer effects, and demonstrated that DIC could induce apoptosis and inhibit cell migration of HMGA2 overexpressing colon cancer cells.	Dicumarol	34-37	high mobility group AT-hook 2	Homo sapiens	233-238
32063361-6	2020	Moreover, we utilized dicoumarol (DIC), a derivative of coumarin which has been suggested to be involved in oxidation regulation with anticancer effects, and demonstrated that DIC could induce apoptosis and inhibit cell migration of HMGA2 overexpressing colon cancer cells.	Dicumarol	176-179	high mobility group AT-hook 2	Homo sapiens	233-238
30077781-0	2018	Dicoumarol derivatives: Green synthesis and molecular modelling studies of their anti-LOX activity.	Dicumarol	0-10	seed linoleate 9S-lipoxygenase-3	Glycine max	86-89
31165578-3	2019	We show that the binding of dicoumarol and related compounds to NQO1 generates negative cooperativity between the monomers.	Dicumarol	28-38	NAD(P)H quinone dehydrogenase 1	Homo sapiens	64-68
31726777-4	2019	Herein, we have used hydrogen/deuterium exchange monitored by mass spectrometry (HDXMS) to investigate the structural dynamics of NQO1 in three ligation states: without ligands (NQO1apo), with FAD (NQO1holo) and with FAD and the inhibitor dicoumarol (NQO1dic).	Dicumarol	239-249	NAD(P)H quinone dehydrogenase 1	Homo sapiens	130-134
31726777-5	2019	We show that NQO1apo has a minimally stable folded core holding the protein dimer, with FAD and dicoumarol binding sites populating binding non-competent conformations.	Dicumarol	96-106	NAD(P)H quinone dehydrogenase 1	Homo sapiens	13-17
31431515-1	2019	Human NAD(P)H quinone oxidoreductase (DT-diaphorase, NQO1) exhibits negative cooperativity towards its potent inhibitor, dicoumarol.	Dicumarol	121-131	NAD(P)H quinone dehydrogenase 1	Homo sapiens	38-51
31431515-1	2019	Human NAD(P)H quinone oxidoreductase (DT-diaphorase, NQO1) exhibits negative cooperativity towards its potent inhibitor, dicoumarol.	Dicumarol	121-131	NAD(P)H quinone dehydrogenase 1	Homo sapiens	53-57
31480790-6	2019	Dicoumarol and gene silencing (siRNA) were used to modulate NQO1 expression and to assess its potential drug-detoxifying role.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	60-64
30342342-0	2019	Excited state hydrogen atom transfer in micro-solvated dicoumarol: A TDDFT/EFP1 study.	Dicumarol	55-65	thioredoxin domain containing 11	Homo sapiens	75-79
30518535-6	2019	Dicoumarol and some structurally related compounds act as competitive inhibitors of NQO1.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	84-88
30062552-7	2018	In coronary arteries, repeated acute hypoxia caused similar augmentations as those to quinones that were inhibited by the NQO-1 inhibitor dicoumarol.	Dicumarol	138-148	NAD(P)H quinone dehydrogenase 1	Sus scrofa	122-127
30443714-0	2019	Dicoumarol Inhibits Multidrug Resistance Protein 1-Mediated Export Processes in Cultured Primary Rat Astrocytes.	Dicumarol	0-10	ATP binding cassette subfamily C member 1	Rattus norvegicus	20-50
30443714-1	2019	Dicoumarol is frequently used as inhibitor of the detoxifying enzyme NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1).	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	69-110
30443714-1	2019	Dicoumarol is frequently used as inhibitor of the detoxifying enzyme NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1).	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	112-116
30443714-4	2019	However, unexpectedly dicoumarol inhibited the cellular multidrug resistance protein (Mrp) 1-dependent export of GSH in a time- and concentration-dependent manner with half-maximal effects observed at low micromolar concentrations of dicoumarol.	Dicumarol	22-32	ATP binding cassette subfamily C member 1	Rattus norvegicus	56-92
30443714-4	2019	However, unexpectedly dicoumarol inhibited the cellular multidrug resistance protein (Mrp) 1-dependent export of GSH in a time- and concentration-dependent manner with half-maximal effects observed at low micromolar concentrations of dicoumarol.	Dicumarol	234-244	ATP binding cassette subfamily C member 1	Rattus norvegicus	56-92
30443714-6	2019	In addition, dicoumarol inhibited also the Mrp1-mediated export of GSSG during menadione-induced oxidative stress and the export of the GSH-bimane-conjugate (GS-B) that had been generated in the cells after exposure to monochlorobimane.	Dicumarol	13-23	ATP binding cassette subfamily C member 1	Rattus norvegicus	43-47
30443714-7	2019	Half-maximal inhibition of the export of Mrp1 substrates was observed at dicoumarol concentrations of around 4 microM (GSH and GSSG) and 30 microM (GS-B).	Dicumarol	73-83	ATP binding cassette subfamily C member 1	Rattus norvegicus	41-45
30443714-8	2019	These data demonstrate that dicoumarol strongly affects the GSH metabolism of viable cultured astrocytes by inhibiting Mrp1-mediated export processes and identifies for the first time Mrp1 as additional cellular target of dicoumarol.	Dicumarol	28-38	ATP binding cassette subfamily C member 1	Rattus norvegicus	119-123
30443714-8	2019	These data demonstrate that dicoumarol strongly affects the GSH metabolism of viable cultured astrocytes by inhibiting Mrp1-mediated export processes and identifies for the first time Mrp1 as additional cellular target of dicoumarol.	Dicumarol	222-232	ATP binding cassette subfamily C member 1	Rattus norvegicus	184-188
29950865-2	2018	SPL-A is derived from dicoumarol which inhibits the activity of NAD(P)H dehydrogenase quinone oxidoreductase 1 (NQO1).	Dicumarol	22-32	NAD(P)H quinone dehydrogenase 1	Homo sapiens	64-110
29950865-2	2018	SPL-A is derived from dicoumarol which inhibits the activity of NAD(P)H dehydrogenase quinone oxidoreductase 1 (NQO1).	Dicumarol	22-32	NAD(P)H quinone dehydrogenase 1	Homo sapiens	112-116
28807907-6	2017	Functional and structural similarities between this new chemical series and dicoumarol, which was reported before to inhibit pyrimidine biosynthesis at the dihydroorotate dehydrogenase (DHODH) step, are discussed.	Dicumarol	76-86	dihydroorotate dehydrogenase (quinone)	Homo sapiens	156-184
29319808-5	2018	We could not identify the participation of reactive oxygen species in the apoptosis induction, but observed that an NAD(P)H dehydrogenase (quinone) 1 (NQO1) inhibitor, dicumarol, could inhibit not only the intracellular reduction of the homologues but also apoptosis.	Dicumarol	168-177	NAD(P)H quinone dehydrogenase 1	Homo sapiens	116-149
29319808-5	2018	We could not identify the participation of reactive oxygen species in the apoptosis induction, but observed that an NAD(P)H dehydrogenase (quinone) 1 (NQO1) inhibitor, dicumarol, could inhibit not only the intracellular reduction of the homologues but also apoptosis.	Dicumarol	168-177	NAD(P)H quinone dehydrogenase 1	Homo sapiens	151-155
28807907-6	2017	Functional and structural similarities between this new chemical series and dicoumarol, which was reported before to inhibit pyrimidine biosynthesis at the dihydroorotate dehydrogenase (DHODH) step, are discussed.	Dicumarol	76-86	dihydroorotate dehydrogenase (quinone)	Homo sapiens	186-191
28639725-7	2017	The effects of streptonigrin were reversed in pancreatic cancer cells pretreated with dicumarol, a known inhibitor of NQO1.	Dicumarol	86-95	NAD(P)H quinone dehydrogenase 1	Homo sapiens	118-122
28411284-6	2017	In direct support of this notion, we demonstrate that treatment with a known NQO1 inhibitor (dicoumarol) is indeed sufficient to revert the tamoxifen-resistance phenotype.	Dicumarol	93-103	NAD(P)H quinone dehydrogenase 1	Homo sapiens	77-81
28617852-0	2017	Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells.	Dicumarol	0-9	pyruvate dehydrogenase kinase 1	Homo sapiens	19-23
28617852-3	2017	In this study, we used the ovarian cancer cell line SKOV3 as the model system and examined whether dicumarol (DIC), a coumarin compound, could inhibit ovarian cancer through targeting PDK1.	Dicumarol	99-108	pyruvate dehydrogenase kinase 1	Homo sapiens	184-188
26201483-8	2017	Dicoumarol (and warfarin) also inhibit a second enzyme, NAD(P)H quinone oxidoreductase 1 (NQO1).	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Bos taurus	56-88
26201483-8	2017	Dicoumarol (and warfarin) also inhibit a second enzyme, NAD(P)H quinone oxidoreductase 1 (NQO1).	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Bos taurus	90-94
24552538-5	2014	Addition of NQO1 to the incubations strongly reduced the formation of all corresponding GSH conjugates, and this activity could be prevented by dicoumarol, a selective NQO1 inhibitor.	Dicumarol	144-154	NAD(P)H quinone dehydrogenase 1	Homo sapiens	12-16
27653744-0	2016	Targeting PSG1 to enhance chemotherapeutic efficacy: new application for anti-coagulant the dicumarol.	Dicumarol	92-101	pregnancy specific beta-1-glycoprotein 1	Homo sapiens	10-14
27653744-5	2016	Drug screening then identified dicumarol (DCM) to target the PSG1 and inhibit chemoresistance to TA-based chemotherapy in vitro, in vivo, and in clinical samples.	Dicumarol	31-40	pregnancy specific beta-1-glycoprotein 1	Homo sapiens	61-65
27168424-4	2016	DT-diaphorase is constitutively expressed in U373MG cells, and its inhibition by dicoumarol induced a significant increase of aminochrome-induced cell death.	Dicumarol	81-91	NAD(P)H quinone dehydrogenase 1	Homo sapiens	0-13
26681508-6	2016	Dicoumarol partly suppressed the activity of the compounds against A-594 and MCF-7 cell lines, suggesting that their cytotoxic action might be partially influenced by NQO1-mediated bioreductive activation.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	167-171
26219569-6	2015	Although expression of NQO1 was decreased in H3122/DR-1 and H3122/DR-2, NQO1 inhibition by dicumarol did not affect the response of parental cells (H2228 and H3122) to 17-DMAG.	Dicumarol	91-100	NAD(P)H quinone dehydrogenase 1	Homo sapiens	72-76
26023160-6	2015	NDC1 displayed Michaelis-Menten kinetics and was markedly inhibited by dicumarol, a competitive inhibitor of naphthoquinone oxidoreductases.	Dicumarol	71-80	NAD(P)H dehydrogenase C1	Arabidopsis thaliana	0-4
26612783-11	2016	We also assessed whether DC inhibits cell proliferation and viability through NQO1 [NAD(P)H Quinone Oxidoreductase 1], an intracellular inhibitor of reactive oxygen species (ROS).	Dicumarol	25-27	NAD(P)H dehydrogenase, quinone 1	Mus musculus	78-82
26612783-11	2016	We also assessed whether DC inhibits cell proliferation and viability through NQO1 [NAD(P)H Quinone Oxidoreductase 1], an intracellular inhibitor of reactive oxygen species (ROS).	Dicumarol	25-27	NAD(P)H dehydrogenase, quinone 1	Mus musculus	84-116
26059226-5	2015	Tat is stabilized in the presence of NAD(P)H: quinine oxidoreductase 1 (NQO1), and potent degradation of Tat is induced by dicoumarol, an NQO1 inhibitor.	Dicumarol	123-133	Tat	Human immunodeficiency virus 1	0-3
26059226-5	2015	Tat is stabilized in the presence of NAD(P)H: quinine oxidoreductase 1 (NQO1), and potent degradation of Tat is induced by dicoumarol, an NQO1 inhibitor.	Dicumarol	123-133	NAD(P)H quinone dehydrogenase 1	Homo sapiens	72-76
26059226-5	2015	Tat is stabilized in the presence of NAD(P)H: quinine oxidoreductase 1 (NQO1), and potent degradation of Tat is induced by dicoumarol, an NQO1 inhibitor.	Dicumarol	123-133	Tat	Human immunodeficiency virus 1	105-108
26059226-5	2015	Tat is stabilized in the presence of NAD(P)H: quinine oxidoreductase 1 (NQO1), and potent degradation of Tat is induced by dicoumarol, an NQO1 inhibitor.	Dicumarol	123-133	NAD(P)H quinone dehydrogenase 1	Homo sapiens	138-142
24874653-5	2014	Determination of superoxide (O2( -)) production and in vitro cytotoxicity evaluation in the presence of the NQO1 inhibitor dicoumarol confirmed that the ortho-quinones exerted their antitumor activity through NQO1-mediated ROS production by redox cycling.	Dicumarol	123-133	NAD(P)H quinone dehydrogenase 1	Homo sapiens	108-112
24874653-5	2014	Determination of superoxide (O2( -)) production and in vitro cytotoxicity evaluation in the presence of the NQO1 inhibitor dicoumarol confirmed that the ortho-quinones exerted their antitumor activity through NQO1-mediated ROS production by redox cycling.	Dicumarol	123-133	NAD(P)H quinone dehydrogenase 1	Homo sapiens	209-213
24512128-8	2014	NQO1 inhibition (dicoumarol) or H2O2 scavenging (catalase [CAT]) blocked all responses.	Dicumarol	17-27	NAD(P)H quinone dehydrogenase 1	Homo sapiens	0-4
24598128-4	2014	Inhibition of renal NQO1 activity by dicoumarol has been shown in mice.	Dicumarol	37-47	NAD(P)H dehydrogenase, quinone 1	Mus musculus	20-24
24598128-9	2014	The combination of dicoumarol with AAI induced NQO1 protein level and activity in both organs.	Dicumarol	19-29	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	47-51
24598128-12	2014	Because of these unexpected results, we examined CYP2C activity in microsomes and found that treatment of rats with dicoumarol alone and in combination with AAI inhibited CYP2C6/11 in liver.	Dicumarol	116-126	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	49-54
24598128-12	2014	Because of these unexpected results, we examined CYP2C activity in microsomes and found that treatment of rats with dicoumarol alone and in combination with AAI inhibited CYP2C6/11 in liver.	Dicumarol	116-126	cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1	Rattus norvegicus	171-177
24552538-5	2014	Addition of NQO1 to the incubations strongly reduced the formation of all corresponding GSH conjugates, and this activity could be prevented by dicoumarol, a selective NQO1 inhibitor.	Dicumarol	144-154	NAD(P)H quinone dehydrogenase 1	Homo sapiens	168-172
24462458-0	2014	Dicoumarol sensitizes renal cell carcinoma Caki cells to TRAIL-induced apoptosis through down-regulation of Bcl-2, Mcl-1 and c-FLIP in a NQO1-independent manner.	Dicumarol	0-10	TNF superfamily member 10	Homo sapiens	57-62
24462458-0	2014	Dicoumarol sensitizes renal cell carcinoma Caki cells to TRAIL-induced apoptosis through down-regulation of Bcl-2, Mcl-1 and c-FLIP in a NQO1-independent manner.	Dicumarol	0-10	BCL2 apoptosis regulator	Homo sapiens	108-113
24462458-0	2014	Dicoumarol sensitizes renal cell carcinoma Caki cells to TRAIL-induced apoptosis through down-regulation of Bcl-2, Mcl-1 and c-FLIP in a NQO1-independent manner.	Dicumarol	0-10	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	115-120
24462458-0	2014	Dicoumarol sensitizes renal cell carcinoma Caki cells to TRAIL-induced apoptosis through down-regulation of Bcl-2, Mcl-1 and c-FLIP in a NQO1-independent manner.	Dicumarol	0-10	CASP8 and FADD like apoptosis regulator	Homo sapiens	125-131
24462458-0	2014	Dicoumarol sensitizes renal cell carcinoma Caki cells to TRAIL-induced apoptosis through down-regulation of Bcl-2, Mcl-1 and c-FLIP in a NQO1-independent manner.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	137-141
24462458-1	2014	In the study, we investigated the effect of dicoumarol, an anti-coagulant agent with the inhibitory activity of NAD(P)H quinone oxidoreductase 1 (NQO1), on TRAIL-induced apoptosis in renal cancer cell.	Dicumarol	44-54	NAD(P)H quinone dehydrogenase 1	Homo sapiens	112-144
24462458-1	2014	In the study, we investigated the effect of dicoumarol, an anti-coagulant agent with the inhibitory activity of NAD(P)H quinone oxidoreductase 1 (NQO1), on TRAIL-induced apoptosis in renal cancer cell.	Dicumarol	44-54	NAD(P)H quinone dehydrogenase 1	Homo sapiens	146-150
24462458-1	2014	In the study, we investigated the effect of dicoumarol, an anti-coagulant agent with the inhibitory activity of NAD(P)H quinone oxidoreductase 1 (NQO1), on TRAIL-induced apoptosis in renal cancer cell.	Dicumarol	44-54	TNF superfamily member 10	Homo sapiens	156-161
24462458-4	2014	We found that dicoumarol transcriptionally down-regulated Bcl-2 expression via inhibition of NF-kappaB and CREB activity, whereas it down-regulated Mcl-1 and c-FLIP expression at the post-translational level.	Dicumarol	14-24	BCL2 apoptosis regulator	Homo sapiens	58-63
24462458-4	2014	We found that dicoumarol transcriptionally down-regulated Bcl-2 expression via inhibition of NF-kappaB and CREB activity, whereas it down-regulated Mcl-1 and c-FLIP expression at the post-translational level.	Dicumarol	14-24	cAMP responsive element binding protein 1	Homo sapiens	107-111
24462458-4	2014	We found that dicoumarol transcriptionally down-regulated Bcl-2 expression via inhibition of NF-kappaB and CREB activity, whereas it down-regulated Mcl-1 and c-FLIP expression at the post-translational level.	Dicumarol	14-24	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	148-153
24462458-4	2014	We found that dicoumarol transcriptionally down-regulated Bcl-2 expression via inhibition of NF-kappaB and CREB activity, whereas it down-regulated Mcl-1 and c-FLIP expression at the post-translational level.	Dicumarol	14-24	CASP8 and FADD like apoptosis regulator	Homo sapiens	158-164
24462458-5	2014	Overexpression of Bcl-2, Mcl-1, or c-FLIP overcame the dicoumarol plus TRAIL-induced apoptosis, indicating that down-regualtion of these anti-apoptotic proteins may critically contribute to the sensitizing effect of dicoumarol on TRAIL-mediated apoptosis.	Dicumarol	55-65	BCL2 apoptosis regulator	Homo sapiens	18-23
24462458-5	2014	Overexpression of Bcl-2, Mcl-1, or c-FLIP overcame the dicoumarol plus TRAIL-induced apoptosis, indicating that down-regualtion of these anti-apoptotic proteins may critically contribute to the sensitizing effect of dicoumarol on TRAIL-mediated apoptosis.	Dicumarol	55-65	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	25-30
24462458-5	2014	Overexpression of Bcl-2, Mcl-1, or c-FLIP overcame the dicoumarol plus TRAIL-induced apoptosis, indicating that down-regualtion of these anti-apoptotic proteins may critically contribute to the sensitizing effect of dicoumarol on TRAIL-mediated apoptosis.	Dicumarol	55-65	CASP8 and FADD like apoptosis regulator	Homo sapiens	35-41
24462458-5	2014	Overexpression of Bcl-2, Mcl-1, or c-FLIP overcame the dicoumarol plus TRAIL-induced apoptosis, indicating that down-regualtion of these anti-apoptotic proteins may critically contribute to the sensitizing effect of dicoumarol on TRAIL-mediated apoptosis.	Dicumarol	55-65	TNF superfamily member 10	Homo sapiens	230-235
24462458-5	2014	Overexpression of Bcl-2, Mcl-1, or c-FLIP overcame the dicoumarol plus TRAIL-induced apoptosis, indicating that down-regualtion of these anti-apoptotic proteins may critically contribute to the sensitizing effect of dicoumarol on TRAIL-mediated apoptosis.	Dicumarol	216-226	BCL2 apoptosis regulator	Homo sapiens	18-23
24462458-5	2014	Overexpression of Bcl-2, Mcl-1, or c-FLIP overcame the dicoumarol plus TRAIL-induced apoptosis, indicating that down-regualtion of these anti-apoptotic proteins may critically contribute to the sensitizing effect of dicoumarol on TRAIL-mediated apoptosis.	Dicumarol	216-226	CASP8 and FADD like apoptosis regulator	Homo sapiens	35-41
24462458-5	2014	Overexpression of Bcl-2, Mcl-1, or c-FLIP overcame the dicoumarol plus TRAIL-induced apoptosis, indicating that down-regualtion of these anti-apoptotic proteins may critically contribute to the sensitizing effect of dicoumarol on TRAIL-mediated apoptosis.	Dicumarol	216-226	TNF superfamily member 10	Homo sapiens	71-76
22678775-6	2012	The activation of ERK1/2 proteins by dioscoreanone was due to both an arylating reaction, which was suppressed by N-acetyl cysteine, and a redox cycling reaction of NQOR, which was inhibited by dicoumarol.	Dicumarol	194-204	mitogen-activated protein kinase 3	Mus musculus	18-24
25638376-0	2014	Dicoumarol inhibits rat NAD(P)H:quinone oxidoreductase in vitro and induces its expression in vivo.	Dicumarol	0-10	crystallin zeta	Rattus norvegicus	32-54
25638376-1	2014	OBJECTIVES: Dicoumarol is known to act as an inhibitor of NAD(P)H: quinone oxidoreductase (NQO1).	Dicumarol	12-22	crystallin zeta	Rattus norvegicus	67-89
25638376-1	2014	OBJECTIVES: Dicoumarol is known to act as an inhibitor of NAD(P)H: quinone oxidoreductase (NQO1).	Dicumarol	12-22	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	91-95
25638376-5	2014	However, it is still not known how dicoumarol influences the NQO1-mediated reductive bioactivation of AAI.	Dicumarol	35-45	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	61-65
25638376-8	2014	RESULTS: In this study, dicoumarol inhibited AAI bioactivation to form AAI-DNA adducts mediated by rat and human NQO1 in vitro as expected.	Dicumarol	24-34	NAD(P)H quinone dehydrogenase 1	Homo sapiens	113-117
25638376-9	2014	We however, demonstrated that dicoumarol acts as an inducer of NQO1 in kidney and lung of rats treated with this NQO1 inhibitor in vivo, both at protein and activity levels.	Dicumarol	30-40	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	63-67
25638376-9	2014	We however, demonstrated that dicoumarol acts as an inducer of NQO1 in kidney and lung of rats treated with this NQO1 inhibitor in vivo, both at protein and activity levels.	Dicumarol	30-40	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	113-117
25638376-11	2014	NQO1 mRNA levels were induced in liver only by dicoumarol.	Dicumarol	47-57	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	0-4
25638376-12	2014	CONCLUSION: Our results indicate a dual role of dicoumarol in NQO1-mediated genotoxicty of AAI.	Dicumarol	48-58	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	62-66
23047025-4	2012	We hypothesize that the cytotoxicity of CGQ in dicoumarol-treated hepatocytes was the result of inhibition of the NQO1 detoxification pathway, thus allowing more quinone to be metabolized towards the one-electron pathway to form reactive semiquinones and/or reactive oxygen species.	Dicumarol	47-57	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	114-118
24466103-5	2014	ATO dose-dependently induced c-Jun NH2-terminal kinase (JNK) activation, and JNK specific inhibitor dicumarol obviously reduced ATO-induced DeltaPsim depolarization in platelets.	Dicumarol	100-109	mitogen-activated protein kinase 8	Homo sapiens	77-80
22960073-4	2012	Western Blot analysis showed that MCF-7 cells expressed high levels of cytoprotective NADPH quinone oxidoreductase 1 (NQO1), which was responsible for TQ-resistance since inhibition of NQO1 with dicoumarol rendered MCF-7 cells TQ-sensitive.	Dicumarol	195-205	NAD(P)H quinone dehydrogenase 1	Homo sapiens	86-116
22692362-7	2012	The treatment of HOS cells with dicumarol, a NQO1 inhibitor, caused a dose-dependent decline in p53 protein levels, proving the effect of an antioxidant enzyme on p53 expression and, potentially, down-stream processes.	Dicumarol	32-41	NAD(P)H quinone dehydrogenase 1	Homo sapiens	45-49
22692362-7	2012	The treatment of HOS cells with dicumarol, a NQO1 inhibitor, caused a dose-dependent decline in p53 protein levels, proving the effect of an antioxidant enzyme on p53 expression and, potentially, down-stream processes.	Dicumarol	32-41	tumor protein p53	Homo sapiens	96-99
22692362-7	2012	The treatment of HOS cells with dicumarol, a NQO1 inhibitor, caused a dose-dependent decline in p53 protein levels, proving the effect of an antioxidant enzyme on p53 expression and, potentially, down-stream processes.	Dicumarol	32-41	tumor protein p53	Homo sapiens	163-166
22960073-4	2012	Western Blot analysis showed that MCF-7 cells expressed high levels of cytoprotective NADPH quinone oxidoreductase 1 (NQO1), which was responsible for TQ-resistance since inhibition of NQO1 with dicoumarol rendered MCF-7 cells TQ-sensitive.	Dicumarol	195-205	NAD(P)H quinone dehydrogenase 1	Homo sapiens	118-122
22960073-4	2012	Western Blot analysis showed that MCF-7 cells expressed high levels of cytoprotective NADPH quinone oxidoreductase 1 (NQO1), which was responsible for TQ-resistance since inhibition of NQO1 with dicoumarol rendered MCF-7 cells TQ-sensitive.	Dicumarol	195-205	NAD(P)H quinone dehydrogenase 1	Homo sapiens	185-189
21947872-8	2012	PG-induced NQO1 activity was inhibited with dicoumarol, which did not affect PG-induced cytoprotection.	Dicumarol	44-54	NAD(P)H quinone dehydrogenase 1	Homo sapiens	11-15
21947872-9	2012	Dicoumarol treatment alone potentiated Dox-induced caspase-3 activity.	Dicumarol	0-10	caspase 3	Homo sapiens	51-60
22115979-9	2012	Menadione-dependent redox cycling was sensitive to the NQO1 inhibitor dicoumarol and the flavoprotein inhibitor diphenylene iodonium, suggesting a role for NQO1 and other oxidoreductases in this process.	Dicumarol	70-80	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	55-59
22086148-6	2012	If the quinone is maintained in the reduced state, a task that in some cell types appears to be performed by dicoumarol-sensitive NAD(P)H:quinone oxidoreductase 1 [Haefeli et al.	Dicumarol	109-119	NAD(P)H quinone dehydrogenase 1	Homo sapiens	130-162
22115979-9	2012	Menadione-dependent redox cycling was sensitive to the NQO1 inhibitor dicoumarol and the flavoprotein inhibitor diphenylene iodonium, suggesting a role for NQO1 and other oxidoreductases in this process.	Dicumarol	70-80	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	156-160
21613233-0	2011	Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity.	Dicumarol	37-47	NAD(P)H dehydrogenase, quinone 1	Mus musculus	20-24
22984577-9	2012	In studies with BxPc-3 human pancreatic cancer cells the association of NQO1 with mitotic spindles appeared to be unchanged in the presence of NQO1 inhibitors ES936 or dicoumarol suggesting that NQO1 can associate with the mitotic spindle and still retain catalytic activity.	Dicumarol	168-178	NAD(P)H quinone dehydrogenase 1	Homo sapiens	72-76
21613233-5	2011	Inhibition of NQO1 activity by dicoumarol pretreatment significantly decreased renal aristolactam I (ALI) levels, a major reductive metabolite of AAI, whereas it increased renal AAI and its major oxidative metabolite 8-hydroxy-aristolochic acid I (AAIa) levels in male C57BL/6 mice.	Dicumarol	31-41	NAD(P)H dehydrogenase, quinone 1	Mus musculus	14-18
21505151-7	2011	Overexpression of cytosolic NAD(P)H-quinone oxidoreductase (NQO1) increased PMET activity in the presence of 10 mM glucose while inhibition of NQO1 by its inhibitor dicoumarol abolished this activity.	Dicumarol	165-175	NAD(P)H quinone dehydrogenase 1	Homo sapiens	60-64
21505151-7	2011	Overexpression of cytosolic NAD(P)H-quinone oxidoreductase (NQO1) increased PMET activity in the presence of 10 mM glucose while inhibition of NQO1 by its inhibitor dicoumarol abolished this activity.	Dicumarol	165-175	NAD(P)H quinone dehydrogenase 1	Homo sapiens	143-147
21239697-6	2011	Dicoumarol, an NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) inhibitor, behaved similarly to warfarin in both cell lines.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	15-57
21399655-13	2011	Dicoumarol 100 mumol/L, a JNK1/2 inhibitor, markedly suppressed the formation of apoptotic bodies and JNK activation induced by genipin 400 mumol/L.	Dicumarol	0-10	mitogen-activated protein kinase 8	Homo sapiens	26-32
21399655-13	2011	Dicoumarol 100 mumol/L, a JNK1/2 inhibitor, markedly suppressed the formation of apoptotic bodies and JNK activation induced by genipin 400 mumol/L.	Dicumarol	0-10	mitogen-activated protein kinase 8	Homo sapiens	26-29
21354327-6	2011	The addition of dicoumarol, a DT-diaphorase inhibitor, decreased the number of danthron-induced histidine revertants by 35-39%, indicating that DT-diaphorase is involved in the metabolic activation of danthron in the presence of NADH as an electron donor.	Dicumarol	16-26	NAD(P)H quinone dehydrogenase 1	Homo sapiens	30-43
21354327-6	2011	The addition of dicoumarol, a DT-diaphorase inhibitor, decreased the number of danthron-induced histidine revertants by 35-39%, indicating that DT-diaphorase is involved in the metabolic activation of danthron in the presence of NADH as an electron donor.	Dicumarol	16-26	NAD(P)H quinone dehydrogenase 1	Homo sapiens	144-157
21296895-7	2011	DQ reduction in NQO1(+/+) lungs was inhibited by 90 +- 4% with dicumarol; there was no inhibition in NQO1(-/-) lungs.	Dicumarol	63-72	NAD(P)H dehydrogenase, quinone 1	Mus musculus	16-20
21239697-6	2011	Dicoumarol, an NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) inhibitor, behaved similarly to warfarin in both cell lines.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	59-63
20970406-0	2011	Inhibitors of NQO1: identification of compounds more potent than dicoumarol without associated off-target effects.	Dicumarol	65-75	NAD(P)H quinone dehydrogenase 1	Homo sapiens	14-18
20970406-2	2011	The latter property has been extensively characterized by the use of dicoumarol which inhibits the chaperone properties of NQO1 in cells.	Dicumarol	69-79	NAD(P)H quinone dehydrogenase 1	Homo sapiens	123-127
20919992-6	2010	Although a number of active compounds, including cromolyn disodium and dicumarol, displayed similar potency at both orthologues of GPR35, a number of ligands, including pamoate and niflumic acid, had detectable activity only at human GPR35 whereas others, including zaprinast and luteolin, were markedly selective for the rat orthologue.	Dicumarol	71-80	G protein-coupled receptor 35	Homo sapiens	131-136
21035436-5	2011	beta-Lapachone-induced cell death gradually increased in a time-dependent manner in U87 MG cells, which were partly prevented by pretreatment of a specific inhibitor of NQO1 (dicoumarol).	Dicumarol	175-185	NAD(P)H quinone dehydrogenase 1	Homo sapiens	169-173
22178938-6	2011	Exposure of erythrocytes for 48 hours to dicoumarol (=10 muM) significantly increased [Ca(2+)](i), enhanced cation channel activity, decreased forward scatter, triggered annexin-V-binding and elicited hemolysis.	Dicumarol	41-51	latexin	Homo sapiens	57-60
22178938-6	2011	Exposure of erythrocytes for 48 hours to dicoumarol (=10 muM) significantly increased [Ca(2+)](i), enhanced cation channel activity, decreased forward scatter, triggered annexin-V-binding and elicited hemolysis.	Dicumarol	41-51	annexin A5	Homo sapiens	170-179
22178938-7	2011	Following exposure to 30 muM dicoumarol, annexin-V-binding affected approximately 15%, and hemolysis 2% of treated erythrocytes.	Dicumarol	29-39	latexin	Homo sapiens	25-28
22178938-7	2011	Following exposure to 30 muM dicoumarol, annexin-V-binding affected approximately 15%, and hemolysis 2% of treated erythrocytes.	Dicumarol	29-39	annexin A5	Homo sapiens	41-50
22178938-8	2011	The stimulation of annexin-V-binding by dicoumarol was abrogated in the nominal absence of Ca(2+).	Dicumarol	40-50	annexin A5	Homo sapiens	19-28
20849151-2	2010	There are several studies supporting this idea, but in all studies, we used dicoumarol, an inhibitor of DT-diaphorase.	Dicumarol	76-86	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	104-117
20940411-6	2010	Radiosensitization by beta-lap was blocked by the NQO1 inhibitor dicoumarol or the PARP-1 inhibitor DPQ.	Dicumarol	65-75	LAP	Homo sapiens	27-30
20940411-6	2010	Radiosensitization by beta-lap was blocked by the NQO1 inhibitor dicoumarol or the PARP-1 inhibitor DPQ.	Dicumarol	65-75	NAD(P)H quinone dehydrogenase 1	Homo sapiens	50-54
20970406-4	2011	Coumarin-based compounds that are more potent than dicoumarol as inhibitors of NQO1 in cells have been identified (Nolan et al., Biochem Pharmacol 2010;80:977-81).	Dicumarol	51-61	NAD(P)H quinone dehydrogenase 1	Homo sapiens	79-83
20732396-5	2010	The protective effect of SFN on ROS production and cell viability was prevented by buthionine sulfoximine (BSO), an inhibitor of gammaGCL, and by dicoumarol, an inhibitor of NQO1.	Dicumarol	146-156	14-3-3 protein sigma	Sus scrofa	25-28
20732396-5	2010	The protective effect of SFN on ROS production and cell viability was prevented by buthionine sulfoximine (BSO), an inhibitor of gammaGCL, and by dicoumarol, an inhibitor of NQO1.	Dicumarol	146-156	NAD(P)H quinone dehydrogenase 1	Sus scrofa	174-178
20480521-0	2010	Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	61-65
20599803-3	2010	The inhibitor, dicoumarol, is classically used to probe the biological properties of NQO1, but interpretation of enzyme function is compromised by the multiple "off-target" effects of this agent.	Dicumarol	15-25	NAD(P)H quinone dehydrogenase 1	Homo sapiens	85-89
20599803-4	2010	Coumarin-based compounds that are more potent than dicoumarol as inhibitors of recombinant human NQO1 have been identified (Nolan et al., J Med Chem 2009;52:7142-56) The purpose of the work reported here is to demonstrate the functional activity of these agents for inhibiting NQO1 in cells.	Dicumarol	51-61	NAD(P)H quinone dehydrogenase 1	Homo sapiens	97-101
20599803-4	2010	Coumarin-based compounds that are more potent than dicoumarol as inhibitors of recombinant human NQO1 have been identified (Nolan et al., J Med Chem 2009;52:7142-56) The purpose of the work reported here is to demonstrate the functional activity of these agents for inhibiting NQO1 in cells.	Dicumarol	51-61	NAD(P)H quinone dehydrogenase 1	Homo sapiens	277-281
20599803-8	2010	In conclusion, agents have been identified that may be more pharmacologically useful than dicoumarol for probing the function of NQO1 in cells and tissues.	Dicumarol	90-100	NAD(P)H quinone dehydrogenase 1	Homo sapiens	129-133
20430442-9	2010	The VEGF-mediated decrease in amyloid beta is dependent on a functional Flt-1 receptor and is inhibited by dicoumarol, a multifunctional inhibitor of stress-activated protein kinase (SAPK)/JNK and NFkappaB pathways.	Dicumarol	107-117	vascular endothelial growth factor A	Homo sapiens	4-8
20430442-9	2010	The VEGF-mediated decrease in amyloid beta is dependent on a functional Flt-1 receptor and is inhibited by dicoumarol, a multifunctional inhibitor of stress-activated protein kinase (SAPK)/JNK and NFkappaB pathways.	Dicumarol	107-117	mitogen-activated protein kinase 8	Homo sapiens	189-192
20430442-9	2010	The VEGF-mediated decrease in amyloid beta is dependent on a functional Flt-1 receptor and is inhibited by dicoumarol, a multifunctional inhibitor of stress-activated protein kinase (SAPK)/JNK and NFkappaB pathways.	Dicumarol	107-117	nuclear factor kappa B subunit 1	Homo sapiens	197-205
20480521-1	2010	AIM: To investigate whether dicoumarol, a potent inhibitor of NAD(P)H quinone oxidoreductase-1 (NQO1), potentiates gemcitabine to induce cytotoxicity in cholangiocarcinoma cells (CCA) and the role of reactive oxygen generation in sensitizing the cells.	Dicumarol	28-38	NAD(P)H quinone dehydrogenase 1	Homo sapiens	62-94
20480521-1	2010	AIM: To investigate whether dicoumarol, a potent inhibitor of NAD(P)H quinone oxidoreductase-1 (NQO1), potentiates gemcitabine to induce cytotoxicity in cholangiocarcinoma cells (CCA) and the role of reactive oxygen generation in sensitizing the cells.	Dicumarol	28-38	NAD(P)H quinone dehydrogenase 1	Homo sapiens	96-100
20480521-9	2010	RESULTS: Dicoumarol markedly enhanced the cytotoxicity of gemcitabine in KKU-100 and KKU-OCA17, the high NQO1 activity and mRNA expressing cells, but not in the other cells with low NQO1 activity.	Dicumarol	9-19	NAD(P)H quinone dehydrogenase 1	Homo sapiens	105-109
20480521-9	2010	RESULTS: Dicoumarol markedly enhanced the cytotoxicity of gemcitabine in KKU-100 and KKU-OCA17, the high NQO1 activity and mRNA expressing cells, but not in the other cells with low NQO1 activity.	Dicumarol	9-19	NAD(P)H quinone dehydrogenase 1	Homo sapiens	182-186
20480521-11	2010	Dicoumarol at concentrations that inhibited NQO1 activity did not alter mitochondrial transmembrane potential and production of reactive oxygen species.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	44-48
20480521-13	2010	However, gemcitabine and dicoumarol combination induced increased p53 and decreased Bcl-(XL) levels in KKU-100, but not in KKU-M214 cells.	Dicumarol	25-35	tumor protein p53	Homo sapiens	66-69
20480521-13	2010	However, gemcitabine and dicoumarol combination induced increased p53 and decreased Bcl-(XL) levels in KKU-100, but not in KKU-M214 cells.	Dicumarol	25-35	BCL2 like 1	Homo sapiens	84-91
19460413-8	2009	Inhibition of nitroreductive metabolism by dicoumarol attenuated the induction of DNA damage, intracellular ROS levels and GRP78 expression.	Dicumarol	43-53	heat shock protein family A (Hsp70) member 5	Homo sapiens	123-128
19583730-0	2010	Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wild-type urothelial cancer cells through p38 activation.	Dicumarol	0-10	tumor protein p53	Homo sapiens	56-59
19583730-0	2010	Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wild-type urothelial cancer cells through p38 activation.	Dicumarol	0-10	mitogen-activated protein kinase 14	Homo sapiens	102-105
19583730-3	2010	Then, dicoumarol-mediated enhancement of doxorubicin-induced cytotoxicity was screened in urothelial cancer cell lines with different p53 statuses or RT112 stable transfectants with a dominant-negative mutant of p53 (p53DN).	Dicumarol	6-16	tumor protein p53	Homo sapiens	134-137
19583730-3	2010	Then, dicoumarol-mediated enhancement of doxorubicin-induced cytotoxicity was screened in urothelial cancer cell lines with different p53 statuses or RT112 stable transfectants with a dominant-negative mutant of p53 (p53DN).	Dicumarol	6-16	tumor protein p53	Homo sapiens	212-215
19583730-4	2010	To clarify the importance of the modification of p53 function by dicoumarol to enhance doxorubicin toxicity, the change in the p53-p21 pathway and mitogen-activated protein kinase (MAPK)-mitochondria pathway by the combined treatment were elucidated by Western blot analysis.	Dicumarol	65-75	tumor protein p53	Homo sapiens	49-52
19583730-7	2010	Dicoumarol (100 microm) also enhanced the cytotoxicity of doxorubicin in other bladder cancer cell lines with wild-type p53 (wt-p53; three times in 253J and 13 times in KK47), but not in those with mutant-type p53 (TCCsup, J82 and EJ) or in RT112 p53DN.	Dicumarol	0-10	tumor protein p53	Homo sapiens	120-123
19583730-7	2010	Dicoumarol (100 microm) also enhanced the cytotoxicity of doxorubicin in other bladder cancer cell lines with wild-type p53 (wt-p53; three times in 253J and 13 times in KK47), but not in those with mutant-type p53 (TCCsup, J82 and EJ) or in RT112 p53DN.	Dicumarol	0-10	tumor protein p53	Homo sapiens	128-131
19583730-7	2010	Dicoumarol (100 microm) also enhanced the cytotoxicity of doxorubicin in other bladder cancer cell lines with wild-type p53 (wt-p53; three times in 253J and 13 times in KK47), but not in those with mutant-type p53 (TCCsup, J82 and EJ) or in RT112 p53DN.	Dicumarol	0-10	tumor protein p53	Homo sapiens	128-131
19583730-8	2010	The combined treatment with dicoumarol suppressed p53/p21 induction by doxorubicin and resulted in sequential p38 MAPK activation, myeloid cell leukaemia 1 suppression and caspase cleavage.	Dicumarol	28-38	tumor protein p53	Homo sapiens	50-53
19583730-8	2010	The combined treatment with dicoumarol suppressed p53/p21 induction by doxorubicin and resulted in sequential p38 MAPK activation, myeloid cell leukaemia 1 suppression and caspase cleavage.	Dicumarol	28-38	H3 histone pseudogene 16	Homo sapiens	54-57
19583730-8	2010	The combined treatment with dicoumarol suppressed p53/p21 induction by doxorubicin and resulted in sequential p38 MAPK activation, myeloid cell leukaemia 1 suppression and caspase cleavage.	Dicumarol	28-38	mitogen-activated protein kinase 14	Homo sapiens	110-113
19583730-9	2010	The synergistic effect of doxorubicin/dicoumarol was suppressed by the p38 MAPK inhibitor SB202190 and, furthermore, p21 knockdown with shRNA transfection made RT112 cells six times more susceptible to doxorubicin with p38 MAPK activation.	Dicumarol	38-48	mitogen-activated protein kinase 14	Homo sapiens	71-74
19583730-9	2010	The synergistic effect of doxorubicin/dicoumarol was suppressed by the p38 MAPK inhibitor SB202190 and, furthermore, p21 knockdown with shRNA transfection made RT112 cells six times more susceptible to doxorubicin with p38 MAPK activation.	Dicumarol	38-48	mitogen-activated protein kinase 14	Homo sapiens	219-222
19583730-10	2010	CONCLUSION: These results suggest that concomitant use of dicoumarol could enhance the cytotoxicity of doxorubicin in urothelial cancer cells with wt-p53 through the p53/p21/p38 MAPK pathways.	Dicumarol	58-68	tumor protein p53	Homo sapiens	150-153
19583730-10	2010	CONCLUSION: These results suggest that concomitant use of dicoumarol could enhance the cytotoxicity of doxorubicin in urothelial cancer cells with wt-p53 through the p53/p21/p38 MAPK pathways.	Dicumarol	58-68	tumor protein p53	Homo sapiens	166-169
19583730-10	2010	CONCLUSION: These results suggest that concomitant use of dicoumarol could enhance the cytotoxicity of doxorubicin in urothelial cancer cells with wt-p53 through the p53/p21/p38 MAPK pathways.	Dicumarol	58-68	H3 histone pseudogene 16	Homo sapiens	170-173
19583730-10	2010	CONCLUSION: These results suggest that concomitant use of dicoumarol could enhance the cytotoxicity of doxorubicin in urothelial cancer cells with wt-p53 through the p53/p21/p38 MAPK pathways.	Dicumarol	58-68	mitogen-activated protein kinase 14	Homo sapiens	174-177
19932748-2	2010	DMNQ-dependent WST-1 reduction by MDCK cells was strongly inhibited by low concentrations of the NQO1 inhibitor dicoumarol and was also inhibited by diphenyleneiodonium, capsaicin, and superoxide dismutase (SOD), but not by the uncoupler FCCP or the complex IV inhibitor cyanide.	Dicumarol	112-122	NAD(P)H quinone dehydrogenase 1	Canis lupus familiaris	97-101
20028737-4	2010	Treatment of cells with dicumarol (dicoumarol), a pharmacological inhibitor of NQO1 known to preclude NQO1 binding to its protein partners, provokes eIF4GI degradation by the proteasome.	Dicumarol	24-33	NAD(P)H quinone dehydrogenase 1	Homo sapiens	79-83
20028737-4	2010	Treatment of cells with dicumarol (dicoumarol), a pharmacological inhibitor of NQO1 known to preclude NQO1 binding to its protein partners, provokes eIF4GI degradation by the proteasome.	Dicumarol	24-33	NAD(P)H quinone dehydrogenase 1	Homo sapiens	102-106
20028737-4	2010	Treatment of cells with dicumarol (dicoumarol), a pharmacological inhibitor of NQO1 known to preclude NQO1 binding to its protein partners, provokes eIF4GI degradation by the proteasome.	Dicumarol	24-33	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	149-155
20028737-4	2010	Treatment of cells with dicumarol (dicoumarol), a pharmacological inhibitor of NQO1 known to preclude NQO1 binding to its protein partners, provokes eIF4GI degradation by the proteasome.	Dicumarol	35-45	NAD(P)H quinone dehydrogenase 1	Homo sapiens	79-83
20028737-4	2010	Treatment of cells with dicumarol (dicoumarol), a pharmacological inhibitor of NQO1 known to preclude NQO1 binding to its protein partners, provokes eIF4GI degradation by the proteasome.	Dicumarol	35-45	NAD(P)H quinone dehydrogenase 1	Homo sapiens	102-106
20028737-4	2010	Treatment of cells with dicumarol (dicoumarol), a pharmacological inhibitor of NQO1 known to preclude NQO1 binding to its protein partners, provokes eIF4GI degradation by the proteasome.	Dicumarol	35-45	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	149-155
20028737-6	2010	We further reveal that treatment of cells with dicumarol frees eIF4GI from mRNA translation initiation complexes due to strong activation of its natural competitor, the translational repressor 4E-BP1.	Dicumarol	47-56	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	63-69
19877692-7	2009	Thus, we provide a computational, synthetic, and biological platform to generate competitive NQO1 inhibitors with superior pharmacological properties to dicoumarol.	Dicumarol	153-163	NAD(P)H quinone dehydrogenase 1	Homo sapiens	93-97
19738461-5	2009	The expression and enzymatic activity of NQO1 also increased during the 24 h after cisplatin treatment, and dicoumarol, an inhibitor of NQO1, was found to nullify the cisplatin-induced increase in beta-lap sensitivity.	Dicumarol	108-118	NAD(P)H quinone dehydrogenase 1	Homo sapiens	136-140
19394313-5	2009	Genetic (siRNA) or pharmacological (dicoumarol) antagonism of NQO1 strongly sensitized G361 cells to DCPIP apoptogenic activity.	Dicumarol	36-46	NAD(P)H quinone dehydrogenase 1	Homo sapiens	62-66
19265190-5	2009	However, a different cell death mechanism was observed when 100 microm copper dopamine complex was incubated in the presence of 100 microm dicoumarol, an inhibitor of NAD(P)H quinone:oxidoreductase (EC 1.6.99.2, also known as DT-diaphorase and NQ01), because a more extensive and rapid cell death was observed.	Dicumarol	139-149	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	226-239
20387640-2	2009	This is the first report demonstrating that troglitazone and alpha-tocopherol C6, unlike a-tocopherol and pioglitazone substantially inhibited the activity of NAD(P)H:quinone oxidoreductase (DT-diaphorase) and this effect is increased with specific DT-diaphorase inhibitor, dicoumarol.	Dicumarol	274-284	crystallin zeta	Rattus norvegicus	167-189
20387640-2	2009	This is the first report demonstrating that troglitazone and alpha-tocopherol C6, unlike a-tocopherol and pioglitazone substantially inhibited the activity of NAD(P)H:quinone oxidoreductase (DT-diaphorase) and this effect is increased with specific DT-diaphorase inhibitor, dicoumarol.	Dicumarol	274-284	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	191-204
19332539-4	2009	Dicoumarols were identified as a class of compounds that inhibited furin non-competitively and reversibly with Ki values in the micromolar range.	Dicumarol	0-11	furin, paired basic amino acid cleaving enzyme	Homo sapiens	67-72
19332539-6	2009	Compounds tested exhibited distinct patterns of inhibition of other furin-family PCs (rat PACE4, human PC5/6 and human PC7), showing that dicoumarol derivatives might be developed as either generic or selective inhibitors of the PCs.	Dicumarol	138-148	furin, paired basic amino acid cleaving enzyme	Homo sapiens	68-73
19332539-6	2009	Compounds tested exhibited distinct patterns of inhibition of other furin-family PCs (rat PACE4, human PC5/6 and human PC7), showing that dicoumarol derivatives might be developed as either generic or selective inhibitors of the PCs.	Dicumarol	138-148	proprotein convertase subtilisin/kexin type 6	Rattus norvegicus	90-95
19332539-6	2009	Compounds tested exhibited distinct patterns of inhibition of other furin-family PCs (rat PACE4, human PC5/6 and human PC7), showing that dicoumarol derivatives might be developed as either generic or selective inhibitors of the PCs.	Dicumarol	138-148	proprotein convertase subtilisin/kexin type 5	Homo sapiens	103-108
19332539-6	2009	Compounds tested exhibited distinct patterns of inhibition of other furin-family PCs (rat PACE4, human PC5/6 and human PC7), showing that dicoumarol derivatives might be developed as either generic or selective inhibitors of the PCs.	Dicumarol	138-148	proprotein convertase subtilisin/kexin type 7	Homo sapiens	119-122
19332539-7	2009	The extensive clinical use, high bioavailability and relatively low toxicity of dicoumarols suggests that the dicoumarol structure will be a good starting point for development of drug-like inhibitors of furin and other PCs that can act both intracellularly and at the cell surface.	Dicumarol	80-91	furin, paired basic amino acid cleaving enzyme	Homo sapiens	204-209
19332539-7	2009	The extensive clinical use, high bioavailability and relatively low toxicity of dicoumarols suggests that the dicoumarol structure will be a good starting point for development of drug-like inhibitors of furin and other PCs that can act both intracellularly and at the cell surface.	Dicumarol	80-90	furin, paired basic amino acid cleaving enzyme	Homo sapiens	204-209
19059883-5	2009	In primary human airway epithelial cells, inhibition of NQO1 by dicumarol blocks ozone-induced F(2)-isoprostane production and IL-8 gene expression.	Dicumarol	64-73	NAD(P)H quinone dehydrogenase 1	Homo sapiens	56-60
19059883-5	2009	In primary human airway epithelial cells, inhibition of NQO1 by dicumarol blocks ozone-induced F(2)-isoprostane production and IL-8 gene expression.	Dicumarol	64-73	C-X-C motif chemokine ligand 8	Homo sapiens	127-131
18810995-5	2008	In addition, the cytotoxicity of nitroaromatics is also partly prevented by an inhibitor of NQO1, dicumarol.	Dicumarol	98-107	NAD(P)H dehydrogenase, quinone 1	Mus musculus	92-96
18785111-5	2008	Blocking the enzyme activity of NQO1 with dicoumarol, a known NQO1 inhibitor, or preventing an increase in intracellular calcium levels using BAPTA-AM, an intracellular calcium chelator, substantially inhibited MAPK phosphorylation, abolished the activation of calpain, caspase-12 and caspase-7, and provided significant protection of beta-lapachone-treated cells.	Dicumarol	42-52	NAD(P)H quinone dehydrogenase 1	Homo sapiens	32-36
18785111-5	2008	Blocking the enzyme activity of NQO1 with dicoumarol, a known NQO1 inhibitor, or preventing an increase in intracellular calcium levels using BAPTA-AM, an intracellular calcium chelator, substantially inhibited MAPK phosphorylation, abolished the activation of calpain, caspase-12 and caspase-7, and provided significant protection of beta-lapachone-treated cells.	Dicumarol	42-52	mitogen-activated protein kinase 1	Homo sapiens	211-215
18703762-4	2008	In normoxic lungs, CoQ(1)H(2) efflux rates when CoQ(1) was infused decreased by 58 and 33% in the presence of rotenone (mitochondrial complex I inhibitor) and dicumarol [NAD(P)H-quinone oxidoreductase 1 (NQO1) inhibitor], respectively.	Dicumarol	159-168	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	204-208
18661957-8	2008	The nonselective derivative, 2, suffered bioreduction in both conditions and, according to the inhibition studies with dicoumarol and ketoconazole, involves both DT-diaphorase and cytochrome P450.	Dicumarol	119-129	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	162-175
18661957-8	2008	The nonselective derivative, 2, suffered bioreduction in both conditions and, according to the inhibition studies with dicoumarol and ketoconazole, involves both DT-diaphorase and cytochrome P450.	Dicumarol	119-129	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	180-195
18661957-6	2008	Dicoumarol and ketoconazole were found to inhibit the hypoxic metabolism of the most selective phenazine 5,10-dioxide, 1, inferring a role for DT-diaphorase and cytochrome P450.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	143-156
18661957-6	2008	Dicoumarol and ketoconazole were found to inhibit the hypoxic metabolism of the most selective phenazine 5,10-dioxide, 1, inferring a role for DT-diaphorase and cytochrome P450.	Dicumarol	0-10	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	161-176
17979524-7	2007	Immunoblot analysis showed that whereas the level of HO-1 protein was elevated, that of NAD(P)H:quinone oxidoreductase (NQO1) was decreased after the treatment with capsaicin or the inhibitor of NQO1, dicumarol.	Dicumarol	201-210	heme oxygenase 1	Homo sapiens	53-57
18500786-2	2008	Therefore, the aim of this study was to evaluate whether CuSO4 neurotoxicity in vivo, which was evaluated by determining the contralateral rotation and loss of tyrosine hydroxylase immunostaining, was dependent on DT-diaphorase inhibition by dicoumarol.	Dicumarol	242-252	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	214-227
17847068-5	2008	Dicoumarol, a diaphorase inhibitor, and 1-bromoheptane, a GSH depleting agent, increased 4-HEB toxicity towards SK-MEL-28 cells indicating o-quinone formation played an important role in 4-HEB induced cell toxicity.	Dicumarol	0-10	transcription factor 12	Homo sapiens	91-94
17847068-5	2008	Dicoumarol, a diaphorase inhibitor, and 1-bromoheptane, a GSH depleting agent, increased 4-HEB toxicity towards SK-MEL-28 cells indicating o-quinone formation played an important role in 4-HEB induced cell toxicity.	Dicumarol	0-10	transcription factor 12	Homo sapiens	189-192
17847068-9	2008	4-HEB also led to reactive oxygen species (ROS) formation in melanoma cells which exacerbated by dicoumarol and 1-bromoheptane whereas cyclosporin A and trifluoperazine prevented it.	Dicumarol	97-107	transcription factor 12	Homo sapiens	2-5
18522901-3	2008	In addition, this cell line expresses serotonin transporters, divalent metal transporter, DMT1, dopamine receptor 1 mRNA under proliferating conditions, and dopamine receptor 5 mRNA after incubation with dopamine or dicoumarol.	Dicumarol	216-226	dopamine receptor D5	Rattus norvegicus	157-176
18347135-0	2008	Dicoumarol down-regulates human PTTG1/Securin mRNA expression through inhibition of Hsp90.	Dicumarol	0-10	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	32-37
18347135-0	2008	Dicoumarol down-regulates human PTTG1/Securin mRNA expression through inhibition of Hsp90.	Dicumarol	0-10	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	38-45
18347135-0	2008	Dicoumarol down-regulates human PTTG1/Securin mRNA expression through inhibition of Hsp90.	Dicumarol	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	84-89
18347135-3	2008	Dicoumarol, a long-established oral anticoagulant, is a new Hsp90 inhibitor that represses PTTG1/Securin gene expression and provokes apoptosis through a complex trait involving both intrinsic and extrinsic pathways.	Dicumarol	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	60-65
18347135-3	2008	Dicoumarol, a long-established oral anticoagulant, is a new Hsp90 inhibitor that represses PTTG1/Securin gene expression and provokes apoptosis through a complex trait involving both intrinsic and extrinsic pathways.	Dicumarol	0-10	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	91-96
18347135-3	2008	Dicoumarol, a long-established oral anticoagulant, is a new Hsp90 inhibitor that represses PTTG1/Securin gene expression and provokes apoptosis through a complex trait involving both intrinsic and extrinsic pathways.	Dicumarol	0-10	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	97-104
18347135-4	2008	Dicoumarol activity as an Hsp90 inhibitor is confirmed by smaller levels of Hsp90 clients in treated cells and inhibition of in vivo heat shock luciferase activity recovery assays.	Dicumarol	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	26-31
18347135-4	2008	Dicoumarol activity as an Hsp90 inhibitor is confirmed by smaller levels of Hsp90 clients in treated cells and inhibition of in vivo heat shock luciferase activity recovery assays.	Dicumarol	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	76-81
18347135-6	2008	Also, overexpression of human Hsp90 in yeast makes them hypersensitive to dicoumarol.	Dicumarol	74-84	heat shock protein 90 alpha family class A member 1	Homo sapiens	30-35
18347135-7	2008	Both apoptosis and PTTG1/Securin gene repression exerted by dicoumarol in cancer cells are independent of three of the most important signaling pathways affected by Hsp90 inhibition: nuclear factor-kappaB, p53, or Akt/protein kinase B signaling pathways.	Dicumarol	60-70	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	19-24
18347135-7	2008	Both apoptosis and PTTG1/Securin gene repression exerted by dicoumarol in cancer cells are independent of three of the most important signaling pathways affected by Hsp90 inhibition: nuclear factor-kappaB, p53, or Akt/protein kinase B signaling pathways.	Dicumarol	60-70	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	25-32
18347135-9	2008	Overall, we show that expression of PTTG1/Securin gene is Hsp90 dependent and that dicoumarol is a bona fide Hsp90 inhibitor.	Dicumarol	83-93	heat shock protein 90 alpha family class A member 1	Homo sapiens	109-114
17979524-7	2007	Immunoblot analysis showed that whereas the level of HO-1 protein was elevated, that of NAD(P)H:quinone oxidoreductase (NQO1) was decreased after the treatment with capsaicin or the inhibitor of NQO1, dicumarol.	Dicumarol	201-210	crystallin zeta	Homo sapiens	96-118
17979524-7	2007	Immunoblot analysis showed that whereas the level of HO-1 protein was elevated, that of NAD(P)H:quinone oxidoreductase (NQO1) was decreased after the treatment with capsaicin or the inhibitor of NQO1, dicumarol.	Dicumarol	201-210	NAD(P)H quinone dehydrogenase 1	Homo sapiens	120-124
17920036-7	2007	Both PD98095 and dicoumarol were capable of blocking TNFalpha production but had only a small effect on p21Waf1 expression.	Dicumarol	17-27	tumor necrosis factor	Homo sapiens	53-61
17669387-1	2007	OBJECTIVES: In a preliminary study, NAD(P)H:quinone oxidoreductase 1 (NQO1) was found to be highly expressed in cultured human aortic smooth muscle cells (HASMC) and dicumarol, a NQO1 inhibitor and a coumarin-derived natural anticoagulant, suppressed tumor necrosis factor (TNF)-alpha-induced HASMC migration.	Dicumarol	166-175	NAD(P)H quinone dehydrogenase 1	Homo sapiens	36-68
17669387-1	2007	OBJECTIVES: In a preliminary study, NAD(P)H:quinone oxidoreductase 1 (NQO1) was found to be highly expressed in cultured human aortic smooth muscle cells (HASMC) and dicumarol, a NQO1 inhibitor and a coumarin-derived natural anticoagulant, suppressed tumor necrosis factor (TNF)-alpha-induced HASMC migration.	Dicumarol	166-175	NAD(P)H quinone dehydrogenase 1	Homo sapiens	70-74
17669387-1	2007	OBJECTIVES: In a preliminary study, NAD(P)H:quinone oxidoreductase 1 (NQO1) was found to be highly expressed in cultured human aortic smooth muscle cells (HASMC) and dicumarol, a NQO1 inhibitor and a coumarin-derived natural anticoagulant, suppressed tumor necrosis factor (TNF)-alpha-induced HASMC migration.	Dicumarol	166-175	NAD(P)H quinone dehydrogenase 1	Homo sapiens	179-183
17669387-1	2007	OBJECTIVES: In a preliminary study, NAD(P)H:quinone oxidoreductase 1 (NQO1) was found to be highly expressed in cultured human aortic smooth muscle cells (HASMC) and dicumarol, a NQO1 inhibitor and a coumarin-derived natural anticoagulant, suppressed tumor necrosis factor (TNF)-alpha-induced HASMC migration.	Dicumarol	166-175	tumor necrosis factor	Homo sapiens	251-284
17669387-3	2007	METHODS AND RESULTS: Gelatin zymography, reporter gene, electrophoretic mobility shift and Western blotting assays showed that dicumarol, but not other coumarin-derived anticoagulants, inhibited TNF-alpha-induced HASMC migration and suppressed TNF-alpha-induced matrix metalloproteinase (MMP)-9 expression and secretion in a dose-dependent manner.	Dicumarol	127-136	tumor necrosis factor	Homo sapiens	195-204
17669387-3	2007	METHODS AND RESULTS: Gelatin zymography, reporter gene, electrophoretic mobility shift and Western blotting assays showed that dicumarol, but not other coumarin-derived anticoagulants, inhibited TNF-alpha-induced HASMC migration and suppressed TNF-alpha-induced matrix metalloproteinase (MMP)-9 expression and secretion in a dose-dependent manner.	Dicumarol	127-136	tumor necrosis factor	Homo sapiens	244-253
17669387-3	2007	METHODS AND RESULTS: Gelatin zymography, reporter gene, electrophoretic mobility shift and Western blotting assays showed that dicumarol, but not other coumarin-derived anticoagulants, inhibited TNF-alpha-induced HASMC migration and suppressed TNF-alpha-induced matrix metalloproteinase (MMP)-9 expression and secretion in a dose-dependent manner.	Dicumarol	127-136	matrix metallopeptidase 9	Homo sapiens	262-294
17669387-4	2007	In addition, down-regulation of NQO1 by transfection of its small interfering RNA similarly inhibited TNF-alpha-induced MMP-9 secretion, indicating that dicumarol-mediated inhibition of MMP-9 expression is due in large part to inhibition of NQO1.	Dicumarol	153-162	NAD(P)H quinone dehydrogenase 1	Homo sapiens	32-36
17669387-4	2007	In addition, down-regulation of NQO1 by transfection of its small interfering RNA similarly inhibited TNF-alpha-induced MMP-9 secretion, indicating that dicumarol-mediated inhibition of MMP-9 expression is due in large part to inhibition of NQO1.	Dicumarol	153-162	tumor necrosis factor	Homo sapiens	102-111
17669387-4	2007	In addition, down-regulation of NQO1 by transfection of its small interfering RNA similarly inhibited TNF-alpha-induced MMP-9 secretion, indicating that dicumarol-mediated inhibition of MMP-9 expression is due in large part to inhibition of NQO1.	Dicumarol	153-162	matrix metallopeptidase 9	Homo sapiens	186-191
17669387-4	2007	In addition, down-regulation of NQO1 by transfection of its small interfering RNA similarly inhibited TNF-alpha-induced MMP-9 secretion, indicating that dicumarol-mediated inhibition of MMP-9 expression is due in large part to inhibition of NQO1.	Dicumarol	153-162	NAD(P)H quinone dehydrogenase 1	Homo sapiens	241-245
17979524-7	2007	Immunoblot analysis showed that whereas the level of HO-1 protein was elevated, that of NAD(P)H:quinone oxidoreductase (NQO1) was decreased after the treatment with capsaicin or the inhibitor of NQO1, dicumarol.	Dicumarol	201-210	NAD(P)H quinone dehydrogenase 1	Homo sapiens	195-199
17395013-6	2007	NE treatment caused lipid peroxidation in A549 cells; this effect was inhibited by pretreatment with dicumarol, suggesting that NQO1 also regulates oxidant stress in A549 cells after NE exposure.	Dicumarol	101-110	elastase, neutrophil expressed	Homo sapiens	0-2
17786182-2	2007	The clonogenic cell death caused by beta-lap could be significantly inhibited by dicoumarol, an inhibitor of NAD(P)H:quinone oxido-reductase (NQO1), and also by siRNA for NQO1, demonstrating that NQO1-induced bioreduction of beta-lap is an essential step in beta-lap-induced cell death.	Dicumarol	81-91	crystallin zeta	Homo sapiens	117-140
17786182-2	2007	The clonogenic cell death caused by beta-lap could be significantly inhibited by dicoumarol, an inhibitor of NAD(P)H:quinone oxido-reductase (NQO1), and also by siRNA for NQO1, demonstrating that NQO1-induced bioreduction of beta-lap is an essential step in beta-lap-induced cell death.	Dicumarol	81-91	NAD(P)H quinone dehydrogenase 1	Homo sapiens	142-146
17603928-5	2007	Unexpectedly, human A375 melanoma cells were resistant to PRC-induced apoptosis, and PRC-sensitive G361 cells were protected by preincubation with the NQO1 inhibitor dicoumarol.	Dicumarol	166-176	NAD(P)H quinone dehydrogenase 1	Homo sapiens	151-155
17609380-10	2007	NQO1- cells (H596, IMR-90) or dicoumarol-exposed NQO1+ A549 cells were resistant (LD50, >40 microM) to ROS formation and all cytotoxic effects of beta-lapachone.	Dicumarol	30-40	NAD(P)H quinone dehydrogenase 1	Homo sapiens	49-53
17395013-3	2007	We found that dicumarol, an inhibitor of the NADP(H):quinone oxidoreductase 1 (NQO1), inhibited MUC5AC mRNA expression in A549 lung adenocarcinoma cells and primary normal human bronchial epithelial cells.	Dicumarol	14-23	NAD(P)H quinone dehydrogenase 1	Homo sapiens	45-77
17395013-3	2007	We found that dicumarol, an inhibitor of the NADP(H):quinone oxidoreductase 1 (NQO1), inhibited MUC5AC mRNA expression in A549 lung adenocarcinoma cells and primary normal human bronchial epithelial cells.	Dicumarol	14-23	NAD(P)H quinone dehydrogenase 1	Homo sapiens	79-83
17395013-3	2007	We found that dicumarol, an inhibitor of the NADP(H):quinone oxidoreductase 1 (NQO1), inhibited MUC5AC mRNA expression in A549 lung adenocarcinoma cells and primary normal human bronchial epithelial cells.	Dicumarol	14-23	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	96-102
17395013-6	2007	NE treatment caused lipid peroxidation in A549 cells; this effect was inhibited by pretreatment with dicumarol, suggesting that NQO1 also regulates oxidant stress in A549 cells after NE exposure.	Dicumarol	101-110	NAD(P)H quinone dehydrogenase 1	Homo sapiens	128-132
17395013-6	2007	NE treatment caused lipid peroxidation in A549 cells; this effect was inhibited by pretreatment with dicumarol, suggesting that NQO1 also regulates oxidant stress in A549 cells after NE exposure.	Dicumarol	101-110	elastase, neutrophil expressed	Homo sapiens	183-185
16682409-5	2006	The treatment of wild-type cells with dicoumarol, a known inhibitor of NQO1, also abolished TNF-induced NF-kappaB activation.	Dicumarol	38-48	NAD(P)H dehydrogenase, quinone 1	Mus musculus	71-75
17425337-4	2007	No significant difference in the cell death was observed when the cells were treated 100 microM dopamine and 25 microM reserpine in the absence or presence of 100 microM dicoumarol, an inhibitor of DT-diaphorase.	Dicumarol	170-180	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	198-211
17298444-8	2007	Dicoumarol and Cibacron Marine, two well-known inhibitors of the quinone reductase family, bind to Lot6p and inhibit its activity.	Dicumarol	0-10	flavin-dependent quinone reductase	Saccharomyces cerevisiae S288C	99-104
17040906-3	2006	Although dicumarol has been used as an inhibitor of the two-electron reductase NAD(P)H:quinone oxidoreductase (NQO1), dicumarol is also thought to affect quinone-mediated electron transfer reactions in the mitochondria, leading to the production of superoxide (O2*-) and hydrogen peroxide (H(2)O(2)).	Dicumarol	9-18	NAD(P)H quinone dehydrogenase 1	Homo sapiens	111-115
17040906-5	2006	Dicumarol decreased clonogenic survival equally in both MDA-MB-468 NQO1(-) and MDA-MB-468 NQO1+ breast cancer cells.	Dicumarol	0-9	NAD(P)H quinone dehydrogenase 1	Homo sapiens	67-71
17040906-5	2006	Dicumarol decreased clonogenic survival equally in both MDA-MB-468 NQO1(-) and MDA-MB-468 NQO1+ breast cancer cells.	Dicumarol	0-9	NAD(P)H quinone dehydrogenase 1	Homo sapiens	90-94
17330453-3	2006	Investigation of hemorrhagic disease in cattle by Francis Schofield of the Ontario Veterinary College found an anti-thrombin substance in spoiled clover which was later characterized as dicoumarol, a vitamin K antagonist, and led to the development of warfarin.	Dicumarol	186-196	coagulation factor II, thrombin	Bos taurus	116-124
16494910-7	2006	Arsenite-mediated MMC susceptibility was abrogated by dicumarol (DIC), an NQO1 inhibitor, indicating that NQO1 is one of the key regulators of arsenite-mediated MMC susceptibility.	Dicumarol	54-63	NAD(P)H quinone dehydrogenase 1	Homo sapiens	74-78
16494910-7	2006	Arsenite-mediated MMC susceptibility was abrogated by dicumarol (DIC), an NQO1 inhibitor, indicating that NQO1 is one of the key regulators of arsenite-mediated MMC susceptibility.	Dicumarol	54-63	NAD(P)H quinone dehydrogenase 1	Homo sapiens	106-110
16494910-7	2006	Arsenite-mediated MMC susceptibility was abrogated by dicumarol (DIC), an NQO1 inhibitor, indicating that NQO1 is one of the key regulators of arsenite-mediated MMC susceptibility.	Dicumarol	65-68	NAD(P)H quinone dehydrogenase 1	Homo sapiens	74-78
16494910-7	2006	Arsenite-mediated MMC susceptibility was abrogated by dicumarol (DIC), an NQO1 inhibitor, indicating that NQO1 is one of the key regulators of arsenite-mediated MMC susceptibility.	Dicumarol	65-68	NAD(P)H quinone dehydrogenase 1	Homo sapiens	106-110
17123468-1	2007	Dicoumarol, a competitive inhibitor of NAD(P)H:quinone oxidoreductase 1 (NQO1), increases intracellular superoxide and affects cell growth of tumor cells.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	39-71
17123468-1	2007	Dicoumarol, a competitive inhibitor of NAD(P)H:quinone oxidoreductase 1 (NQO1), increases intracellular superoxide and affects cell growth of tumor cells.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	73-77
17305492-8	2007	Dicoumarol, a specific inhibitor of the NAD(P)H dependent quinone oxidoreductase (NQO1), significantly inhibited the metabolic elimination of TS in a noncompetitive way, suggesting that NQO1 was responsible for the quinone reduction of TS to form the catechol intermediate.	Dicumarol	0-10	crystallin zeta	Rattus norvegicus	58-80
17305492-8	2007	Dicoumarol, a specific inhibitor of the NAD(P)H dependent quinone oxidoreductase (NQO1), significantly inhibited the metabolic elimination of TS in a noncompetitive way, suggesting that NQO1 was responsible for the quinone reduction of TS to form the catechol intermediate.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	82-86
17305492-8	2007	Dicoumarol, a specific inhibitor of the NAD(P)H dependent quinone oxidoreductase (NQO1), significantly inhibited the metabolic elimination of TS in a noncompetitive way, suggesting that NQO1 was responsible for the quinone reduction of TS to form the catechol intermediate.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	186-190
17305492-10	2007	Dicoumarol exhibited a significant inhibitory effect on the hydrogen peroxide generation, further supporting that the reduction of TS was catalyzed by NQO1.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	151-155
16682409-5	2006	The treatment of wild-type cells with dicoumarol, a known inhibitor of NQO1, also abolished TNF-induced NF-kappaB activation.	Dicumarol	38-48	tumor necrosis factor	Mus musculus	92-95
16773182-7	2006	Inhibitors of mitogen-activated protein/extracellular signal regulated kinase (MEK), such as ERK inhibitor PD98059 and JNK inhibitors dicumarol and SP60015, but not p38 inhibitor SB203580, inhibited PMA-induced MUC5AC reporter activity.	Dicumarol	134-143	mitogen-activated protein kinase kinase 7	Homo sapiens	79-82
16773182-7	2006	Inhibitors of mitogen-activated protein/extracellular signal regulated kinase (MEK), such as ERK inhibitor PD98059 and JNK inhibitors dicumarol and SP60015, but not p38 inhibitor SB203580, inhibited PMA-induced MUC5AC reporter activity.	Dicumarol	134-143	mitogen-activated protein kinase 1	Homo sapiens	93-96
16773182-7	2006	Inhibitors of mitogen-activated protein/extracellular signal regulated kinase (MEK), such as ERK inhibitor PD98059 and JNK inhibitors dicumarol and SP60015, but not p38 inhibitor SB203580, inhibited PMA-induced MUC5AC reporter activity.	Dicumarol	134-143	mitogen-activated protein kinase 8	Homo sapiens	119-122
16773182-7	2006	Inhibitors of mitogen-activated protein/extracellular signal regulated kinase (MEK), such as ERK inhibitor PD98059 and JNK inhibitors dicumarol and SP60015, but not p38 inhibitor SB203580, inhibited PMA-induced MUC5AC reporter activity.	Dicumarol	134-143	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	211-217
16891456-2	2006	A recent study showed that inhibition of NQO1 in pancreatic cancer cells using the nonselective inhibitor dicumarol suppressed the malignant phenotype.	Dicumarol	106-115	NAD(P)H quinone dehydrogenase 1	Homo sapiens	41-45
16003741-7	2005	The effects of streptonigrin were reversed in pancreatic cancer cells pretreated with dicumarol, a known inhibitor of NQO1.	Dicumarol	86-95	NAD(P)H quinone dehydrogenase 1	Homo sapiens	118-122
16700548-0	2006	The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol.	Dicumarol	95-105	NAD(P)H quinone dehydrogenase 1	Homo sapiens	25-57
16700548-3	2006	Dicoumarol is a widely used potent competitive inhibitor of NQO1 enzymatic activity, which competes with NAD(P)H for binding to NQO1.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	60-64
16700548-3	2006	Dicoumarol is a widely used potent competitive inhibitor of NQO1 enzymatic activity, which competes with NAD(P)H for binding to NQO1.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	128-132
16700548-4	2006	Dicoumarol also disrupts the binding of NQO1 to p53, p73, and ODC and induces their ubiquitin-independent proteasomal degradation.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	40-44
16700548-4	2006	Dicoumarol also disrupts the binding of NQO1 to p53, p73, and ODC and induces their ubiquitin-independent proteasomal degradation.	Dicumarol	0-10	tumor protein p53	Homo sapiens	48-51
16700548-4	2006	Dicoumarol also disrupts the binding of NQO1 to p53, p73, and ODC and induces their ubiquitin-independent proteasomal degradation.	Dicumarol	0-10	tumor protein p73	Homo sapiens	53-56
16700548-4	2006	Dicoumarol also disrupts the binding of NQO1 to p53, p73, and ODC and induces their ubiquitin-independent proteasomal degradation.	Dicumarol	0-10	ornithine decarboxylase 1	Homo sapiens	62-65
16700548-5	2006	We report here the crystal structure of human NQO1 in complex with dicoumarol at 2.75 A resolution.	Dicumarol	67-77	NAD(P)H quinone dehydrogenase 1	Homo sapiens	46-50
16700548-6	2006	We have identified the interactions of dicoumarol with the different residues of NQO1 and the conformational changes imposed upon dicoumarol binding.	Dicumarol	39-49	NAD(P)H quinone dehydrogenase 1	Homo sapiens	81-85
16700548-7	2006	The most prominent conformational changes that occur in the presence of dicoumarol involve Tyr 128 and Phe 232 that are present on the surface of the NQO1 catalytic pocket.	Dicumarol	72-82	NAD(P)H quinone dehydrogenase 1	Homo sapiens	150-154
16929382-6	2006	Another important but poorly understood factor enhancing the reactivity of nitroaromatics is their ability to bind at the dicumarol/quinone binding site in the active center of NQO1.	Dicumarol	122-131	NAD(P)H quinone dehydrogenase 1	Homo sapiens	177-181
16518417-0	2006	Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines.	Dicumarol	0-10	mitogen-activated protein kinase 8	Homo sapiens	63-86
16518417-0	2006	Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines.	Dicumarol	0-10	tumor protein p53	Homo sapiens	90-93
16518417-1	2006	3-3"-Methylene-bis [4-hydroxycoumarin] (dicoumarol), an inhibitor of NADPH:quinone oxidoreductase 1, has been reported to possess potential antineoplastic effects and the ability to abrogate p53 protein.	Dicumarol	0-38	tumor protein p53	Homo sapiens	191-194
16518417-1	2006	3-3"-Methylene-bis [4-hydroxycoumarin] (dicoumarol), an inhibitor of NADPH:quinone oxidoreductase 1, has been reported to possess potential antineoplastic effects and the ability to abrogate p53 protein.	Dicumarol	40-50	tumor protein p53	Homo sapiens	191-194
16518417-4	2006	On the other hand, pretreatment with dicoumarol enhanced cytotoxicity of CDDP in three cell lines with wild type of p53 (RT112, 253J and LNCap), but not in three other cell lines with mutant p53 or in RT112 stable transfectants with a dominant-negative mutant of p53.	Dicumarol	37-47	tumor protein p53	Homo sapiens	116-119
16518417-4	2006	On the other hand, pretreatment with dicoumarol enhanced cytotoxicity of CDDP in three cell lines with wild type of p53 (RT112, 253J and LNCap), but not in three other cell lines with mutant p53 or in RT112 stable transfectants with a dominant-negative mutant of p53.	Dicumarol	37-47	tumor protein p53	Homo sapiens	191-194
16518417-4	2006	On the other hand, pretreatment with dicoumarol enhanced cytotoxicity of CDDP in three cell lines with wild type of p53 (RT112, 253J and LNCap), but not in three other cell lines with mutant p53 or in RT112 stable transfectants with a dominant-negative mutant of p53.	Dicumarol	37-47	tumor protein p53	Homo sapiens	191-194
16518417-5	2006	In RT112 and LNCap, CDDP induced p53 and p21 expression, while pretreatment of dicoumarol suppressed induction of p53/p21 and resulted in sequential activation of c-Jun N-terminal kinase (JNK) in a time-dependent manner.	Dicumarol	79-89	tumor protein p53	Homo sapiens	114-117
16518417-5	2006	In RT112 and LNCap, CDDP induced p53 and p21 expression, while pretreatment of dicoumarol suppressed induction of p53/p21 and resulted in sequential activation of c-Jun N-terminal kinase (JNK) in a time-dependent manner.	Dicumarol	79-89	H3 histone pseudogene 16	Homo sapiens	118-121
16518417-5	2006	In RT112 and LNCap, CDDP induced p53 and p21 expression, while pretreatment of dicoumarol suppressed induction of p53/p21 and resulted in sequential activation of c-Jun N-terminal kinase (JNK) in a time-dependent manner.	Dicumarol	79-89	mitogen-activated protein kinase 8	Homo sapiens	163-186
16518417-5	2006	In RT112 and LNCap, CDDP induced p53 and p21 expression, while pretreatment of dicoumarol suppressed induction of p53/p21 and resulted in sequential activation of c-Jun N-terminal kinase (JNK) in a time-dependent manner.	Dicumarol	79-89	mitogen-activated protein kinase 8	Homo sapiens	188-191
16518417-6	2006	Furthermore, inhibition of JNK, using SP600125, completely suppressed activity of caspases and poly-(ADP-ribose) polymerase cleavage, leading to suppression of enhancement of CDDP-mediated apoptosis by dicoumarol.	Dicumarol	202-212	mitogen-activated protein kinase 8	Homo sapiens	27-30
16518417-7	2006	These results suggested that dicoumarol could enhance cytotoxicity of CDDP in urogenital cancer cells with wild-type p53 through the p53/p21/JNK pathways.	Dicumarol	29-39	tumor protein p53	Homo sapiens	117-120
16518417-7	2006	These results suggested that dicoumarol could enhance cytotoxicity of CDDP in urogenital cancer cells with wild-type p53 through the p53/p21/JNK pathways.	Dicumarol	29-39	tumor protein p53	Homo sapiens	133-136
16518417-7	2006	These results suggested that dicoumarol could enhance cytotoxicity of CDDP in urogenital cancer cells with wild-type p53 through the p53/p21/JNK pathways.	Dicumarol	29-39	H3 histone pseudogene 16	Homo sapiens	137-140
16518417-7	2006	These results suggested that dicoumarol could enhance cytotoxicity of CDDP in urogenital cancer cells with wild-type p53 through the p53/p21/JNK pathways.	Dicumarol	29-39	mitogen-activated protein kinase 8	Homo sapiens	141-144
16499885-6	2006	Reduction of CoQ(1) to CoQ(1)H(2) by astrocytes was partially blocked by the NQO1 inhibitor dicumarol but was not affected by DHAA.	Dicumarol	92-101	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	77-81
16111645-3	2005	Dapsone, an inhibitor of myeloperoxidase, did not affect the cytotoxicity of polyphenols in HL-60 cells, whereas dicumarol, an inhibitor of DT-diaphorase, showed controversial effects on their cytotoxicity in FLK cells.	Dicumarol	113-122	NAD(P)H quinone dehydrogenase 1	Homo sapiens	140-153
16061648-8	2005	Stabilization of p53 by FIP200 could be partially reversed by NQO1 inhibitor, dicoumarol.	Dicumarol	78-88	tumor protein p53	Homo sapiens	17-20
16061648-8	2005	Stabilization of p53 by FIP200 could be partially reversed by NQO1 inhibitor, dicoumarol.	Dicumarol	78-88	RB1 inducible coiled-coil 1	Homo sapiens	24-30
16061648-8	2005	Stabilization of p53 by FIP200 could be partially reversed by NQO1 inhibitor, dicoumarol.	Dicumarol	78-88	NAD(P)H quinone dehydrogenase 1	Homo sapiens	62-66
15964517-5	2005	Applying this method to determine the inhibitory effects of reported in vitro NQO1 inhibitors (dicoumarol, 7,8-dihydroxyflavone, chrysin) showed that for all inhibitors tested, the IC50 in intact cells was at least 3 orders of magnitude higher than the IC50 in cell lysates.	Dicumarol	95-105	NAD(P)H quinone dehydrogenase 1	Homo sapiens	78-82
15893762-7	2005	In cultures pretreated with 4 microM dicumarol (DT-diaphorase inhibitor), the protective effect of AK-135 and menadione was abolished completely (1.67+/-1.43 and 2.97+/-0.57 nmol/mg protein, respectively).	Dicumarol	37-46	NAD(P)H quinone dehydrogenase 1	Homo sapiens	48-61
15896341-8	2005	5-Methoxy-1,2-dimethyl-3-[(4-nitrophenol)methyl]-indole-4,7-dione (ES936), a mechanism-based irreversible inhibitor of NAD(P)H:quinone oxidoreductase 1 (NQO1), did not promote S phase entry, and dicoumarol still inhibited G0/1 blockade in the presence of ES936.	Dicumarol	195-205	NAD(P)H quinone dehydrogenase 1	Homo sapiens	119-151
15809436-2	2005	NQO1 binds and stabilizes WT p53, whereas NQO1 inhibitors including dicoumarol and various other coumarins and flavones induce ubiquitin-independent proteasomal p53 degradation and thus inhibit p53-induced apoptosis.	Dicumarol	68-78	NAD(P)H quinone dehydrogenase 1	Homo sapiens	42-46
15809436-2	2005	NQO1 binds and stabilizes WT p53, whereas NQO1 inhibitors including dicoumarol and various other coumarins and flavones induce ubiquitin-independent proteasomal p53 degradation and thus inhibit p53-induced apoptosis.	Dicumarol	68-78	tumor protein p53	Homo sapiens	161-164
15809436-4	2005	Like dicoumarol, curcumin inhibited the activity of recombinant NQO1 in vitro, inhibited the activity of endogenous cellular NQO1 in vivo, and dissociated NQO1-WT p53 complexes.	Dicumarol	5-15	NAD(P)H quinone dehydrogenase 1	Homo sapiens	64-68
15805261-5	2005	Inhibition of adduct formation by dicoumarol, an NQO1 inhibitor, supported this finding and was confirmed with human recombinant NQO1.	Dicumarol	34-44	NAD(P)H quinone dehydrogenase 1	Homo sapiens	49-53
15805261-5	2005	Inhibition of adduct formation by dicoumarol, an NQO1 inhibitor, supported this finding and was confirmed with human recombinant NQO1.	Dicumarol	34-44	NAD(P)H quinone dehydrogenase 1	Homo sapiens	129-133
15809436-2	2005	NQO1 binds and stabilizes WT p53, whereas NQO1 inhibitors including dicoumarol and various other coumarins and flavones induce ubiquitin-independent proteasomal p53 degradation and thus inhibit p53-induced apoptosis.	Dicumarol	68-78	tumor protein p53	Homo sapiens	161-164
15749015-6	2005	Dicoumarol, an inhibitor of NQO1, dissociates ODC-NQO1 interaction and enhances ubiquitin-independent ODC proteasomal degradation.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	28-32
15749015-6	2005	Dicoumarol, an inhibitor of NQO1, dissociates ODC-NQO1 interaction and enhances ubiquitin-independent ODC proteasomal degradation.	Dicumarol	0-10	ornithine decarboxylase 1	Homo sapiens	46-49
15749015-6	2005	Dicoumarol, an inhibitor of NQO1, dissociates ODC-NQO1 interaction and enhances ubiquitin-independent ODC proteasomal degradation.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	50-54
15749015-6	2005	Dicoumarol, an inhibitor of NQO1, dissociates ODC-NQO1 interaction and enhances ubiquitin-independent ODC proteasomal degradation.	Dicumarol	0-10	ornithine decarboxylase 1	Homo sapiens	102-105
15749015-7	2005	We further show that dicoumarol sensitizes ODC monomers to proteasomal degradation in an antizyme-independent manner.	Dicumarol	21-31	ornithine decarboxylase 1	Homo sapiens	43-46
15639223-1	2005	Dicumarol [3,3"-methylene-bis(4-hydroxycoumarin)] is a potent inhibitor of NAD(P)H:quinone oxidoreductase-1.	Dicumarol	0-9	NAD(P)H quinone dehydrogenase 1	Homo sapiens	75-107
15715653-6	2005	However, 100 microm Fe(III)-dopamine in the presence of 100 microm dicoumarol, an inhibitor of DT-diaphorase, induced toxicity (44% cell death; p < 0.001), which was inhibited by 2 microm nomifensine, 30 microm reboxetine and 2 mm norepinephrine.	Dicumarol	67-77	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	95-108
15666291-9	2005	Dicumarol, a potent DT-diaphorase inhibitor, inhibited MGd metabolism in both rat and human liver cytosol.	Dicumarol	0-9	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	20-33
15639223-1	2005	Dicumarol [3,3"-methylene-bis(4-hydroxycoumarin)] is a potent inhibitor of NAD(P)H:quinone oxidoreductase-1.	Dicumarol	11-48	NAD(P)H quinone dehydrogenase 1	Homo sapiens	75-107
15639223-2	2005	Exposure of rat liver epithelial cells or of human skin fibroblasts to dicumarol resulted in a rapid and complete inhibition of connexin-43-dependent gap junctional intercellular communication (GJC).	Dicumarol	71-80	gap junction protein alpha 1	Homo sapiens	128-139
15639223-6	2005	Dicumarol-induced downregulation of GJC was found not to be due to an interference with pathways enhancing the phosphorylation of connexin-43, such as epidermal growth factor receptor and extracellular signal-regulated kinase pathways.	Dicumarol	0-9	epidermal growth factor receptor	Homo sapiens	151-183
15467770-4	2004	The mice were then treated with saline, 2.0, 3.5 or 2.0 mg kg(-1) MMC and dicoumarol, an NQO1 inhibitor.	Dicumarol	74-84	NAD(P)H dehydrogenase, quinone 1	Mus musculus	89-93
15535962-6	2004	Incubation of dicumarol in the microsomal PROD or ethoxyresorufin-O-dealkylase (EROD) assay led to significant decrease in the consumption of NADPH with a ratio of 4:1 and 7:1 for NADPH/PRF-ERF which is due to inhibition of NADPH cytochrome c (P-450) reductase.	Dicumarol	14-23	2,4-dienoyl-CoA reductase 1	Homo sapiens	180-185
15940348-4	2005	The antioxidant N,N"-diphenyl-p-phenylene diamine, desferrioxamine, and the inhibitor of NQO1 dicumarol, protected against apoptosis induction by all compounds investigated, but to a different extent.	Dicumarol	94-103	NAD(P)H dehydrogenase [quinone] 1	Ovis aries	89-93
15662131-4	2005	The cytotoxic in vitro effects of beta-lapachone were inhibited with coadministration of dicumarol, a specific inhibitor of NQO1.	Dicumarol	89-98	NAD(P)H quinone dehydrogenase 1	Homo sapiens	124-128
15535962-6	2004	Incubation of dicumarol in the microsomal PROD or ethoxyresorufin-O-dealkylase (EROD) assay led to significant decrease in the consumption of NADPH with a ratio of 4:1 and 7:1 for NADPH/PRF-ERF which is due to inhibition of NADPH cytochrome c (P-450) reductase.	Dicumarol	14-23	2,4-dienoyl-CoA reductase 1	Homo sapiens	142-147
15535962-6	2004	Incubation of dicumarol in the microsomal PROD or ethoxyresorufin-O-dealkylase (EROD) assay led to significant decrease in the consumption of NADPH with a ratio of 4:1 and 7:1 for NADPH/PRF-ERF which is due to inhibition of NADPH cytochrome c (P-450) reductase.	Dicumarol	14-23	2,4-dienoyl-CoA reductase 1	Homo sapiens	180-193
15535962-6	2004	Incubation of dicumarol in the microsomal PROD or ethoxyresorufin-O-dealkylase (EROD) assay led to significant decrease in the consumption of NADPH with a ratio of 4:1 and 7:1 for NADPH/PRF-ERF which is due to inhibition of NADPH cytochrome c (P-450) reductase.	Dicumarol	14-23	cytochrome c, somatic	Homo sapiens	230-242
15315711-8	2004	Treatment with NQO1 inhibitor, dicoumarol (50 microM), prior to exposure of PC3 to bLap led to significant decrease in bLap toxicity concurrent with significant decrease in treatment-induced apoptosis; thus implicating NQO1 as the major target in beta-lapachone-induced apoptosis in PC3.	Dicumarol	31-41	NAD(P)H quinone dehydrogenase 1	Homo sapiens	15-19
15315711-8	2004	Treatment with NQO1 inhibitor, dicoumarol (50 microM), prior to exposure of PC3 to bLap led to significant decrease in bLap toxicity concurrent with significant decrease in treatment-induced apoptosis; thus implicating NQO1 as the major target in beta-lapachone-induced apoptosis in PC3.	Dicumarol	31-41	NAD(P)H quinone dehydrogenase 1	Homo sapiens	219-223
15315711-8	2004	Treatment with NQO1 inhibitor, dicoumarol (50 microM), prior to exposure of PC3 to bLap led to significant decrease in bLap toxicity concurrent with significant decrease in treatment-induced apoptosis; thus implicating NQO1 as the major target in beta-lapachone-induced apoptosis in PC3.	Dicumarol	31-41	proprotein convertase subtilisin/kexin type 1	Homo sapiens	283-286
15240547-3	2004	We have recently demonstrated that inhibition of NQO(1) with dicumarol increases intracellular O(2)(.-) production and inhibits the in vitro malignant phenotype of pancreatic cancer cells (J. Cullen et al., Cancer Res., 63: 5513-5520, 2003).	Dicumarol	61-70	NAD(P)H quinone dehydrogenase 1	Homo sapiens	49-55
15388230-5	2004	Inhibition of c-jun-NH2-terminal kinase (JNK) by using both dicoumarol and SP600125 totally inhibited the stimulatory effect of hypoosmolarity.	Dicumarol	60-70	mitogen-activated protein kinase 8	Homo sapiens	14-39
15388230-5	2004	Inhibition of c-jun-NH2-terminal kinase (JNK) by using both dicoumarol and SP600125 totally inhibited the stimulatory effect of hypoosmolarity.	Dicumarol	60-70	mitogen-activated protein kinase 8	Homo sapiens	41-44
15240547-6	2004	Dicumarol increased the percentage of apoptotic cells in a time-dependent and dose-dependent manner as measured by 3,3"-diaminobenzidine staining and flow cytometry, which was associated with cytochrome c release and poly(ADP-ribose) polymerase cleavage.	Dicumarol	0-9	cytochrome c, somatic	Homo sapiens	192-204
15240547-6	2004	Dicumarol increased the percentage of apoptotic cells in a time-dependent and dose-dependent manner as measured by 3,3"-diaminobenzidine staining and flow cytometry, which was associated with cytochrome c release and poly(ADP-ribose) polymerase cleavage.	Dicumarol	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	217-244
15240547-9	2004	CONCLUSIONS: Inhibition of NQO(1) with dicumarol induces cell killing and oxidative stress in pancreatic cancer cells and speculate that dicumarol may prove to be useful in pancreatic cancer therapeutics.	Dicumarol	39-48	NAD(P)H quinone dehydrogenase 1	Homo sapiens	27-33
15240547-9	2004	CONCLUSIONS: Inhibition of NQO(1) with dicumarol induces cell killing and oxidative stress in pancreatic cancer cells and speculate that dicumarol may prove to be useful in pancreatic cancer therapeutics.	Dicumarol	137-146	NAD(P)H quinone dehydrogenase 1	Homo sapiens	27-33
15183197-3	2004	Studies were carried out under control conditions and with dicumarol, to inhibit NAD(P)H:quinone oxidoreductase 1 (NQO1), or cyanide, to inhibit mitochondrial electron transport.	Dicumarol	59-68	NAD(P)H quinone dehydrogenase 1	Homo sapiens	115-119
15511084-0	2004	Dicumarol, an inhibitor of ADP-ribosylation of CtBP3/BARS, fragments golgi non-compact tubular zones and inhibits intra-golgi transport.	Dicumarol	0-9	C-terminal binding protein 1	Homo sapiens	53-57
15511084-7	2004	In permeabilized cells, dicumarol activity depends on the function of CtBP3/BARS protein and pre-ADP-ribosylation of cytosol inhibits the breakdown of Golgi tubules by dicumarol.	Dicumarol	24-33	C-terminal binding protein 1	Homo sapiens	76-80
15183197-5	2004	Dicumarol blocked the appearance of DQH2 when DQ was added to the cell medium, and cyanide blocked the appearance of DQ when DQH2 was added to the cell medium, suggesting that the two electron reductase NQO1 dominates DQ reduction and mitochondrial electron transport complex III is the predominant route of DQH2 oxidation.	Dicumarol	0-9	NAD(P)H quinone dehydrogenase 1	Homo sapiens	203-207
15111234-0	2004	Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats.	Dicumarol	39-48	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	15-28
14701702-7	2004	Furthermore, treatment of arsenic trioxide-sensitive APL cells with the JNK inhibitor, dicumarol, significantly increased growth and survival in response to As(2)O(3) but did not protect cells from doxorubicin.	Dicumarol	87-96	mitogen-activated protein kinase 8	Homo sapiens	72-75
15044619-5	2004	Inhibitors of MRP1 (sulfinpyrazone, verapamil) and GST (dicumarol, curcumin) completely reversed the GSTM1-associated resistance to VCR, indicating that a MRP efflux function is necessary to potentiate GSTM1-mediated resistance to VCR.	Dicumarol	56-65	glutathione S-transferase mu 1	Homo sapiens	101-106
15202509-0	2004	Dicoumarol alters cellular redox state and inhibits nuclear factor kappa B to enhance arsenic trioxide-induced apoptosis.	Dicumarol	0-10	nuclear factor kappa B subunit 1	Homo sapiens	52-74
15202509-2	2004	In the present study, we attempt to explore if dicoumarol, an inhibitor of NADPH: quinone oxidoreductase (NQO1), alters the cellular redox state and how this alteration affects the redox-related apoptosis.	Dicumarol	47-57	crystallin zeta	Homo sapiens	82-104
15202509-2	2004	In the present study, we attempt to explore if dicoumarol, an inhibitor of NADPH: quinone oxidoreductase (NQO1), alters the cellular redox state and how this alteration affects the redox-related apoptosis.	Dicumarol	47-57	NAD(P)H quinone dehydrogenase 1	Homo sapiens	106-110
15202509-6	2004	More notably, this enhanced susceptibility was associated with a ROS-mediated inhibition of NF-kappaB activation in which the combinative treatment with dicoumarol prevented NF-kappaB from binding to target DNA.	Dicumarol	153-163	nuclear factor kappa B subunit 1	Homo sapiens	92-101
15202509-6	2004	More notably, this enhanced susceptibility was associated with a ROS-mediated inhibition of NF-kappaB activation in which the combinative treatment with dicoumarol prevented NF-kappaB from binding to target DNA.	Dicumarol	153-163	nuclear factor kappa B subunit 1	Homo sapiens	174-183
14751451-0	2004	Behavioral effects of manganese injected in the rat substantia nigra are potentiated by dicumarol, a DT-diaphorase inhibitor.	Dicumarol	88-97	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	101-114
14751451-2	2004	The neurotoxicity to nigrostriatal DA neurons was induced by injection of manganese pyrophosphate (Mn(3+)) complex as a prooxidizing agent alone or together with the DT-diaphorase inhibitor dicumarol into the right rat substantia nigra.	Dicumarol	190-199	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	166-179
15111240-1	2004	The present study shows that intranigral injection of dicoumarol, a DT-diaphorase inhibitor, potentiates the neurotoxic effect of salsolinol (salsolinol 1.25 nmoles plus dicoumarol 2 nmoles; in 2 microl).	Dicumarol	54-64	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	68-81
14634213-3	2003	The NQO1 inhibitor dicoumarol induces ubiquitin-independent p53 degradation.	Dicumarol	19-29	NAD(P)H quinone dehydrogenase 1	Homo sapiens	4-8
14634213-3	2003	The NQO1 inhibitor dicoumarol induces ubiquitin-independent p53 degradation.	Dicumarol	19-29	tumor protein p53	Homo sapiens	60-63
14634213-4	2003	We now show that, like dicoumarol, several other coumarin and flavone inhibitors of NQO1 activity, which compete with NAD(P)H for binding to NQO1, induced ubiquitin-independent p53 degradation and inhibited wild-type p53-mediated apoptosis.	Dicumarol	23-33	NAD(P)H quinone dehydrogenase 1	Homo sapiens	84-88
14634213-4	2003	We now show that, like dicoumarol, several other coumarin and flavone inhibitors of NQO1 activity, which compete with NAD(P)H for binding to NQO1, induced ubiquitin-independent p53 degradation and inhibited wild-type p53-mediated apoptosis.	Dicumarol	23-33	NAD(P)H quinone dehydrogenase 1	Homo sapiens	141-145
14634213-4	2003	We now show that, like dicoumarol, several other coumarin and flavone inhibitors of NQO1 activity, which compete with NAD(P)H for binding to NQO1, induced ubiquitin-independent p53 degradation and inhibited wild-type p53-mediated apoptosis.	Dicumarol	23-33	tumor protein p53	Homo sapiens	177-180
14634213-4	2003	We now show that, like dicoumarol, several other coumarin and flavone inhibitors of NQO1 activity, which compete with NAD(P)H for binding to NQO1, induced ubiquitin-independent p53 degradation and inhibited wild-type p53-mediated apoptosis.	Dicumarol	23-33	tumor protein p53	Homo sapiens	217-220
14634213-5	2003	Although wild-type p53 and several p53 mutants were sensitive to dicoumarol-induced degradation, the most frequent "hot-spot" p53 mutants in human cancer, R175H, R248H, and R273H, were resistant to dicoumarol-induced degradation, but remained sensitive to Mdm2-ubiquitin-mediated degradation.	Dicumarol	65-75	tumor protein p53	Homo sapiens	19-22
14634213-5	2003	Although wild-type p53 and several p53 mutants were sensitive to dicoumarol-induced degradation, the most frequent "hot-spot" p53 mutants in human cancer, R175H, R248H, and R273H, were resistant to dicoumarol-induced degradation, but remained sensitive to Mdm2-ubiquitin-mediated degradation.	Dicumarol	65-75	tumor protein p53	Homo sapiens	35-38
14634213-5	2003	Although wild-type p53 and several p53 mutants were sensitive to dicoumarol-induced degradation, the most frequent "hot-spot" p53 mutants in human cancer, R175H, R248H, and R273H, were resistant to dicoumarol-induced degradation, but remained sensitive to Mdm2-ubiquitin-mediated degradation.	Dicumarol	65-75	tumor protein p53	Homo sapiens	35-38
14634213-5	2003	Although wild-type p53 and several p53 mutants were sensitive to dicoumarol-induced degradation, the most frequent "hot-spot" p53 mutants in human cancer, R175H, R248H, and R273H, were resistant to dicoumarol-induced degradation, but remained sensitive to Mdm2-ubiquitin-mediated degradation.	Dicumarol	65-75	MDM2 proto-oncogene	Homo sapiens	256-260
14634213-7	2003	Further mutational analysis showed that arginines at positions 175 and 248 were essential for dicoumarol-induced p53 degradation.	Dicumarol	94-104	tumor protein p53	Homo sapiens	113-116
14634213-8	2003	NQO1 bound to wild-type p53 and dicoumarol, which induced a conformational change in NQO1, inhibited this binding.	Dicumarol	32-42	NAD(P)H quinone dehydrogenase 1	Homo sapiens	0-4
14634213-8	2003	NQO1 bound to wild-type p53 and dicoumarol, which induced a conformational change in NQO1, inhibited this binding.	Dicumarol	32-42	NAD(P)H quinone dehydrogenase 1	Homo sapiens	85-89
14634213-9	2003	Compared with wild-type p53, the hot-spot p53 mutants showed increased binding to NQO1, which can explain their resistance to dicoumarol-induced degradation.	Dicumarol	126-136	tumor protein p53	Homo sapiens	24-27
14634213-9	2003	Compared with wild-type p53, the hot-spot p53 mutants showed increased binding to NQO1, which can explain their resistance to dicoumarol-induced degradation.	Dicumarol	126-136	tumor protein p53	Homo sapiens	42-45
14634213-9	2003	Compared with wild-type p53, the hot-spot p53 mutants showed increased binding to NQO1, which can explain their resistance to dicoumarol-induced degradation.	Dicumarol	126-136	NAD(P)H quinone dehydrogenase 1	Homo sapiens	82-86
15558955-1	2004	Dicoumarols 1-10 with substituted phenyl residues at C-11 were synthesized and screened for their urease inhibition effects.	Dicumarol	0-11	RNA polymerase III subunit K	Homo sapiens	53-57
14729138-6	2004	When LY83583 was applied to PC12 cells, ROS formation was completely inhibited by both the flavoenzyme inhibitor DPI and the DT-diaphorase inhibitor dicumarol.	Dicumarol	149-158	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	125-138
12882764-8	2003	The dicumarol sensitivity along with immunodetectable expression of NAD(P)H-quinone oxidoreductase 1 (NQO1) in the rat lung tissue suggest cytoplasmic NQO1 as the dominant site of DQ reduction.	Dicumarol	4-13	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	151-155
12859987-8	2003	The inhibitor of NQO1, dicumarol, protected against the toxicity of aziridinyl-benzoquinones except of 2,5-bis-(2"-hydroxyethylamino)-3,6-diaziridinyl-1,4-benzoquinone (BZQ), which was almost inactive as NQO1 substrate.	Dicumarol	23-32	NAD(P)H quinone dehydrogenase 1	Homo sapiens	17-21
15706061-5	2004	The XTC-UC1 cell line exhibited enhanced activity with respect to control of dicoumarol-sensitive DCIP reduction, identified with membrane bound DT-diaphorase, whereas dicoumarol insensitive DCIP reduction was not significantly changed.	Dicumarol	77-87	NAD(P)H quinone dehydrogenase 1	Homo sapiens	145-158
14500388-0	2003	Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism.	Dicumarol	0-9	crystallin zeta	Homo sapiens	30-52
12920209-1	2003	The specific involvement of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the bioactivation of quinone prodrugs has been shown through the use of the inhibitor of NQO1, dicoumarol.	Dicumarol	166-176	NAD(P)H quinone dehydrogenase 1	Homo sapiens	28-60
12920209-1	2003	The specific involvement of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the bioactivation of quinone prodrugs has been shown through the use of the inhibitor of NQO1, dicoumarol.	Dicumarol	166-176	NAD(P)H quinone dehydrogenase 1	Homo sapiens	62-66
12920209-2	2003	Disadvantages of using dicoumarol to inhibit NQO1 include its lack of specificity and its competitive mechanism of inhibition.	Dicumarol	23-33	NAD(P)H quinone dehydrogenase 1	Homo sapiens	45-49
12920209-3	2003	The concentration of dicoumarol required for inhibition of NQO1 varies according to the substrate under evaluation, which may lead to either false conclusions of the involvement of NQO1 or the alteration of other cellular processes.	Dicumarol	21-31	NAD(P)H quinone dehydrogenase 1	Homo sapiens	59-63
12920209-3	2003	The concentration of dicoumarol required for inhibition of NQO1 varies according to the substrate under evaluation, which may lead to either false conclusions of the involvement of NQO1 or the alteration of other cellular processes.	Dicumarol	21-31	NAD(P)H quinone dehydrogenase 1	Homo sapiens	181-185
12859987-8	2003	The inhibitor of NQO1, dicumarol, protected against the toxicity of aziridinyl-benzoquinones except of 2,5-bis-(2"-hydroxyethylamino)-3,6-diaziridinyl-1,4-benzoquinone (BZQ), which was almost inactive as NQO1 substrate.	Dicumarol	23-32	NAD(P)H quinone dehydrogenase 1	Homo sapiens	204-208
12849725-4	2003	On the other hand, inhibition of NQO1 in both types of cells by dicoumarol significantly potentiated the inhibitory effect of quercetin on cell proliferation, revealing the role of NQO1 in cellular protection against quercetin.	Dicumarol	64-74	NAD(P)H dehydrogenase [quinone] 1	Cricetulus griseus	33-37
12815004-10	2003	This protective effect was reversed in rats treated with the NQO1 inhibitor, dicoumarol.	Dicumarol	77-87	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	61-65
12626122-9	2003	The quinone reductase inhibitor dicoumarol blocked activation of SAPK by menadione and DMNQ, suggesting that two-electron reduction is important.	Dicumarol	32-42	mitogen-activated protein kinase 9	Homo sapiens	65-69
12590933-5	2003	Ninety percent of H(2)O(2) generation by both the quinones can be prevented by dicumarol, an inhibitor of NAD(P)H quinone oxidoreductase (NQO1), at the submicromolar level, regardless of the quinone concentrations.	Dicumarol	79-88	crystallin zeta	Homo sapiens	114-136
12590933-5	2003	Ninety percent of H(2)O(2) generation by both the quinones can be prevented by dicumarol, an inhibitor of NAD(P)H quinone oxidoreductase (NQO1), at the submicromolar level, regardless of the quinone concentrations.	Dicumarol	79-88	NAD(P)H quinone dehydrogenase 1	Homo sapiens	138-142
12768337-9	2003	Both cytosolic and membrane-bound dicumarol-sensitive NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase, EC 1.6.99.2) activities were decreased by diets supplemented with CoQ(10).	Dicumarol	34-43	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	97-110
12683939-7	2003	its inhibition by dicumarol prevented caspase-3 activation and apoptosis, (ii).	Dicumarol	18-27	caspase 3	Mus musculus	38-47
12603827-6	2003	Inhibition of the NQO1 activity by dicoumarol, cibacron blue or chrysin (1-100 nM) protected the cells both after exposure to AF64A or OGD as assessed by the decreased release of lactate dehydrogenase.	Dicumarol	35-45	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	18-22
12584558-9	2003	In addition, dicumarol, an inhibitor of the phase II detoxifying enzyme NQO1, a downstream target of Nrf2, sensitized cells.	Dicumarol	13-22	NAD(P)H quinone dehydrogenase 1	Homo sapiens	72-76
12584558-9	2003	In addition, dicumarol, an inhibitor of the phase II detoxifying enzyme NQO1, a downstream target of Nrf2, sensitized cells.	Dicumarol	13-22	NFE2 like bZIP transcription factor 2	Homo sapiens	101-105
12476010-4	2002	We also determined the inter- and intrabatch variability and demonstrate that NQR activity can be significantly inhibited by dicumarol treatment.	Dicumarol	125-134	crystallin zeta	Homo sapiens	78-81
14715443-8	2003	The inhibition of DT-diaphorase by dicoumarol supports the idea that oxidative metabolism of dopamine is involved in MPP+ toxicity in RCSN-3 cells.	Dicumarol	35-45	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	18-31
12232053-3	2002	Inhibition of NQO1 activity by dicoumarol induces p53 and p73 proteasomal degradation.	Dicumarol	31-41	NAD(P)H quinone dehydrogenase 1	Homo sapiens	14-18
12232053-3	2002	Inhibition of NQO1 activity by dicoumarol induces p53 and p73 proteasomal degradation.	Dicumarol	31-41	tumor protein p53	Homo sapiens	50-53
12232053-3	2002	Inhibition of NQO1 activity by dicoumarol induces p53 and p73 proteasomal degradation.	Dicumarol	31-41	tumor protein p73	Homo sapiens	58-61
12232053-4	2002	A mutant p53 (p53([22,23])), which is resistant to Mdm-2-mediated degradation, was susceptible to dicoumarol-induced degradation.	Dicumarol	98-108	tumor protein p53	Homo sapiens	9-12
12232053-4	2002	A mutant p53 (p53([22,23])), which is resistant to Mdm-2-mediated degradation, was susceptible to dicoumarol-induced degradation.	Dicumarol	98-108	tumor protein p53	Homo sapiens	14-17
12232053-4	2002	A mutant p53 (p53([22,23])), which is resistant to Mdm-2-mediated degradation, was susceptible to dicoumarol-induced degradation.	Dicumarol	98-108	MDM2 proto-oncogene	Homo sapiens	51-56
12232053-6	2002	The tumor suppressor p14(ARF) and the viral oncogenes SV40 LT and adenovirus E1A that are known to stabilize p53 inhibited dicoumarol-induced p53 degradation.	Dicumarol	123-133	ribonuclease P/MRP subunit p14	Homo sapiens	21-24
12232053-6	2002	The tumor suppressor p14(ARF) and the viral oncogenes SV40 LT and adenovirus E1A that are known to stabilize p53 inhibited dicoumarol-induced p53 degradation.	Dicumarol	123-133	tumor protein p53	Homo sapiens	109-112
12232053-6	2002	The tumor suppressor p14(ARF) and the viral oncogenes SV40 LT and adenovirus E1A that are known to stabilize p53 inhibited dicoumarol-induced p53 degradation.	Dicumarol	123-133	tumor protein p53	Homo sapiens	142-145
12232053-8	2002	In vitro studies indicate that dicoumarol-induced p53 degradation was ubiquitin-independent and ATP-dependent.	Dicumarol	31-41	tumor protein p53	Homo sapiens	50-53
12130649-9	2002	Specific inhibitors of ERK1/2 activation (PD98059 and U0126), as well as JNK inhibitors (curcumin and dicumarol) antagonized the inhibitory effects of TGF-beta on ALP activity and mineralization, whereas the specific inhibitor of p38 MAPK (SB203580) did not affect them.	Dicumarol	102-111	mitogen-activated protein kinase 8	Mus musculus	73-76
12130649-9	2002	Specific inhibitors of ERK1/2 activation (PD98059 and U0126), as well as JNK inhibitors (curcumin and dicumarol) antagonized the inhibitory effects of TGF-beta on ALP activity and mineralization, whereas the specific inhibitor of p38 MAPK (SB203580) did not affect them.	Dicumarol	102-111	transforming growth factor, beta 1	Mus musculus	151-159
12188909-11	2002	Death of NQO1 expressing cells is prevented by the NQO1 inhibitor dicoumarol, and cells with low NQO1 are resistant.	Dicumarol	66-76	NAD(P)H dehydrogenase, quinone 1	Mus musculus	9-13
12188909-11	2002	Death of NQO1 expressing cells is prevented by the NQO1 inhibitor dicoumarol, and cells with low NQO1 are resistant.	Dicumarol	66-76	NAD(P)H dehydrogenase, quinone 1	Mus musculus	51-55
12188909-11	2002	Death of NQO1 expressing cells is prevented by the NQO1 inhibitor dicoumarol, and cells with low NQO1 are resistant.	Dicumarol	66-76	NAD(P)H dehydrogenase, quinone 1	Mus musculus	51-55
12208500-4	2002	Experiments with iodotubercidin, dicoumarol and z-VAD-fmk, which inhibited AMPK, JNK and caspase activation, respectively, supported the notion that prolonged AMPK activation in liver cells induces apoptosis through an activation pathway that involves JNK and caspase-3.	Dicumarol	33-43	mitogen-activated protein kinase 8	Rattus norvegicus	81-84
12069105-0	2002	Effect of dicumarol, a Nad(P)h: quinone acceptor oxidoreductase 1 (DT-diaphorase) inhibitor on ubiquinone redox cycling in cultured rat hepatocytes.	Dicumarol	10-19	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	67-80
12069105-3	2002	The effect of dicumarol, an inhibitor of NAD(P)H: quinone acceptor oxidoreductase 1 (NQO1 = DT-diaphorase, EC 1.6.99.2), on the reduction of UQ in cultured rat hepatocytes was investigated in order to clarify whether or not NQO1 is involved in reducing intracellular UQ.	Dicumarol	14-23	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	85-89
12069105-3	2002	The effect of dicumarol, an inhibitor of NAD(P)H: quinone acceptor oxidoreductase 1 (NQO1 = DT-diaphorase, EC 1.6.99.2), on the reduction of UQ in cultured rat hepatocytes was investigated in order to clarify whether or not NQO1 is involved in reducing intracellular UQ.	Dicumarol	14-23	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	92-105
12069105-3	2002	The effect of dicumarol, an inhibitor of NAD(P)H: quinone acceptor oxidoreductase 1 (NQO1 = DT-diaphorase, EC 1.6.99.2), on the reduction of UQ in cultured rat hepatocytes was investigated in order to clarify whether or not NQO1 is involved in reducing intracellular UQ.	Dicumarol	14-23	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	224-228
12069105-4	2002	A concentration of 5 microM dicumarol, which does not inhibit cytosolic NADPH-dependent UQ reductase in vitro, was observed to almost completely inhibit NQO1 and thereby to stimulate cytotoxicity of 2-methyl-1,4-naphthoquinone (menadione) in cultured rat hepatocytes.	Dicumarol	28-37	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	153-157
11926994-1	2002	NADPH-menadione reductase activity by rat brain microsomes (Ms) was decreased 40-50% by 10 microM dicumarol, a potent inhibitor of DT-diaphorase, whereas no change in NADPH-paraquat (PQ) and -diquat (DQ) reductase activity was observed.	Dicumarol	98-107	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	131-144
11867746-3	2002	We have reported previously that inhibition of NAD(P)H: quinone oxidoreductase 1 (NQO1) activity by dicoumarol induces degradation of p53, indicating that NQO1 plays a role in p53 stabilization.	Dicumarol	100-110	NAD(P)H quinone dehydrogenase 1	Homo sapiens	47-80
11867746-3	2002	We have reported previously that inhibition of NAD(P)H: quinone oxidoreductase 1 (NQO1) activity by dicoumarol induces degradation of p53, indicating that NQO1 plays a role in p53 stabilization.	Dicumarol	100-110	NAD(P)H quinone dehydrogenase 1	Homo sapiens	82-86
11867746-3	2002	We have reported previously that inhibition of NAD(P)H: quinone oxidoreductase 1 (NQO1) activity by dicoumarol induces degradation of p53, indicating that NQO1 plays a role in p53 stabilization.	Dicumarol	100-110	tumor protein p53	Homo sapiens	134-137
11867746-3	2002	We have reported previously that inhibition of NAD(P)H: quinone oxidoreductase 1 (NQO1) activity by dicoumarol induces degradation of p53, indicating that NQO1 plays a role in p53 stabilization.	Dicumarol	100-110	NAD(P)H quinone dehydrogenase 1	Homo sapiens	155-159
11867746-3	2002	We have reported previously that inhibition of NAD(P)H: quinone oxidoreductase 1 (NQO1) activity by dicoumarol induces degradation of p53, indicating that NQO1 plays a role in p53 stabilization.	Dicumarol	100-110	tumor protein p53	Homo sapiens	176-179
11867746-8	2002	Differences in the effectiveness of dicoumarol and hsp90 inhibitors to induce p53 degradation and suppress apoptosis in these cell types indicate that NQO1 and hsp90 stabilize p53 through different mechanisms.	Dicumarol	36-46	tumor protein p53	Homo sapiens	78-81
11867746-8	2002	Differences in the effectiveness of dicoumarol and hsp90 inhibitors to induce p53 degradation and suppress apoptosis in these cell types indicate that NQO1 and hsp90 stabilize p53 through different mechanisms.	Dicumarol	36-46	NAD(P)H quinone dehydrogenase 1	Homo sapiens	151-155
11867746-8	2002	Differences in the effectiveness of dicoumarol and hsp90 inhibitors to induce p53 degradation and suppress apoptosis in these cell types indicate that NQO1 and hsp90 stabilize p53 through different mechanisms.	Dicumarol	36-46	tumor protein p53	Homo sapiens	176-179
11820804-3	2002	The PMOR of lymphocytes from insulin-dependent diabetic patients is higher than that from age-matched controls and, in addition, has a dicoumarol-sensitive component, lacking in most controls, presumably due to membrane association of DT-diaphorase.	Dicumarol	135-145	NAD(P)H quinone dehydrogenase 1	Homo sapiens	235-248
11862423-10	2002	We also measured the cytotoxic activity of these agents in human tumor cell lines with and without the DT-diaphorase inhibitor, dicoumarol.	Dicumarol	128-138	NAD(P)H quinone dehydrogenase 1	Homo sapiens	103-116
11862423-17	2002	When cells were pretreated with the DT-diaphorase inhibitor, dicoumarol, the cytotoxic activity of BM increased while that of MBM decreased in both cell lines, suggesting that BM was inactivated by DT-diaphorase while MBM was activated by this enzyme.	Dicumarol	61-71	NAD(P)H quinone dehydrogenase 1	Homo sapiens	36-49
11862423-17	2002	When cells were pretreated with the DT-diaphorase inhibitor, dicoumarol, the cytotoxic activity of BM increased while that of MBM decreased in both cell lines, suggesting that BM was inactivated by DT-diaphorase while MBM was activated by this enzyme.	Dicumarol	61-71	NAD(P)H quinone dehydrogenase 1	Homo sapiens	198-211
12180874-5	2002	Dicoumarol toxicosis was suspected based on clinical signs, necropsy findings and prolonged prothrombin and activated partial thromboplastin times.	Dicumarol	0-10	coagulation factor II, thrombin	Bos taurus	92-103
14695936-7	2003	The rate of formation of the CoQ1 sulfate conjugate was markedly increased by the addition of NADH and was prevented by dicumarol, a DT-diaphorase (NQO1) inhibitor.	Dicumarol	120-129	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	133-146
14695936-7	2003	The rate of formation of the CoQ1 sulfate conjugate was markedly increased by the addition of NADH and was prevented by dicumarol, a DT-diaphorase (NQO1) inhibitor.	Dicumarol	120-129	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	148-152
12429349-7	2002	Additional studies in which the NQO1 activity was inhibited by dicoumarol showed that only dicoumarol concentrations of about five times the EC(50) for NQO1 inhibition were able to reduce NQO1 levels below the apparent threshold, making the cells more sensitive.	Dicumarol	63-73	NAD(P)H dehydrogenase [quinone] 1	Cricetulus griseus	32-36
12429349-7	2002	Additional studies in which the NQO1 activity was inhibited by dicoumarol showed that only dicoumarol concentrations of about five times the EC(50) for NQO1 inhibition were able to reduce NQO1 levels below the apparent threshold, making the cells more sensitive.	Dicumarol	91-101	NAD(P)H dehydrogenase [quinone] 1	Cricetulus griseus	32-36
12429349-7	2002	Additional studies in which the NQO1 activity was inhibited by dicoumarol showed that only dicoumarol concentrations of about five times the EC(50) for NQO1 inhibition were able to reduce NQO1 levels below the apparent threshold, making the cells more sensitive.	Dicumarol	91-101	NAD(P)H dehydrogenase [quinone] 1	Cricetulus griseus	152-156
12429349-7	2002	Additional studies in which the NQO1 activity was inhibited by dicoumarol showed that only dicoumarol concentrations of about five times the EC(50) for NQO1 inhibition were able to reduce NQO1 levels below the apparent threshold, making the cells more sensitive.	Dicumarol	91-101	NAD(P)H dehydrogenase [quinone] 1	Cricetulus griseus	152-156
12228181-8	2002	Dicumarol (an NAD(P)H/quinone oxidoreductase inhibitor) also potentiated 4-HA- or HQ-induced toxicity whereas sorbitol, an NADH-generating nutrient, prevented the cytotoxicity.	Dicumarol	0-9	crystallin zeta	Rattus norvegicus	22-44
12171070-8	2002	The function of this novel quinone reductase remains to be elucidated whereas dicumarol inhibition of NQO1 strongly potentiated growth arrest and decreased viability of HL-60 cells in the absence of serum.	Dicumarol	78-87	NAD(P)H quinone dehydrogenase 1	Homo sapiens	102-106
11856743-8	2002	Pretreatment of K562 cells with the JNK inhibitor, dicoumarol, abolished PBOX-6-induced phosphorylation of c-Jun and ATF-2 and inhibited the induced apoptosis, suggesting that JNK activation is an essential component of the apoptotic pathway induced by PBOX-6.	Dicumarol	51-61	mitogen-activated protein kinase 8	Homo sapiens	36-39
11856743-8	2002	Pretreatment of K562 cells with the JNK inhibitor, dicoumarol, abolished PBOX-6-induced phosphorylation of c-Jun and ATF-2 and inhibited the induced apoptosis, suggesting that JNK activation is an essential component of the apoptotic pathway induced by PBOX-6.	Dicumarol	51-61	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	107-112
11856743-8	2002	Pretreatment of K562 cells with the JNK inhibitor, dicoumarol, abolished PBOX-6-induced phosphorylation of c-Jun and ATF-2 and inhibited the induced apoptosis, suggesting that JNK activation is an essential component of the apoptotic pathway induced by PBOX-6.	Dicumarol	51-61	activating transcription factor 2	Homo sapiens	117-122
11856743-8	2002	Pretreatment of K562 cells with the JNK inhibitor, dicoumarol, abolished PBOX-6-induced phosphorylation of c-Jun and ATF-2 and inhibited the induced apoptosis, suggesting that JNK activation is an essential component of the apoptotic pathway induced by PBOX-6.	Dicumarol	51-61	mitogen-activated protein kinase 8	Homo sapiens	176-179
11278392-0	2001	Transient activation of Jun N-terminal kinases and protection from apoptosis by the insulin-like growth factor I receptor can be suppressed by dicumarol.	Dicumarol	143-152	insulin-like growth factor I receptor	Mus musculus	84-121
11412042-6	2001	Atypical PARP cleavage in beta-lap-treated cells was not affected by 100 microM zVAD-fmk; however, coadministration of dicoumarol, a specific inhibitor of NQO1, reduced beta-lap-mediated cytotoxicity, apoptosis, and atypical PARP cleavage in NQO1-expressing cells.	Dicumarol	119-129	poly(ADP-ribose) polymerase 1	Homo sapiens	9-13
11412042-6	2001	Atypical PARP cleavage in beta-lap-treated cells was not affected by 100 microM zVAD-fmk; however, coadministration of dicoumarol, a specific inhibitor of NQO1, reduced beta-lap-mediated cytotoxicity, apoptosis, and atypical PARP cleavage in NQO1-expressing cells.	Dicumarol	119-129	LAP	Homo sapiens	31-34
11412042-6	2001	Atypical PARP cleavage in beta-lap-treated cells was not affected by 100 microM zVAD-fmk; however, coadministration of dicoumarol, a specific inhibitor of NQO1, reduced beta-lap-mediated cytotoxicity, apoptosis, and atypical PARP cleavage in NQO1-expressing cells.	Dicumarol	119-129	NAD(P)H quinone dehydrogenase 1	Homo sapiens	155-159
11412042-6	2001	Atypical PARP cleavage in beta-lap-treated cells was not affected by 100 microM zVAD-fmk; however, coadministration of dicoumarol, a specific inhibitor of NQO1, reduced beta-lap-mediated cytotoxicity, apoptosis, and atypical PARP cleavage in NQO1-expressing cells.	Dicumarol	119-129	LAP	Homo sapiens	174-177
11412042-6	2001	Atypical PARP cleavage in beta-lap-treated cells was not affected by 100 microM zVAD-fmk; however, coadministration of dicoumarol, a specific inhibitor of NQO1, reduced beta-lap-mediated cytotoxicity, apoptosis, and atypical PARP cleavage in NQO1-expressing cells.	Dicumarol	119-129	poly(ADP-ribose) polymerase 1	Homo sapiens	225-229
11412042-6	2001	Atypical PARP cleavage in beta-lap-treated cells was not affected by 100 microM zVAD-fmk; however, coadministration of dicoumarol, a specific inhibitor of NQO1, reduced beta-lap-mediated cytotoxicity, apoptosis, and atypical PARP cleavage in NQO1-expressing cells.	Dicumarol	119-129	NAD(P)H quinone dehydrogenase 1	Homo sapiens	242-246
11412042-9	2001	Dicoumarol increased survival of beta-lap-treated NQO1-expressing LNCaP transfectants.	Dicumarol	0-10	LAP	Homo sapiens	38-41
11412042-9	2001	Dicoumarol increased survival of beta-lap-treated NQO1-expressing LNCaP transfectants.	Dicumarol	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	50-54
11278392-8	2001	The JNK inhibitor dicumarol suppressed IGF-I-mediated activation of JNK and phosphorylation of c-Jun but did not affect p38 and IkappaB phosphorylation or activation of AKT.	Dicumarol	18-27	mitogen-activated protein kinase 8	Mus musculus	4-7
11278392-8	2001	The JNK inhibitor dicumarol suppressed IGF-I-mediated activation of JNK and phosphorylation of c-Jun but did not affect p38 and IkappaB phosphorylation or activation of AKT.	Dicumarol	18-27	insulin-like growth factor 1	Mus musculus	39-44
11278392-8	2001	The JNK inhibitor dicumarol suppressed IGF-I-mediated activation of JNK and phosphorylation of c-Jun but did not affect p38 and IkappaB phosphorylation or activation of AKT.	Dicumarol	18-27	mitogen-activated protein kinase 8	Mus musculus	68-71
11278392-8	2001	The JNK inhibitor dicumarol suppressed IGF-I-mediated activation of JNK and phosphorylation of c-Jun but did not affect p38 and IkappaB phosphorylation or activation of AKT.	Dicumarol	18-27	jun proto-oncogene	Mus musculus	95-100
11278392-9	2001	IGF-I-mediated protection from apoptosis in FL5.12/WT cells was completely suppressed by dicumarol and partially suppressed by a p38 inhibitor.	Dicumarol	89-98	insulin-like growth factor 1	Mus musculus	0-5
11732341-7	2001	Nitrate reductase activity of plasma-membrane-enriched fractions was slightly stimulated by 25 microM dicumarol but was not altered by 100 microM dicumarol, while NADH-ferricyanide oxidoreductase activity was inhibited in the presence of dicumarol.	Dicumarol	102-111	nitrate reductase [NADH] 1	Zea mays	0-17
11355881-3	2001	The levels of catalase and glutathione peroxidase mRNA were decreased when RCSN-3 cells were treated with 100 microM salsolinol alone or in the presence of 100 microM dicoumarol.	Dicumarol	167-177	catalase	Rattus norvegicus	14-22
11158615-5	2001	The NQO1 inhibitor dicoumarol caused a reduction in the level of both endogenous and gamma-irradiation-induced p53 in HCT116 human colon carcinoma cells.	Dicumarol	19-29	NAD(P)H quinone dehydrogenase 1	Homo sapiens	4-8
11158615-5	2001	The NQO1 inhibitor dicoumarol caused a reduction in the level of both endogenous and gamma-irradiation-induced p53 in HCT116 human colon carcinoma cells.	Dicumarol	19-29	tumor protein p53	Homo sapiens	111-114
11158615-6	2001	This reduction was prevented by the proteasome inhibitors MG132 and lactacystin, suggesting enhanced p53 degradation in the presence of dicoumarol.	Dicumarol	136-146	tumor protein p53	Homo sapiens	101-104
11158615-7	2001	Dicoumarol-induced degradation of p53 also was prevented in the presence of simian virus 40 large T antigen, which is known to bind and to stabilize p53.	Dicumarol	0-10	tumor protein p53	Homo sapiens	34-37
11158615-7	2001	Dicoumarol-induced degradation of p53 also was prevented in the presence of simian virus 40 large T antigen, which is known to bind and to stabilize p53.	Dicumarol	0-10	tumor protein p53	Homo sapiens	149-152
11158615-8	2001	Cells overexpressing NQO1 were resistant to dicoumarol, and this finding indicates the direct involvement of NQO1 in p53 stabilization.	Dicumarol	44-54	NAD(P)H quinone dehydrogenase 1	Homo sapiens	21-25
11158615-8	2001	Cells overexpressing NQO1 were resistant to dicoumarol, and this finding indicates the direct involvement of NQO1 in p53 stabilization.	Dicumarol	44-54	tumor protein p53	Homo sapiens	117-120
11158615-10	2001	Dicoumarol also reduced the level of p53 in its mutant form in M1 cells.	Dicumarol	0-10	tumor protein p53	Homo sapiens	37-40
11259488-7	2001	Other muscarinic-induced signals, such as activation of c-Jun NH(2)-terminal kinase (JNK) or an increase in the binding activity of the transcription factors nuclear factor-kappa B and activator protein-1, were inhibited by the antioxidant dicoumarol.	Dicumarol	240-250	mitogen-activated protein kinase 8	Rattus norvegicus	56-83
11259488-7	2001	Other muscarinic-induced signals, such as activation of c-Jun NH(2)-terminal kinase (JNK) or an increase in the binding activity of the transcription factors nuclear factor-kappa B and activator protein-1, were inhibited by the antioxidant dicoumarol.	Dicumarol	240-250	mitogen-activated protein kinase 8	Rattus norvegicus	85-88